Targeting micrornas for metabolic disorders

ABSTRACT

Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.

This application is a divisional of U.S. patent application Ser. No.14/819,648, filed Aug. 6, 2015, which claims the benefit of priority ofU.S. Provisional Application No. 62/034,739, filed Aug. 7, 2014;62/062,749, filed Oct. 10, 2014; and 62/143,434, filed Apr. 6, 2015;each of which is incorporated by reference herein in its entirety forany purpose.

SEQUENCE LISTING

This application is being filed electronically via EFS-Web and includesan electronically submitted sequence listing in .txt format. The .txtfile contains a sequence listing entitled“2015-08-06_01138-0019-00US_SeqListing.txt” was created on Aug. 5, 2015and is 4,596 bytes in size. The sequence listing contained in this .txtfile is part of the specification and is hereby incorporated byreference herein in its entirety.

FIELD OF INVENTION

Provided herein are methods and compositions for the treatment ofmetabolic disorders.

DESCRIPTION OF RELATED ART

MicroRNAs (miRNAs), also known as “mature miRNA” are small(approximately 18-24 nucleotides in length), non-coding RNA moleculesencoded in the genomes of plants and animals. In certain instances,highly conserved, endogenously expressed miRNAs regulate the expressionof genes by binding to the 3′-untranslated regions (3′-UTR) of specificmRNAs. More than 1000 different miRNAs have been identified in plantsand animals. Certain mature miRNAs appear to originate from longendogenous primary miRNA transcripts (also known as pri-miRNAs,pri-mirs, pri-miRs or pri-pre-miRNAs) that are often hundreds ofnucleotides in length (Lee, et al., EMBO J., 2002, 21(17), 4663-4670).

Functional analyses of miRNAs have revealed that these small non-codingRNAs contribute to different physiological processes in animals,including developmental timing, organogenesis, differentiation,patterning, embryogenesis, growth control and programmed cell death.Examples of particular processes in which miRNAs participate includestem cell differentiation, neurogenesis, angiogenesis, hematopoiesis,and exocytosis (reviewed by Alvarez-Garcia and Miska, Development, 2005,132, 4653-4662).

Families of miRNAs can be characterized by nucleotide identity atpositions 2-8 of the miRNA, a region known as the seed sequence. Lewiset al. describe several miRNA families, as well as miRNA superfamilies,which are characterized by related seed sequences (Lewis et al. Cell.2005, 120(1):15-20). MicroRNAs miR-103 and miR-107 are family members,as they have identical seed regions. Thus these two microRNAs willregulate similar, if not identical, sets of target genes.

Inhibiting miR-103 and miR-107 has been shown to reduce blood glucoselevels and improve insulin sensitivity. See, e.g., PCT Publication No.2010/133970 A1.

SUMMARY OF INVENTION Embodiment 1

A compound comprising a modified oligonucleotide having the structure:

[oligo1]-[x-N]_(m)-x-[oligo2]

wherein:

-   oligo1 consists of 7 to 15 linked nucleosides and has a nucleobase    sequence that is complementary to the nucleobase sequence of miR-103    and/or miR-107 with no more than 1 mismatch;-   oligo2 consists of 7 to 15 linked nucleosides and has a nucleobase    sequence that is complementary to the nucleobase sequence of miR-103    and/or miR-107 with no more than 1 mismatch;-   each x is independently selected from a phosphodiester bond and a    phosphorothioate bond;-   each N is independently selected from a modified nucleoside and an    unmodified nucleoside;-   m is an integer from 1 to 5;

wherein at least one x is a phosphodiester bond.

Embodiment 2

The compound of embodiment 1, wherein the modified oligonucleotideconsists of 15 to 32, 15 to 30, 15 to 28, 15 to 26, 15 to 24, or 15 to22, or 15 to 20 nucleosides.

Embodiment 3

The compound of embodiment 1 or embodiment 2, wherein oligo1 has anucleobase sequence that is 100% complementary to the nucleobasesequence of miR-103 and/or miR-107.

Embodiment 4

The compound of any one of the preceding embodiments, wherein oligo1 hasa nucleobase sequence that is complementary to at least 6, at least 7,or 8 nucleotides of the seed region of miR-103 and/or miR-107.

Embodiment 5

The compound of any one of the preceding embodiments, wherein oligo2 hasa nucleobase sequence that is 100% complementary to the nucleobasesequence of miR-103 and/or miR-107.

Embodiment 6

The compound of any one of the preceding embodiments, wherein oligo2 hasa nucleobase sequence that is complementary to at least 6, at least 7,or 8 nucleotides of the seed region of miR-103 and/or miR-107.

Embodiment 7

The compound of any one of embodiments 1, 2, 4, and 6, wherein oligo1has a mismatch with the first nucleotide at the 5′ end of miR-103 andmiR-107.

Embodiment 8

The compound of any one of embodiments 1, 2, 4, 6, and 7, wherein oligo2has a mismatch with the first nucleotide at the 5′ end of miR-103 andmiR-107.

Embodiment 9

The compound of any one of the preceding embodiments, wherein at least2× are phosphodiester bonds.

Embodiment 10

The compound of any one of the preceding embodiments, wherein each x isa phosphodiester bond.

Embodiment 11

The compound of any one of the preceding embodiments, wherein at leastone N is an unmodified nucleoside.

Embodiment 12

The compound of any one of the preceding embodiments, wherein each N isan unmodified nucleoside.

Embodiment 13

The compound of any one of the preceding embodiments, wherein m is 1, 2,3, 4, or 5.

Embodiment 14

The compound of any one of the preceding embodiments, wherein m is 1, 2,or 3.

Embodiment 15

A compound comprising a modified oligonucleotide having the structure:

[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3]

wherein:

-   oligo1 consists of 7 to 15 linked nucleosides and has a nucleobase    sequence that is complementary to the nucleobase sequence of miR-103    and/or miR-107 with no more than 1 mismatch;-   oligo2 consists of 7 to 15 linked nucleosides and has a nucleobase    sequence that is complementary to the nucleobase sequence of miR-103    and/or miR-107 with no more than 1 mismatch;-   oligo3 consists of 7 to 15 linked nucleosides and has a nucleobase    sequence that is complementary to the nucleobase sequence of a third    microRNA with no more than 1 mismatch;-   each x is independently selected from a phosphodiester bond and a    phosphorothioate bond;-   each N is independently selected from a modified nucleoside and an    unmodified nucleoside;-   each m is independently an integer from 1 to 5;

wherein at least one x is a phosphodiester bond.

Embodiment 16

The compound of embodiment 15, wherein at least one x between oligo1 andoligo2 is a phosphodiester bond and at least one x between oligo2 andoligo3 is a phosphodiester bond.

Embodiment 17

The compound of embodiment 15 or embodiment 16, wherein the modifiedoligonucleotide consists of 23 to 55, 23 to 50, 23 to 45, 23 to 40, 23to 35, 23 to 30, or 23 to 26 nucleosides.

Embodiment 18

The compound of any one of embodiments 15 to 17, wherein oligo1 has anucleobase sequence that is 100% complementary to the nucleobasesequence of miR-103 and/or miR-107.

Embodiment 19

The compound of any one of embodiments 15 to 18, wherein oligo1 has anucleobase sequence that is complementary to at least 6, at least 7, or8 nucleotides of the seed region of miR-103 and/or miR-107.

Embodiment 20

The compound of any one of embodiments 15 to 19, wherein oligo2 has anucleobase sequence that is 100% complementary to the nucleobasesequence of miR-103 and/or miR-107.

Embodiment 21

The compound of any one of embodiments 15 to 20, wherein oligo2 has anucleobase sequence that is complementary to at least 6, at least 7, or8 nucleotides of the seed region of miR-103 and/or miR-107.

Embodiment 22

The compound of any one of embodiments 15 to 21, wherein oligo3 has anucleobase sequence that is 100% complementary to the nucleobasesequence of the third microRNA.

Embodiment 23

The compound of any one of embodiments 15 to 22, wherein oligo3 has anucleobase sequence that is complementary to at least 6, at least 7, or8 nucleotides of the seed region of the third microRNA.

Embodiment 24

The compound of any one of embodiments 15 to 23, wherein the thirdmicroRNA is miR-103 and/or miR-107

Embodiment 25

The compound of any one of the preceding embodiments, wherein at least4× are phosphodiester bonds.

Embodiment 26

The compound of embodiment 23, wherein at least 2× between oligo1 andoligo2 are phosphodiester bonds and at least 2× between oligo2 andoligo3 are phosphodiester bonds.

Embodiment 27

The compound of any one of the preceding embodiments, wherein each x isa phosphodiester bond.

Embodiment 28

The compound of any one of the preceding embodiments, wherein at leastone N is an unmodified nucleoside.

Embodiment 29

The compound of embodiment 28, wherein at least one N between oligo1 andoligo2 is an unmodified nucleoside, and at least one N between oligo2and oligo3 is an unmodified nucleoside.

Embodiment 30

The compound of any one of the preceding embodiments, wherein each N isan unmodified nucleoside.

Embodiment 31

The compound of any one of the preceding embodiments, wherein each m isindependently selected from 1, 2, 3, 4, and 5.

Embodiment 32

The compound of any one of the preceding embodiments, wherein each m isindependently selected from 1, 2, or 3.

Embodiment 33

The compound of any one of embodiments 15 to 32, wherein oligo1 has amismatch with the first nucleotide at the 5′ end of miR-103 and miR-107and/or oligo2 has a mismatch with the first nucleotide at the 5′ end ofmiR-103 and miR-107, and/or oligo3 has a mismatch with the firstnucleotide at the 5′ end of miR-103 and miR-107.

Embodiment 34

The compound of any one of the preceding embodiments, wherein thecompound comprises a conjugate moiety linked to the 5′ terminus or the3′ terminus of the modified oligonucleotide, or both.

Embodiment 35

The compound of embodiment 34, wherein the compound comprises aconjugate moiety linked to the 3′ terminus of the modifiedoligonucleotide.

Embodiment 36

The compound of embodiment 34 or embodiment 35, wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus of the modifiedoligonucleotide.

Embodiment 37

The compound of embodiment 34, wherein the compound comprises aconjugate moiety linked to the 5′ terminus or the 3′ terminus of themodified oligonucleotide, but not both.

Embodiment 38

The compound of embodiment 34, wherein the compound comprises a firstconjugate moiety linked to the 3′ terminus of the modifiedoligonucleotide and a second conjugate moiety linked to the 5′ terminusof the modified oligonucleotide.

Embodiment 39

The compound of any one of embodiments 34 to 38, wherein the conjugatemoiety comprises at least one ligand selected from a carbohydrate,cholesterol, a lipid, a phospholipid, an antibody, a lipoprotein, ahormone, a peptide, a vitamin, a steroid, and a cationic lipid.

Embodiment 40

The compound of any one of embodiments 34 to 39, wherein the compoundhas the structure:

L_(n)-linker-MO

-   wherein each L is, independently, a ligand and n is from 1 to 10;    and MO is the modified oligonucleotide.

Embodiment 41

The compound of any of one embodiments 34 to 39, wherein the compoundhas the structure:

L_(n)-linker-X-MO

-   wherein each L is, independently, a ligand and n is from 1 to 10; X    is a phosphodiester linkage or a phosphorothioate linkage; and MO is    the modified oligonucleotide.

Embodiment 42

The compound of any one of embodiments 34 to 39, wherein the compoundhas the structure:

L_(n)-linker-X₁—N_(m)—X₂-MO

-   wherein each L is, independently, a ligand and n is from 1 to 10;    each N of N_(m) is, independently, a modified or unmodified    nucleoside and m is from 1 to 5; X₁ and X₂ are each, independently,    a phosphodiester linkage or a phosphorothioate linkage; and MO is    the modified oligonucleotide.

Embodiment 43

The compound of any one of embodiments 34 to 39, wherein the compoundhas the structure:

L_(n)-linker-X—N_(m)—Y-MO

-   wherein each L is, independently, a ligand and n is from 1 to 10;    each N of N_(m) is, independently, a modified or unmodified    nucleoside and m is from 1 to 5; X is a phosphodiester linkage or a    phosphorothioate linkage; Y is a phosphodiester linkage; and MO is    the modified oligonucleotide.

Embodiment 44

The compound of any one of embodiments 34 to 39, wherein the compoundhas the structure:

L_(n)-linker-Y—N_(m)—Y-MO

-   wherein each L is, independently, a ligand and n is from 1 to 10;    each N of N_(m) is, independently, a modified or unmodified    nucleoside and m is from 1 to 5; each Y is a phosphodiester linkage;    and MO is the modified oligonucleotide.

Embodiment 45

The compound of any of embodiments 40 to 44, wherein if n is greaterthan 1, L_(n)-linker has the structure:

-   wherein each L is, independently, a ligand; n is from 1 to 10; S is    a scaffold; and Q′ and Q″ are, independently, linking groups.

Embodiment 46

The compound of embodiment 45, wherein Q′ and Q″ are each independentlyselected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid.

Embodiment 47

The compound of embodiment 45 or 46, wherein the scaffold links 2, 3, 4,or 5 ligands to a modified oligonucleotide.

Embodiment 48

The compound of embodiment 47, wherein the scaffold links 3 ligands to amodified oligonucleotide.

Embodiment 49

The compound of any one of embodiments 40 to 48, wherein the compoundhas the structure:

wherein:

-   B is selected from —O—, —S—, —N(R^(N))—, —Z—P(Z′)(Z″)O—,    —Z—P(Z′)(Z″)O—N_(m)—X—, and —Z—P(Z′)(Z″)O—N_(m)—Y—;-   MO is the modified oligonucleotide;-   R^(N) is selected from H, methyl, ethyl, propyl, isopropyl, butyl,    and benzyl;-   Z, Z′, and Z″ are each independently selected from O and S;-   each N of N_(m) is, independently, a modified or unmodified    nucleoside;-   m is from 1 to 5;-   X is selected from a phosphodiester linkage and a phosphorothioate    linkage;-   Y is a phosphodiester linkage; and-   the wavy line indicates the connection to the rest of the linker and    ligand(s).

Embodiment 50

The compound of any one of embodiments 41 to 49, wherein X is aphosphodiester linkage.

Embodiment 51

The compound of any one of embodiments 40 to 50, wherein n is from 1 to5, 1 to 4, 1 to 3, or 1 to 2.

Embodiment 52

The compound of any one of embodiments 40 to 51, wherein n is 3.

Embodiment 53

The compound of any one of embodiments 40 to 52, wherein at least oneligand is selected from a carbohydrate, cholesterol, a lipid, aphospholipid, an antibody, a lipoprotein, a hormone, a peptide, avitamin, a steroid, and a cationic lipid.

Embodiment 54

The compound of embodiment 53, wherein at least one ligand is acarbohydrate.

Embodiment 55

The compound of embodiment 54, wherein at least one ligand is selectedfrom mannose, glucose, galactose, ribose, arabinose, fructose, fucose,xylose, D-mannose, L-mannose, D-galactose, L-galactose, D-glucose,L-glucose, D-ribose, L-ribose, D-arabinose, L-arabinose, D-fructose,L-fructose, D-fucose, L-fucose, D-xylose, L-xylose,alpha-D-mannofuranose, beta-D-mannofuranose, alpha-D-mannopyranose,beta-D-mannopyranose, alpha-D-glucofuranose, Beta-D-glucofuranose,alpha-D-glucopyranose, beta-D-glucopyranose, alpha-D-galactofuranose,beta-D-galactofuranose, alpha-D-galactopyranose, beta-D-galactopyranose,alpha-D-ribofuranose, beta-D-ribofuranose, alpha-D-ribopyranose,beta-D-ribopyranose, alpha-D-fructofuranose, alpha-D-fructopyranose,glucosamine, galactosamine, sialic acid, N-acetylgalactosamine.

Embodiment 56

The compound of embodiment 54 or embodiment 55, wherein at least oneligand is selected from N-acetylgalactosamine, galactose, galactosamine,N-formylgalactosamine, N-propionyl-galactosamine,N-n-butanoylgalactosamine, and N-iso-butanoyl-galactosamine.

Embodiment 57

The compound of embodiment 56, wherein each ligand isN-acetylgalactosamine.

Embodiment 58

The compound of any one of embodiments 40 to 57, wherein the compoundhas the structure:

-   wherein each N of N_(m) is, independently, a modified or unmodified    nucleoside and m is from 1 to 5; X₁ and X₂ are each, independently,    a phosphodiester linkage or a phosphorothioate linkage; and MO is    the modified oligonucleotide.

Embodiment 59

The compound of any one of the preceding embodiments, wherein oligo1consists of 7 to 15 linked nucleosides, 7 to 14 linked nucleosides, 7 to13 linked nucleosides, 7 to 12 linked nucleosides, 7 to 11 linkednucleosides, 7 to 10 linked nucleosides, 8 to 15 linked nucleosides, 8to 14 linked nucleosides, 8 to 13 linked nucleosides, 8 to 12 linkednucleosides, 8 to 11 linked nucleosides, 8 to 10 linked nucleosides, or10 linked nucleosides.

Embodiment 60

The compound of embodiment 59, wherein oligo1 comprises at least onenucleoside with a modified sugar moiety.

Embodiment 61

The compound of embodiment 59 or embodiment 60, wherein oligo1 comprisesat least one nucleoside with an unmodified sugar moiety.

Embodiment 62

The compound of any one of embodiments 59 to 61, wherein oligo1comprises a plurality of nucleosides with a modified sugar moiety, and aplurality of nucleosides with an unmodified sugar moiety.

Embodiment 63

The compound of any one of embodiments 59 to 62, wherein at least 4, atleast 5, at least 6, at least 7, or at least 8 nucleosides of oligo1have a modified sugar moiety.

Embodiment 64

The compound of embodiment 63, wherein each nucleoside of oligo1 has amodified sugar moiety.

Embodiment 65

The compound of any one of embodiments 60 to 64, wherein each modifiednucleoside is independently selected from a 2′-O-methyl sugar moiety, a2′-O-methoxyethyl sugar moiety, a 2′-fluoro sugar moiety, and a bicyclicsugar moiety.

Embodiment 66

The compound of embodiment 65, wherein each bicyclic sugar moiety isindependently selected from a cEt sugar moiety and an LNA sugar moiety.

Embodiment 67

The compound of any one of embodiments 60 to 66, wherein each unmodifiedsugar moiety is independently selected from a β-D-deoxyribose and aβ-D-ribose.

Embodiment 68

The compound of any one of the preceding embodiments, wherein oligo2consists of 7 to 15 linked nucleosides, 7 to 14 linked nucleosides, 7 to13 linked nucleosides, 7 to 12 linked nucleosides, 7 to 11 linkednucleosides, 7 to 10 linked nucleosides, 8 to 15 linked nucleosides, 8to 14 linked nucleosides, 8 to 13 linked nucleosides, 8 to 12 linkednucleosides, 8 to 11 linked nucleosides, 8 to 10 linked nucleosides, or10 linked nucleosides.

Embodiment 69

The compound of embodiment 68, wherein oligo2 comprises at least onenucleoside with a modified sugar moiety.

Embodiment 70

The compound of embodiment 68 or embodiment 69, wherein oligo2 comprisesat least one nucleoside with an unmodified sugar moiety.

Embodiment 71

The compound of any one of embodiments 68 to 70, wherein oligo2comprises a plurality of nucleosides with a modified sugar moiety, and aplurality of nucleosides with an unmodified sugar moiety.

Embodiment 72

The compound of any one of embodiments 68 to 71, wherein at least 4, atleast 5, at least 6, at least 7, or at least 8 nucleosides of oligo2have a modified sugar moiety.

Embodiment 73

The compound of embodiment 68, wherein each nucleoside of oligo2 has amodified sugar moiety.

Embodiment 74

The compound of any one of embodiments 68 to 73, wherein each modifiednucleoside is independently selected from a 2′-O-methyl sugar moiety, a2′-O-methoxyethyl sugar moiety, a 2′-fluoro sugar moiety, and a bicyclicsugar moiety.

Embodiment 75

The compound of embodiment 74, wherein each bicyclic sugar moiety isindependently selected from a cEt sugar moiety and an LNA sugar moiety.

Embodiment 76

The compound of any one of embodiments 68 to 75, wherein each unmodifiedsugar moiety is independently selected from a β-D-deoxyribose and aβ-D-ribose.

Embodiment 77

The compound of any one of embodiments 15 to 76, wherein oligo3 consistsof 7 to 15 linked nucleosides, 7 to 14 linked nucleosides, 7 to 13linked nucleosides, 7 to 12 linked nucleosides, 7 to 11 linkednucleosides, 7 to 10 linked nucleosides, 8 to 15 linked nucleosides, 8to 14 linked nucleosides, 8 to 13 linked nucleosides, 8 to 12 linkednucleosides, 8 to 11 linked nucleosides, or 8 to 10 linked nucleosides,or 10 linked nucleosides.

Embodiment 78

The compound of embodiment 77, wherein oligo3 comprises at least onenucleoside with a modified sugar moiety.

Embodiment 79

The compound of embodiment 77 or embodiment 78, wherein oligo3 comprisesat least one nucleoside with an unmodified sugar moiety.

Embodiment 80

The compound of any one of embodiments 77 to 79, wherein oligo3comprises a plurality of nucleosides with a modified sugar moiety, and aplurality of nucleosides with an unmodified sugar moiety.

Embodiment 81

The compound of any one of embodiments 77 to 80, wherein at least 4, atleast 5, at least 6, at least 7, or at least 8 nucleosides of oligo3have a modified sugar moiety.

Embodiment 82

The compound of embodiment 81, wherein each nucleoside of oligo3 has amodified sugar moiety.

Embodiment 83

The compound of any one of embodiments 78 to 82, wherein each modifiednucleoside is independently selected from a 2′-O-methyl sugar moiety, a2′-O-methoxyethyl sugar moiety, a 2′-fluoro sugar moiety, and a bicyclicsugar moiety.

Embodiment 84

The compound of embodiment 83, wherein each bicyclic sugar moiety isindependently selected from a cEt sugar moiety and an LNA sugar moiety.

Embodiment 85

The compound of any one of embodiments 77 to 84, wherein each unmodifiedsugar moiety is independently selected from a β-D-deoxyribose and aβ-D-ribose.

Embodiment 86

The compound of any one of the preceding embodiments, wherein oligo1 hasthe nucleobase sequence 5′-CAAUGCUGCA-3′ (SEQ ID NO: 6).

Embodiment 87

The compound of any one of the preceding embodiments, wherein oligo2 hasthe nucleobase sequence 5′-CAAUGCUGCA-3′ (SEQ ID NO: 6).

Embodiment 88

The compound of any one of the preceding embodiments, wherein thecompound comprises a modified oligonucleotide having nucleobase sequence5′-CAAUGCUGCAAACAAUGCUGCA-3′ (SEQ ID NO: 7).

Embodiment 89

The compound of any one of the preceding embodiments, wherein oligo 1 is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 6),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside.

Embodiment 90

The compound of any one of the preceding embodiments, wherein oligo 2 is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 6),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside.

Embodiment 91

The compound of any one of the preceding embodiments, wherein themodified oligonucleotide consists of5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside and each nucleoside not followed by a subscript is adeoxynucleoside.

Embodiment 92

The compound of any one of embodiments 89 to 91, wherein eachinternucleoside linkage linking two S-cEt nucleosides is aphosphorothioate linkage.

Embodiment 93

The compound of embodiment 91 or embodiment 92, wherein at least oneinternucleoside linkage linking a deoxynucleoside nucleoside to anothernucleoside is a phosphodiester linkage.

Embodiment 94

The compound of embodiment 93, wherein each internucleoside linkagelinking a deoxynucleoside nucleoside to another nucleoside is aphosphodiester linkage.

Embodiment 95

A compound comprising the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages.

Embodiment 96

A method for reducing a blood glucose level of a subject comprisingadministering to the subject a compound of any one of embodiments 1 to95, 148, 156-163, 178, and 184.

Embodiment 97

The method of embodiment 96, wherein the subject has an elevated bloodglucose level.

Embodiment 98

The method of embodiment 96 or embodiment 97, comprising measuring theblood glucose level of the subject.

Embodiment 99

The method of any one of embodiments 96 to 98, wherein the subject hasan elevated blood glucose level.

Embodiment 100

The method of any one of embodiments 96 to 99, wherein the blood glucoselevel is a fasted blood glucose level, a post-prandial blood glucoselevel, a whole blood glucose level, or a plasma blood glucose level.

Embodiment 101

The method of any one of embodiments 96 to 100, comprising reducing theblood glucose level to below 200 mg/dL, below 175 mg/dL, below 150mg/dL, below 125 mg/dL, below 120 mg/dL, below 115 mg/dL, below 110mg/dL, below 105 mg/dL, or below 100 mg/dL.

Embodiment 101.2

The method of any one of embodiments 96 to 101, comprising reducing thehemoglobin Alc (HbAlc) level of a subject to below 8%, to below 7.5%, tobelow 7%, to below 6.5%, to below 6%, to below 5.5%, to below 5%, or tobelow 4.5%.

Embodiment 102

A method for preventing or delaying the onset of an elevated bloodglucose level in a subject at risk for developing an elevated glucoselevel comprising administering to the subject a compound of any one ofembodiments 1 to 95, 148, 156-163, 178, and 184.

Embodiment 103

A method for improving insulin sensitivity in a subject comprisingadministering to the subject a compound of any one of embodiments 1 to95, 148, 156-163, and 178.

Embodiment 104

The method of embodiment 103, wherein the subject has insulinresistance.

Embodiment 105

A method for preventing or delaying the onset of insulin resistance in asubject at risk for developing insulin resistance comprisingadministering to the subject a compound of any one of embodiments 1 to95, 148, 156-163, 178, and 184.

Embodiment 106

A method for improving glucose tolerance in a subject comprisingadministering to the subject a compound of any one of embodiments 1 to95, 148, 156-163, 178, and 184.

Embodiment 107

The method of embodiment 106, wherein the subject has impaired glucosetolerance.

Embodiment 108

A method of treating at least one metabolic disorder in a subject,comprising administering to the subject having a metabolic disorder acompound of any one of embodiments 1 to 95, 148, 156-163, 178, and 184.

Embodiment 109

A method of preventing or delaying the onset of at least one metabolicdisorder in a subject, comprising administering to the subject having ametabolic disorder a compound of any one of embodiments 1 to 95, 148,156-163, 178, and 184.

Embodiment 110

The method of embodiment 108 or embodiment 109, wherein at least onemetabolic disorder is selected from among pre-diabetes, diabetes,metabolic syndrome, obesity, diabetic dyslipidemia, hyperlipdemia,hypertension, hypertriglyceridemia, hyperfattyacidemia,hypercholesterolemia, and hyperinsulinemia.

Embodiment 111

A method of increasing adipocyte differentiation in a subject comprisingadministering to the subject a compound of any one of embodiments 1 to95, 148, 156-163, 178, and 184.

Embodiment 112

A method of increasing the number of small adipocytes in a subjectcomprising administering to the subject a compound of any one ofembodiments 1 to 95, 148, 156-163, 178, and 184.

Embodiment 113

The method of any one of embodiments 96 to 112, comprising reducing bodyweight of the subject.

Embodiment 114

The method of any of any one of embodiments 96 to 113, comprisingreducing body fat in the subject.

Embodiment 115

The method of any of any one of embodiments 96 to 114, wherein theadministering comprises parenteral administration, such as intravenousadministration or subcutaneous administration; or oral administration.

Embodiment 116

The method of any of any one of embodiments 96 to 115, comprisingadministering at least one additional therapy.

Embodiment 117

The method of embodiment 116, wherein the at least one additionaltherapy is a glucose-lowering agent or a lipid lowering agent.

Embodiment 118

The method of embodiment 117, wherein the glucose-lowering agent isselected from among a PPAR agonist (gamma, dual, or pan), a dipeptidylpeptidase (IV) inhibitor, a GLP-I analog, insulin or an insulin analog,an insulin secretagogue, a SGLT2 inhibitor, a human amylin analog, abiguanide, an alpha-glucosidase inhibitor, a meglitinide, athiazolidinedione, and sulfonylurea.

Embodiment 119

The method of any one of embodiments 116 to 118, wherein the at leastone additional therapy is administered at the same time asadministration of the compound, prior to administration of the compound,or after administration of the compound.

Embodiment 120

The method of any one of embodiments 116 to 118, wherein the at leastone additional therapy is administered less frequently than the compoundor more frequently than the compound.

Embodiment 121

The method of any one of embodiments 96 to 120, wherein the compound isadministered as a pharmaceutical composition.

Embodiment 122

A method of improving insulin resistance in a cell or tissue comprisingcontacting the cell or tissue with a compound of any one of embodiments1 to 95, 148, 156-163, 178, and 184.

Embodiment 123

The method of embodiment 122, wherein the cell or tissue is a liver,fat, or skeletal muscle cell or tissue.

Embodiment 124

A method of increasing insulin sensitivity in a cell or tissuecomprising contacting the cell or tissue with a compound of any one ofembodiments 1 to 95, 148, 156-163, 178, and 184.

Embodiment 125

The method of embodiment 124, wherein the cell is an adipocyte cell.

Embodiment 126

A method of inducing adipocyte differentiation comprising contacting anundifferentiated adipocyte with a compound of any one of embodiments 1to 95, 148, 156-163, 178, and 184.

Embodiment 127

A pharmaceutical composition comprising a compound of any one ofembodiments 1 to 95, 148, and 156-163 and a pharmaceutically acceptablecarrier.

Embodiment 128

The method of any one of embodiments 96 to 107, wherein the subject hasat least one metabolic disorder.

Embodiment 129

The method of embodiment 128, wherein the wherein at least one metabolicdisorder is selected from among pre-diabetes, diabetes, metabolicsyndrome, obesity, diabetic dyslipidemia, hyperlipdemia, hypertension,hypertriglyceridemia, hyperfattyacidemia, hypercholesterolemia, andhyperinsulinemia.

Embodiment 130

Use of a compound of any one of embodiments 1 to 95, 148, 156-163, 178,and 184 for use in therapy.

Embodiment 131

The use of embodiment 130, wherein the therapy is reduction of a bloodglucose level in a subject, or prevention of an elevated blood glucoselevel in a subject.

Embodiment 132

The use of embodiment 130, wherein the therapy is treatment of ametabolic disorder.

Embodiment 133

The use of embodiment 132, wherein the metabolic disorder is selectedfrom among pre-diabetes, diabetes, metabolic syndrome, obesity, diabeticdyslipidemia, hyperlipdemia, hypertension, hypertriglyceridemia,hyperfattyacidemia, hypercholesterolemia, and hyperinsulinemia.

Embodiment 134

The method of embodiment 124, wherein the cell is a liver cell or thetissue is a liver tissue.

Embodiment 135

A method of treating fatty liver disease comprising administering to asubject a compound of any one of embodiments 1 to 95, 148, 156-163, 178,and 184.

Embodiment 136

The method of embodiment 135, wherein the fatty liver disease isselected from non-alcoholic fatty liver disease (NAFLD), alcoholic fattyliver disease, alcoholic steatohepatitis, and non-alcoholicsteatohepatitis (NASH).

Embodiment 137

The use of any one of embodiments 130 to 133, wherein the therapy istreatment of fatty liver disease in a subject.

Embodiment 138

The use of embodiment 137, wherein the fatty liver disease is selectedfrom non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liverdisease, alcoholic steatohepatitis, and non-alcoholic steatohepatitis(NASH).

Embodiment 139

A method of reducing liver triglycerides comprising administering to asubject a compound of any one of embodiments 1 to 95, 148, 156-163, and179.

Embodiment 140

The method of any one of embodiments 96 to 126, 128, 129, 134, and 139,wherein the subject has fatty liver disease.

Embodiment 141

The method of embodiment 140, wherein the fatty liver disease isselected from non-alcoholic fatty liver disease (NAFLD), alcoholic fattyliver disease, alcoholic steatohepatitis, and non-alcoholicsteatohepatitis (NASH).

Embodiment 142

The use of embodiment 130, wherein the therapy comprises reducing livertriglycerides in a subject.

Embodiment 143

The use of embodiment 142, wherein wherein the subject has fatty liverdisease.

Embodiment 144

The use of embodiment 143, wherein the fatty liver disease is selectedfrom non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liverdisease, alcoholic steatohepatitis, and non-alcoholic steatohepatitis(NASH).

Embodiment 145

A method of treating a metabolic disorder comprising administering to asubject a compound comprising a modified oligonucleotide consisting of asingle region of 8 to 25 linked nucleosides, wherein the nucleobasesequence of the single region is complementary to miR-103 and/ormiR-107, and wherein the compound comprises a conjugate moiety linked tothe 5′ terminus or the 3′ terminus of the modified oligonucleotide, andwherein the conjugate moiety comprises a ligand that improves cellularuptake in a liver cell.

Embodiment 146

The method of embodiment 145, wherein the conjugate moiety comprises aligand having affinity for the asialoglycoprotein receptor.

Embodiment 147

The method of embodiment 145 or 146, wherein the ligand is selected fromN-acetylgalactosamine, galactose, galactosamine, N-formylgalactosamine,N-propionyl-galactosamine, N-n-butanoylgalactosamine, andN-iso-butanoyl-galactosamine.

Embodiment 148

The compound of embodiment 95, wherein Y is linked to the 3′ terminus ofMO.

Embodiment 149

A method of treating a metabolic disorder comprising administering to asubject a compound comprising a modified oligonucleotide consisting of asingle region of 8 to 25 linked nucleosides, wherein the nucleobasesequence of the single region is complementary to miR-103 and/or miR-107with a mismatch to the 5′ terminal A of miR-103 or miR-107.

Embodiment 150

The method of embodiment 149, wherein the 3′ terminal nucleotide of themodified oligonucleotide is the mismatched position.

Embodiment 151

The method of embodiment 149 or embodiment 150, wherein the 3′ terminalnucleotide of the modified oligonucleotide is selected from A, C, and G.

Embodiment 152

The method of any one of embodiments 149 to 151, wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus or the 3′terminus of the modified oligonucleotide, and wherein the conjugatemoiety comprises a ligand that improves cellular uptake in a liver cell.

Embodiment 153

The method of embodiment 152, wherein the conjugate moiety comprises aligand having affinity for the asialoglycoprotein receptor.

Embodiment 154

The method of embodiment 152 or 153, wherein the ligand is selected fromN-acetylgalactosamine, galactose, galactosamine, N-formylgalactosamine,N-propionyl-galactosamine, N-n-butanoylgalactosamine, andN-iso-butanoyl-galactosamine.

Embodiment 155

The method of any one of embodiments 152 to 153, wherein the modifiedoligonucleotide is fully complementary to miR-103 or miR-107 except forthe mismatch to the 5′ terminal A of miR-103 or miR-107.

Embodiment 156

A compound comprising a modified oligonucleotide consisting of a singleregion of 8 to 25 linked nucleosides, wherein the nucleobase sequence ofthe single region is complementary to miR-103 and/or miR-107 with amismatch to the 5′ terminal A of miR-103 and miR-107.

Embodiment 157

The compound of embodiment 156, wherein the 3′ terminal nucleotide ofthe modified oligonucleotide is the mismatched position.

Embodiment 158

The compound of embodiment 156 or embodiment 157, wherein the 3′terminal nucleotide of the modified oligonucleotide is selected from A,C, and G.

Embodiment 159

The compound of any one of embodiments 156 to 158, wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus or the 3′terminus of the modified oligonucleotide, and wherein the conjugatemoiety comprises a ligand that improves cellular uptake in a liver cell.

Embodiment 160

The compound of embodiment 159, wherein the conjugate moiety comprises aligand having affinity for the asialoglycoprotein receptor.

Embodiment 161

The compound of embodiment 159 or 160, wherein the ligand is selectedfrom N-acetylgalactosamine, galactose, galactosamine,N-formylgalactosamine, N-propionyl-galactosamine,N-n-butanoylgalactosamine, and N-iso-butanoyl-galactosamine.

Embodiment 162

The compound of any one of embodiments 156 to 161, wherein the modifiedoligonucleotide is fully complementary to miR-103 or miR-107 except forthe mismatch to the 5′ terminal A of miR-103 or miR-107.

Embodiment 163

A compound having the structure:

Embodiment 164

A pharmaceutical composition comprising the compound of embodiment 163and a pharmaceutically acceptable carrier.

Embodiment 165

The pharmaceutical composition of embodiment 164, which comprises 30 mg,35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg of the compound of claim 163.

Embodiment 166

The pharmaceutical composition of embodiment 164 or embodiment 165,which is an aqueous composition.

Embodiment 167

The pharmaceutical composition of embodiment 164 or embodiment 165,which is a lyophilized composition.

Embodiment 168

The method of any one of embodiments 135, 136, 139 to 141, and 145-155,wherein the subject has a metabolic disorder selected from amongpre-diabetes, diabetes, metabolic syndrome, obesity, diabeticdyslipidemia, hyperlipdemia, hypertension, hypertriglyceridemia,hyperfattyacidemia, hypercholesterolemia, and hyperinsulinemia.

Embodiment 169

The method of any one of embodiments 135, 136, 139, 140, 141, and145-155, wherein the subject has a metabolic disorder selected frompre-diabetes and type 2 diabetes.

Embodiment 170

The method of embodiment 135 or embodiment 140, wherein the fatty liverdisease is selected from non-alcoholic fatty liver disease (NAFLD) andnon-alcoholic steatohepatitis (NASH).

Embodiment 171

The method of embodiment 170, wherein the subject has a metabolicdisorder selected from pre-diabetes and type 2 diabetes.

Embodiment 172

The method of embodiment 170, wherein the subject has insulinresistance, elevated blood glucose levels, or elevated HbAlc levels.

Embodiment 173

The use of embodiment 130, wherein the therapy is for treatment of fattyliver disease in a subject with at least one metabolic disorder selectedfrom pre-diabetes, diabetes, metabolic syndrome, obesity, diabeticdyslipidemia, hyperlipdemia, hypertension, hypertriglyceridemia,hyperfattyacidemia, hypercholesterolemia, and hyperinsulinemia.

Embodiment 174

The use of embodiment 130, wherein the therapy is for treatment of fattyliver disease in a subject with a metabolic disorder selected frompre-diabetes and type 2 diabetes.

Embodiment 175

The use of embodiment 130, wherein the therapy is for treatment of fattyliver disease in a subject with insulin resistance, elevated bloodglucose levels or elevated HbAlc levels.

Embodiment 176

The use of any of embodiments 173, 174 and 175, wherein the fatty liverdisease is selected from non-alcoholic fatty liver disease (NAFLD),alcoholic fatty liver disease, alcoholic steatohepatitis, andnon-alcoholic steatohepatitis (NASH).

Embodiment 177

The use of any one of embodiments 137, 143, 173, 174, and 175, whereinthe fatty liver disease is selected from non-alcoholic fatty liverdisease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Embodiment 178

The method of any one of embodiments 96-121, 128, 129, 135, 139-141, and168-172, wherein the compound is administered at a dose of 50 to 150 mg,at a frequency of once per week.

Embodiment 179

The compound of Embodiment 95, wherein the compound consists of thestructure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; Y is linkedto the 3′-terminus of MO; MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages; or apharmaceutically acceptable salt thereof.

Embodiment 180

A pharmaceutical composition comprising the compound of Embodiment 179and a pharmaceutically acceptable carrier.

Embodiment 181

A compound for treating a metabolic disorder in a subject, comprising amodified oligonucleotide consisting of 8 to 25 linked nucleosides,wherein the nucleobase sequence of the modified oligonucleotide iscomplementary to miR-103 and/or miR-107, and wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus or the 3′terminus of the modified oligonucleotide, and wherein the conjugatemoiety comprises a ligand that improves cellular uptake in a liver cell.

Embodiment 182

The compound of embodiment 150, wherein the conjugate moiety comprises aligand having affinity for the asialoglycoprotein receptor.

Embodiment 183

The compound of embodiment 150 or 151, wherein the ligand is selectedfrom N-acetylgalactosamine, galactose, galactosamine,N-formylgalactosamine, N-propionyl-galactosamine,N-n-butanoylgalactosamine, and N-iso-butanoyl-galactosamine.

Embodiment 184

The compound of embodiment 156, wherein the compound consists of thestructure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; Y is linkedto the 3′ terminus of MO; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 6),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage; or a pharmaceuticallyacceptable salt thereof.

Embodiment 185

A pharmaceutical composition comprising the compound of embodiment 184and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1. Structure of conjugate moiety comprising three GalNAc ligands.

FIG. 2A-C. Conjugated modified oligonucleotide structures.

FIG. 3 shows fasting glucose, fasting insulin, and HOMA IR at 2 weeks inmice administered the indicated compound, as described in the Examples.

FIG. 4 shows fasting glucose, fasting insulin, and HOMA IR at 3 weeks inmice administered the indicated compound, as described in the Examples.

FIG. 5 shows fasting glucose, fasting insulin, and HOMA IR at 2 weeks inmice administered the indicated compound, as described in the Examples.

FIG. 6 shows fasting glucose, fasting insulin, and HOMA IR at 3 weeks inmice administered the indicated compound, as described in the Examples.

FIG. 7 shows blood glucose and plasma insulin following oral glucosechallenge in mice administered the indicated compound, as described inthe Examples.

FIG. 8 shows liver triglyceride content in mice administered theindicated compound, as described in the Examples.

FIG. 9A-E shows improvements in insulin sensitivity, and triglyceridereductions in DIO mice administered the indicated compound, as describedin the Examples.

FIG. 10 shows HOMA IR at 1 week in mice administered the indicatedcompound, as described in the Examples.

FIG. 11A-B shows fasting glucose and liver triglycerides in db/db miceadministered the indicated compound, as described in the Examples.

FIG. 12A-E shows a hyperinsulinemic euglycemic clamp study in DIO miceadministered the indicated compound, as described in the Examples.

FIG. 13 shows the structure of compound 47043.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in thearts to which the invention belongs. Unless specific definitions areprovided, the nomenclature utilized in connection with, and theprocedures and techniques of, analytical chemistry, synthetic organicchemistry, and medicinal and pharmaceutical chemistry described hereinare those well known and commonly used in the art. In the event thatthere is a plurality of definitions for terms herein, those in thissection prevail. Standard techniques may be used for chemical synthesis,chemical analysis, pharmaceutical preparation, formulation and delivery,and treatment of subjects. Certain techniques and procedures may befound for example in “Carbohydrate Modifications in Antisense Research”Edited by Sangvi and Cook, American Chemical Society, Washington D.C.,1994; and “Remington's Pharmaceutical Sciences,” Mack Publishing Co.,Easton, Pa., 18th edition, 1990; and which is hereby incorporated byreference for any purpose. Where permitted, all patents, patentapplications, published applications and publications, GENBANKsequences, websites and other published materials referred to throughoutthe entire disclosure herein, unless noted otherwise, are incorporatedby reference in their entirety. Where reference is made to a URL orother such identifier or address, it is understood that such identifierscan change and particular information on the internet can command go,but equivalent information can be found by searching the internet.Reference thereto evidences the availability and public dissemination ofsuch information.

Before the present compositions and methods are disclosed and described,it is to be understood that the terminology used herein is for thepurpose of describing particular embodiments only and is not intended tobe limiting. It must be noted that, as used in the specification and theappended claims, the singular forms “a,” “an” and “the” include pluralreferents unless the context clearly dictates otherwise.

DEFINITIONS

“Blood glucose level” means the concentration of glucose in the blood ofa subject. In certain embodiments, blood glucose levels are expressed asmilligrams of glucose per deciliter of blood. In certain embodiments,blood glucose levels are expressed as mmol of glucose per liter ofblood.

“Elevated blood glucose level” means a blood glucose level that ishigher than normal.

“Fasted blood glucose level” means a blood glucose level after a subjecthas fasted for a certain length of time. For example, a subject may fastfor at least 8 hours prior to measurement of a fasted blood glucoselevel.

“Post-prandial blood glucose level” means a blood glucose level after asubject has eaten a meal. In certain embodiments, a post-prandial bloodglucose level is measured two hours after a subject has eaten a meal.

“Whole blood gluocose level” means the concentration of glucose in wholeblood which has not been subjected to separation.

“Plasma blood glucose level” means the concentration of glucose inplasma following separation of whole blood into plasma and red bloodcell fractions.

“Insulin sensitivity” means the ability of cells to take up glucose inresponse to insulin action.

“Insulin resistance” means a condition in which normal amounts ofinsulin are inadequate to produce a normal insulin response from fat,muscle and liver cells. Insulin resistance in fat cells results inhydrolysis of stored triglycerides, which elevates free fatty acids inthe blood. Insulin resistance in muscle reduces the uptake of glucosefrom the blood by muscle cells. Insulin resistance in liver reducesglucose storage and a failure to suppress glucose production. Elevatedfree fatty acids, reduced glucose uptake, and elevated glucoseproduction all contribute to elevated blood glucose levels. High plasmalevels of insulin and glucose due to insulin resistance often leads tometabolic syndrome and type 2 diabetes.

“Improving insulin resistance” means increasing the ability of cells toproduce a normal insulin response. In certain embodiments, insulinresistance is improved in muscle cells, leading to an increased uptakeof glucose in muscle cells. In certain embodiments, insulin resistanceis improved in liver cells, leading to increased glucose storage inliver cells. In certain embodiments, insulin resistance is improved infat cells, leading to reduced hydrolysis of triglycerides, andconsequently reduced free fatty acid in the blood.

“Metabolic disorder” means a condition characterized by an alteration ordisturbance in one or more metabolic processes in the body. Metabolicdisorders include, but are not limited to, hyperglycemia, prediabetes,diabetes, type 1 diabetes, type 2 diabetes, obesity, diabeticdyslipidemia, metabolic syndrome, and hyperinsulinemia. “Diabetes” or“diabetes mellitus” means a disease in which the body does not produceor properly use insulin, resulting in abnormally high blood glucoselevels. In certain embodiments, diabetes is type 1 diabetes. In certainembodiments, diabetes is type 2 diabetes.

“Prediabetes” means a condition in which a subject's blood glucoselevels are higher than in a subject with normal blood glucose levels butlower but not high enough for a diagnosis of diabetes.

“Type 1 diabetes” means diabetes characterized by loss of theinsulin-producing beta cells of the islets of Langerhans in the pancreasleading to a deficiency of insulin (also known as insulin-dependentdiabetes mellitus or IDDM). Type I diabetes can affect children oradults, but typically appears between the ages of 10 and 16.

“Type 2 diabetes” means diabetes characterized by insulin resistance andrelative insulin deficiency (also known as diabetes mellitus type 2, andformerly called diabetes mellitus type 2, non-insulin-dependent diabetes(NIDDM), obesity related diabetes, or adult-onset diabetes).

“Obesity” means an excessively high amount of body fat or adipose tissuein relation to lean body mass. The amount of body fat (or adiposity)includes both the distribution of fat throughout the body and the sizeof the adipose tissue deposits. Body fat distribution can be estimatedby skin-fold measures, waist-to-hip circumference ratios, or techniquessuch as ultrasound, computed tomography, or magnetic resonance imaging.According to the Center for Disease Control and Prevention, individualswith a body mass index (BMI) of 30 or more are considered obese.

“Diabetic dyslipidemia” or “Type 2 diabetes with dyslipidemia” means acondition characterized by Type 2 diabetes, reduced HDL-C, elevatedserum triglycerides, and elevated small, dense LDL particles.

“Metabolic syndrome” means a condition characterized by a clustering oflipid and nonlipid risk factors of metabolic origin. In certainembodiments, metabolic syndrome is identified by the presence of any 3of the following factors: waist circumference of greater than 102 cm inmen or greater than 88 cm in women; serum triglyceride of at least 150mg/dL; HDL-C less than 40 mg/dL in men or less than 50 mg/dL in women;blood pressure of at least 130/85 mmHg; and fasting glucose of at least110 mg/dL. These determinants can be readily measured in clinicalpractice (JAMA, 2001, 285: 2486-2497).

“Steatosis” means a condition characterized by the excessiveaccumulation of triglycerides in hepatocytes.

“Steatohepatitis” means steatosis with inflammation.

“Non-alcoholic fatty liver disease (NAFLD)” means a conditioncharacterized by accumulation of fat in the liver in subjects whoconsume little to no alcohol. In certain embodiments, NAFLD is relatedto insulin resistance and the metabolic syndrome. “Nonalcoholicsteatohepatitis (NASH)” means a condition characterized by accumulationof fat in the liver, combined with inflammation and scarring in theliver. In certain embodiments NASH results from a worsening progressionof NAFLD.

“Alcoholic steatohepatitis (ASH)” means an alcohol-induced conditioncharacterized by accumulation of fat in the liver, combined withinflammation and scarring in the liver.

“Glucose Tolerance Test” or “GTT” means a test performed to determinehow quickly glucose is cleared from the blood. Typically, the testinvolves administration of glucose, followed by measurement of glucoselevels in blood at intervals over a period of time. “IPGTT” means a GTTperformed following intraperitoneal injection of glucose. “OGTT” means aGTT performed following oral administration of glucose. In certainembodiments, a GTT is used to test for pre-diabetes. In certainembodiments, a GTT is used to identify a subject with diabetes. Incertain embodiments, a GTT is used to identify a subject at risk fordeveloping diabetes. In certain embodiments a GTT is used to identify asubject having insulin resistance.

“Insulin Tolerance Test (ITT)” means a test performed to measure insulinsensitivity through hormone response to the stress of a low blood sugarlevel. In certain embodiments, a ITT is used to test for pre-diabetes.In certain embodiments, a ITT is used to identify a subject withdiabetes. In certain embodiments, a ITT is used to identify a subject atrisk for developing diabetes. In certain embodiments a ITT is used toidentify a subject having insulin resistance.

“Metabolic rate” means the rate of metabolism or the amount of energyexpended in a given period. “Basal metabolic rate” means the amount ofenergy expended while at rest in a neutrally temperate environment, inthe post-absorptive state (meaning that the digestive system isinactive, which requires about twelve hours of fasting in humans); therelease of energy in this state is sufficient only for the functioningof the vital organs, such as the heart, lungs, brain and the rest of thenervous system, liver, kidneys, sex organs, muscles and skin.

“Target nucleic acid” means a nucleic acid to which an oligonucleotideis designed to hybridize.

“Target RNA” means an RNA to which an oligonucleotide is complementary.

“Targeting” means the process of design and selection of nucleobasesequence that will hybridize to a target nucleic acid.

“Targeted to” means having a nucleobase sequence that will allowhybridization to a target nucleic acid.

“Target engagement” means the interaction of an oligonucleotide with themicroRNA to which it is complementary, in a manner that changes theactivity, expression or level of the microRNA. In certain embodiments,target engagement means an anti-miR interacting with the microRNA towhich it is complementary, such that the activity of the microRNA isinhibited.

“Modulation” means a perturbation of function, amount, or activity. Incertain embodiments, modulation means an increase in function, amount,or activity. In certain embodiments, modulation means a decrease infunction, amount, or activity.

“Expression” means any functions and steps by which a gene's codedinformation is converted into structures present and operating in acell.

“5′ target site” means the nucleobase of a target nucleic acid which iscomplementary to the 3′-most nucleobase of a particular oligonucleotide.

“3′ target site” means the nucleobase of a target nucleic acid which iscomplementary to the 5′-most nucleobase of a particular oligonucleotide.

“Region” means a portion of linked nucleosides within a nucleic acid. Incertain embodiments, an oligonucleotide has a nucleobase sequence thatis complementary to a region of a target nucleic acid. For example, incertain embodiments an oligonucleotide is complementary to a region of amicroRNA stem-loop sequence. In certain embodiments, an oligonucleotideis fully complementary to a region of a microRNA stem-loop sequence.

“Segment” means a smaller or sub-portion of a region.

“MicroRNA” means an endogenous non-coding RNA between 18 and 25nucleobases in length, which is the product of cleavage of apre-microRNA by the enzyme Dicer. Examples of mature microRNAs are foundin the microRNA database known as miRBase(http://microrna.sanger.ac.uk/). In certain embodiments, microRNA isabbreviated as “microRNA” or “miR.”

“Pre-microRNA” or “pre-miR” means a non-coding RNA having a hairpinstructure, which is the product of cleavage of a pri-miR by thedouble-stranded RNA-specific ribonuclease known as Drosha.

“Stem-loop sequence” means an RNA having a hairpin structure andcontaining a mature microRNA sequence. Pre-microRNA sequences andstem-loop sequences may overlap. Examples of stem-loop sequences arefound in the microRNA database known as miRBase(http://microrna.sanger.ac.uk/).

“Pri-microRNA” or “pri-miR” means a non-coding RNA having a hairpinstructure that is a substrate for the double-stranded RNA-specificribonuclease Drosha.

“microRNA precursor” means a transcript that originates from a genomicDNA and that comprises a non-coding, structured RNA comprising one ormore microRNA sequences. For example, in certain embodiments a microRNAprecursor is a pre-microRNA. In certain embodiments, a microRNAprecursor is a pri-microRNA.

“microRNA-regulated transcript” means a transcript that is regulated bya microRNA.

“Monocistronic transcript” means a microRNA precursor containing asingle microRNA sequence.

“Polycistronic transcript” means a microRNA precursor containing two ormore microRNA sequences.

“Seed sequence” means a nucleobase sequence comprising from 6 to 8contiguous nucleobases of nucleobases 1 to 9 of the 5′-end of a maturemicroRNA sequence.

“Seed match sequence” means a nucleobase sequence that is complementaryto a seed sequence, and is the same length as the seed sequence.

“Anti-miR” means an oligonucleotide having nucleobase sequencecomplementary to a microRNA. In certain embodiments, an anti-miR is amodified oligonucleotide.

“Anti-miR-103/107,” means an oligonucleotide having a nucleobasesequence complementary to miR-103 and miR107. In certain embodiments, ananti-miR-103/107 is 90% complementary to miR-103 and miR-107. In somesuch embodiments, an anti-miR-103/107 oligonucleotide consists of 10linked nucleosides wherein 9 linked nucleotides are fully complementaryto miR-103 and miR-107, and one nucleoside is a mismatch. In some suchembodiments, the mismatch is located at the 3′ end of theanti-miR-103/107 oligonucleotide. In certain embodiments, ananti-miR-103/107 is at least 80%, at least 85%, at least 90%, or atleast 95% complementary to miR-103 and miR-107. In certain embodiments,an anti-miR-103/107 is a modified oligonucleotide.

“Fully modified oligonucleotide” means each nucleobase, each sugar,and/or each internucleoside linkage is modified.

“Uniformly modified oligonucleotide” means each nucleobase, each sugar,and/or each internucleoside linkage has the same modification throughoutthe modified oligonucleotide.

“Gapmer” means a modified oligonucleotide having an internal region oflinked β-D-deoxyribonucleosides positioned between two external regionsof linked nucleosides, where each nucleoside of each external regioncomprises a modified sugar moiety. The β-D-deoxyribonucleosides may ormay not have a modified nucleobase.

“Gap” is an internal region of a gapmer that is positioned between theexternal regions.

“Wing” is an external region of a gapmer that is adjacent to a 5′ or 3′end of the internal region of the gapmer.

“Symmetric gapmer” means each nucleoside of each external regioncomprises the same sugar modification.

“Asymmetric gapmer” means each nucleoside of one external regioncomprises a first sugar modification, and each nucleoside of the otherexternal region comprises a second sugar modification.

“Nucleobase sequence” means the order of contiguous nucleobases in anoligomeric compound or nucleic acid, typically listed in a 5′ to 3′orientation, independent of any sugar, linkage, and/or nucleobasemodification.

“Contiguous nucleobases” means nucleobases immediately adjacent to eachother in a nucleic acid.

“Nucleobase complementarity” means the ability of two nucleobases topair non-covalently via hydrogen bonding.

“Complementary” means that one nucleic acid is capable of hybrizing toanother nucleic acid or oligonucleotide. In certain embodiments,complementary refers to an oligonucleotide capable of hybridizing to atarget nucleic acid.

“Fully complementary” means each nucleobase of an oligonucleotide iscapable of pairing with a nucleobase at each corresponding position in atarget nucleic acid. In certain embodiments, an oligonucleotide is fullycomplementary to a microRNA, i.e. each nucleobase of the oligonucleotideis complementary to a nucleobase at a corresponding position in themicroRNA. In certain embodiments, an oligonucleotide wherein eachnucleobase has complementarity to a nucleobase within a region of amicroRNA stem-loop sequence is fully complementary to the microRNAstem-loop sequence.

“Percent complementarity” means the percentage of nucleobases of anoligonucleotide that are complementary to an equal-length portion of atarget nucleic acid. Percent complementarity is calculated by dividingthe number of nucleobases of the oligonucleotide that are complementaryto nucleobases at corresponding positions in the target nucleic acid bythe total number of nucleobases in the oligonucleotide.

“Percent identity” means the number of nucleobases in first nucleic acidthat are identical to nucleobases at corresponding positions in a secondnucleic acid, divided by the total number of nucleobases in the firstnucleic acid. In certain embodiments, the first nucleic acid is amicroRNA and the second nucleic acid is a microRNA. In certainembodiments, the first nucleic acid is an oligonucleotide and the secondnucleic acid is an oligonucleotide.

“Hybridize” means the annealing of complementary nucleic acids thatoccurs through nucleobase complementarity.

“Mismatch” means a nucleobase of a first nucleic acid that is notcapable of pairing with a nucleobase at a corresponding position of asecond nucleic acid.

“Identical” in the context of nucleobase sequences, means having thesame nucleobase sequence, independent of sugar, linkage, and/ornucleobase modifications and independent of the methyl state of anypyrimidines present.

“miR-103” means the mature miRNA having the nucleobase sequence setforth in SEQ ID NO: 1 (AGCAGCAUUGUACAGGGCUAUGA).

“miR-107” means the mature miRNA having the nucleobase sequence setforth in SEQ ID NO: 2 (AGCAGCAUUGUACAGGGCUAUCA). “miR-103-1 stem-loopsequence” means the miR-103 precursor having the nucleobase sequence setforth in SEQ ID NO: 3 (UACUGCCCUCGGCUUCUUUACAGUGCUGCCUUGUUGCAUAUGGAUCAAGCAGCAUUGUACAGGGCUAUG AAGGCAUUG).

“miR-103-2” means the miR-103 precursor having the nucleobase sequenceset forth in SEQ ID NO: 4 (UUGUGCUUUCAGCUUCUUUACAGUGCUGCCUUGUAGCAUUCAGGUCAAGCAGCAUUGUACAGGGCUAUGAAAGAACCA).

“miR-107 stem loop sequence” means the miR-107 precursor having thenucleobase sequence set forth in SEQ ID NO: 5(CUCUCUGCUUUCAGCUUCUUUACAGUGUUGCCUUGUGGCAUGGAGUUCAAGCAGCAUUGUACAGGGCUAUCAAAGCACAGA).

“miR-103/miR-107” means a microRNA having the nucleobase sequence of SEQID NO: 1 or SEQ ID NO: 2.

“Oligomeric compound” means a compound that comprises a plurality oflinked monomeric subunits. Oligomeric compounds includedoligonucleotides.

“Oligonucleotide” means a compound comprising a plurality of linkednucleosides, each of which can be modified or unmodified, independentfrom one another.

“Naturally occurring internucleoside linkage” means a 3′ to 5′phosphodiester linkage between nucleosides.

“Internucleoside linkage” means a covalent linkage between adjacentnucleosides.

“Linked nucleosides” means nucleosides joined by a covalent linkage.

“Nucleobase” means a heterocyclic moiety capable of non-covalentlypairing with another nucleobase.

“Nucleoside” means a nucleobase linked to a sugar moiety.

“Nucleotide” means a nucleoside having a phosphate group covalentlylinked to the sugar portion of a nucleoside.

“Compound comprising a modified oligonucleotide consisting of” a numberof linked nucleosides means a compound that includes a modifiedoligonucleotide having the specified number of linked nucleosides. Thus,the compound may include additional substituents or conjugates. Unlessotherwise indicated, the compound does not include any additionalnucleosides beyond those of the modified oligonucleotide.

“Modified oligonucleotide” means an oligonucleotide having one or moremodifications relative to a naturally occurring terminus, sugar,nucleobase, and/or internucleoside linkage. A modified oligonucleotidemay comprise unmodified nucleosides.

A “region of a modified oligonucleotide” refers to a portion set forthas oligo1, oligo2, or oligo3 in the modified oligonucleotide structuresshown herein (e.g., [oligo1]-[x-N]_(m)-x-[oligo2] or[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3]). A region of amodified oligonucleotide may be an anti-miR-103/107. In someembodiments, each region of a modified oligonucleotide is ananti-miR-103/107. Thus, in some embodiments, a modified oligonucleotidemay have the structure[anti-miR-103/107]-[x-N]_(m)-x-[anti-miR-103/107].

“Single-stranded modified oligonucleotide” means a modifiedoligonucleotide which is not hybridized to a complementary strand.

“Modified nucleoside” means a nucleoside having any change from anaturally occurring nucleoside. A modified nucleoside may have amodified sugar, and unmodified nucleobase. A modified nucleoside mayhave a modified sugar and a modified nucleobase. A modified nucleosidemay have a natural sugar and a modified nucleobase.

“2′-modified nucleoside” means a nucleoside comprising a sugar with anymodification at the position equivalent to the 2′ position of thefuranosyl ring as the positions are numbered in 2-deoxyribose or ribose.It is to be understood that 2′-modified nucleosides include, withoutlimitation, nucleosides comprising bicyclic sugar moieties.

“Modified internucleoside linkage” means any change from a naturallyoccurring internucleoside linkage.

“Phosphorothioate internucleoside linkage” means a linkage betweennucleosides where one of the non-bridging atoms is a sulfur atom.

A “phosphorothioate linkage” means a linkage between two chemicalmoieties having the same structure as a phosphorothioate internucleosidelinkage, e.g., —OP(O)(S)O—.

A “phosphodiester linkage” means a linkage between two chemical moietieshaving the same structure as a phosphodiester internucleoside linkage,e.g., —OP(P)₂O—.

“Unmodified nucleobase” means the naturally occurring heterocyclic basesof RNA or DNA: the purine bases adenine (A) and guanine (G), and thepyrimidine bases thymine (T), cytosine (C) (including 5-methylcytosine),and uracil (U).

“5-methylcytosine” means a cytosine comprising a methyl group attachedto the 5 position.

“Modified nucleobase” means any nucleobase that is not an unmodifiednucleobase.

“Furanosyl” means a structure comprising a 5-membered ring consisting offour carbon atoms and one oxygen atom.

“Naturally occurring furanosyl” means a ribofuranosyl as found innaturally occurring RNA or a deoxyribofuranosyl as found in naturallyoccurring DNA.

“Sugar moiety” means a naturally occurring furanosyl or a modified sugarmoiety.

“Modified sugar moiety” means a substituted sugar moiety or a sugarsurrogate.

“Substituted sugar moiety” means a furanosyl that is not a naturallyoccurring furanosyl. Substituted sugar moieties include, but are notlimited to sugar moieties comprising modifications at the 2′-position,the 5′-position and/or the 4′-position of a naturally occurringfuranosyl. Certain substituted sugar moieties are bicyclic sugarmoieties.

“Sugar surrogate” means a structure that does not comprise a furanosyland that is capable of replacing the naturally occurring furanosyl of anucleoside, such that the resulting nucleoside is capable of (1)incorporation into an oligonucleotide and (2) hybridization to acomplementary nucleoside. Such structures include relatively simplechanges to the furanosyl, such as rings comprising a different number ofatoms (e.g., 4, 6, or 7-membered rings); replacement of the oxygen ofthe furanosyl with a non-oxygen atom (e.g., carbon, sulfur, ornitrogen); or both a change in the number of atoms and a replacement ofthe oxygen. Such structures may also comprise substitutionscorresponding with those described for substituted sugar moieties (e.g.,6-membered carbocyclic bicyclic sugar surrogates optionally comprisingadditional substituents). Sugar surrogates also include more complexsugar replacements (e.g., the non-ring systems of peptide nucleic acid).Sugar surrogates include without limitation morpholinos, cyclohexenylsand cyclohexitols.

“β-D-deoxyribose” means a naturally occurring DNA sugar moiety.

“β-D-ribose” means a naturally occurring RNA sugar moiety.

“2′-O-methyl sugar” or “2′-OMe sugar” means a sugar having a O-methylmodification at the 2′ position.

“2′-O-methoxyethyl sugar” or “2′-MOE sugar” means a sugar having aO-methoxyethyl modification at the 2′ position.

“2′-fluoro” or “2′-F” means a sugar having a fluoro modification of the2′ position.

“Bicyclic sugar moiety” means a modified sugar moiety comprising a 4 to7 membered ring (including by not limited to a furanosyl) comprising abridge connecting two atoms of the 4 to 7 membered ring to form a secondring, resulting in a bicyclic structure. In certain embodiments, the 4to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7membered ring is a furanosyl. In certain such embodiments, the bridgeconnects the 2′-carbon and the 4′-carbon of the furanosyl. Nonlimitingexemplary bicyclic sugar moieties include LNA, ENA, cEt, S-cEt, andR-cEt.

“Locked nucleic acid (LNA) sugar moiety” means a substituted sugarmoiety comprising a (CH₂)—O bridge between the 4′ and 2′ furanose ringatoms.

“ENA sugar moiety” means a substituted sugar moiety comprising a(CH₂)₂—O bridge between the 4′ and 2′ furanose ring atoms.

“Constrained ethyl (cEt) sugar moiety” means a substituted sugar moietycomprising a CH(CH₃)—O bridge between the 4′ and the 2′ furanose ringatoms. In certain embodiments, the CH(CH₃)—O bridge is constrained inthe S orientation. In certain embodiments, the CH(CH₃)—O bridge isconstrained in the R orientation.

“S-cEt sugar moiety” means a substituted sugar moiety comprising anS-constrained CH(CH₃)—O bridge between the 4′ and the 2′ furanose ringatoms.

“R-cEt sugar moiety” means a substituted sugar moiety comprising anR-constrained CH(CH₃)—O bridge between the 4′ and the 2′ furanose ringatoms.

“2′-O-methyl nucleoside” means a modified nucleoside having a2′-O-methyl sugar modification.

“2′-O-methoxyethyl nucleoside” means a modified nucleoside having a2′-O-methoxyethyl sugar modification. A 2′-O-methoxyethyl nucleoside maycomprise a modified or unmodified nucleobase.

“2′-fluoro nucleoside” means a modified nucleoside having a 2′-fluorosugar modification. A 2′-fluoro nucleoside may comprise a modified orunmodified nucleobase.

“Bicyclic nucleoside” means a modified nucleoside having a bicyclicsugar moiety. A bicyclic nucleoside may have a modified or unmodifiednucleobase.

“cEt nucleoside” means a nucleoside comprising a cEt sugar moiety. A cEtnucleoside may comprise a modified or unmodified nucleobase.

“S-cEt nucleoside” means a nucleoside comprising an S-cEt sugar moiety.

“R-cEt nucleoside” means a nucleoside comprising an R-cEt sugar moiety.

“Non-bicyclic nucleoside” means a nucleoside that has a sugar other thana bicyclic sugar. In certain embodiments, a non-bicyclic nucleosidecomprises a naturally occurring sugar. In certain embodiments, anon-bicyclic nucleoside comprises a modified sugar. In certainembodiments, a non-bicyclic nucleoside is a β-D-deoxyribonucleoside. Incertain embodiments, a non-bicyclic nucleoside is a 2′-O-methoxyethylnucleoside.

“β-D-deoxyribonucleoside” means a naturally occurring DNA nucleoside.

“β-D-ribonucleoside” means a naturally occurring RNA nucleoside.

“LNA nucleoside” means a nucleoside comprising a LNA sugar moiety.

“ENA nucleoside” means a nucleoside comprising an ENA sugar moiety.

“Motif” means a pattern of modified and/or unmodified nucleobases,sugars, and/or internucleoside linkages in an oligonucleotide. Incertain embodiments, a motif is a nucleoside pattern.

“Nucleoside pattern” means a pattern of nucleoside modifications in anoligonucleotide or a region thereof. A nucleoside pattern is a motifthat describes the arrangement of nucleoside modifications in anoligonucleotide.

“Stabilizing modification” means a modification to a nucleoside thatprovides enhanced stability to a modified oligonucleotide, in thepresence of nucleases, relative to that provided by 2′-deoxynucleosideslinked by phosphodiester internucleoside linkages. For example, incertain embodiments, a stabilizing modification is a stabilizingnucleoside modification. In certain embodiments, a stabilizingmodification is a internucleoside linkage modification.

“Stabilizing nucleoside” means a nucleoside modified to provide enhancednuclease stability to an oligonucleotide, relative to that provided by a2′-deoxynucleoside. In one embodiment, a stabilizing nucleoside is a2′-modified nucleoside.

“Stabilizing internucleoside linkage” means an internucleoside linkagethat provides improved nuclease stability to an oligonucleotide relativeto that provided by a phosphodiester internucleoside linkage. In oneembodiment, a stabilizing internucleoside linkage is a phosphorothioateinternucleoside linkage.

A “linking group” as used herein refers to an atom or group of atomsthat attach a first chemical entity to a second chemical entity via oneor more covalent bonds.

A “linker” as used herein, refers to an atom or group of atoms thatattach one or more ligands to a modified or unmodified nucleoside viaone or more covalent bonds. The modified or unmodified nucleoside may bepart of a modified oligonucleotide as described herein, or may beattached to a modified oligonucleotide through a phosphodiester orphosphorothioate bond. In some embodiments, the linker attaches one ormore ligands to the 3′ end of a modified oligonucleotide. In someembodiments, the linker attaches one or more ligands to the 5′ end of amodified oligonucleotide. In some embodiments, the linker attaches oneor more ligands to a modified or unmodified nucleoside that is attachedto the 3′ end of a modified oligonucleotide. In some embodiments, thelinker attaches one or more ligands to a modified or unmodifiednucleoside that is attached to the 5′ end of a modified oligonucleotide.When the linker attaches one or more ligands to the 3′ end of a modifiedoligonucleotide or to a modified or unmodified nucleoside attached tothe 3′ end of a modified oligonucleotide, in some embodiments, theattachment point for the linker may be the 3′ carbon of a modified orunmodified sugar moiety. When the linker attaches one or more ligands tothe 5′ end of a modified oligonucleotide or to a modified or unmodifiednucleoside attached to the 5′ end of a modified oligonucleotide, in someembodiments, the attachment point for the linker may be the 5′ carbon ofa modified or unmodified sugar moiety.

“Subject” means a human or non-human animal selected for treatment ortherapy.

“Subject in need thereof” means the state in which a subject isidentified as in need of a therapy or treatment.

“Subject suspected of having” means a subject exhibiting one or moreclinical indicators of a disease.

“Administering” means providing a pharmaceutical agent or composition toa subject, and includes, but is not limited to, administering by amedical professional and self-administering.

“Parenteral administration” means administration through injection orinfusion. Parenteral administration includes, but is not limited to,subcutaneous administration, intravenous administration, orintramuscular administration.

“Subcutaneous administration” means administration just below the skin.

“Intravenous administration” means administration into a vein.

“Intracardial administration” means administration into the heart. Incertain embodiments, intracardial administration occurs by way of acatheter. In certain embodiments, intracardial administration occurs byway of open heart surgery.

“Pulmonary administration” means administration to the lungs.

“Administered concomitantly” refers to the co-administration of twoagents in any manner in which the pharmacological effects of both aremanifest in the patient at the same time. Concomitant administrationdoes not require that both agents be administered in a singlepharmaceutical composition, in the same dosage form, or by the sameroute of administration. The effects of both agents need not manifestthemselves at the same time. The effects need only be overlapping for aperiod of time and need not be coextensive.

“Duration” means the period of time during which an activity or eventcontinues. In certain embodiments, the duration of treatment is theperiod of time during which doses of a pharmaceutical agent orpharmaceutical composition are administered.

“Therapy” means a disease treatment method. In certain embodiments,therapy includes, but is not limited to, chemotherapy, radiationtherapy, or administration of a pharmaceutical agent.

“Treatment” means the application of one or more specific proceduresused for the cure or amelioration of a disease. In certain embodiments,the specific procedure is the administration of one or morepharmaceutical agents.

“Amelioration” means a lessening of severity of at least one indicatorof a condition or disease. In certain embodiments, amelioration includesa delay or slowing in the progression of one or more indicators of acondition or disease. The severity of indicators may be determined bysubjective or objective measures which are known to those skilled in theart.

“At risk for developing” means the state in which a subject ispredisposed to developing a condition or disease. In certainembodiments, a subject at risk for developing a condition or diseaseexhibits one or more symptoms of the condition or disease, but does notexhibit a sufficient number of symptoms to be diagnosed with thecondition or disease. In certain embodiments, a subject at risk fordeveloping a condition or disease exhibits one or more symptoms of thecondition or disease, but to a lesser extent required to be diagnosedwith the condition or disease.

“Prevent the onset of” means to prevent the development a condition ordisease in a subject who is at risk for developing the disease orcondition. In certain embodiments, a subject at risk for developing thedisease or condition receives treatment similar to the treatmentreceived by a subject who already has the disease or condition.

“Delay the onset of” means to delay the development of a condition ordisease in a subject who is at risk for developing the disease orcondition. In certain embodiments, a subject at risk for developing thedisease or condition receives treatment similar to the treatmentreceived by a subject who already has the disease or condition.

“Therapeutic agent” means a pharmaceutical agent used for the cure,amelioration or prevention of a disease.

“Dose” means a specified quantity of a pharmaceutical agent provided ina single administration. In certain embodiments, a dose may beadministered in two or more boluses, tablets, or injections. Forexample, in certain embodiments, where subcutaneous administration isdesired, the desired dose requires a volume not easily accommodated by asingle injection. In such embodiments, two or more injections may beused to achieve the desired dose. In certain embodiments, a dose may beadministered in two or more injections to minimize injection sitereaction in an individual.

“Dosage unit” means a form in which a pharmaceutical agent is provided.In certain embodiments, a dosage unit is a vial containing lyophilizedoligonucleotide. In certain embodiments, a dosage unit is a vialcontaining reconstituted oligonucleotide.

“Therapeutically effective amount” refers to an amount of apharmaceutical agent that provides a therapeutic benefit to an animal.

“Pharmaceutical composition” means a mixture of substances suitable foradministering to an individual that includes a pharmaceutical agent. Forexample, a pharmaceutical composition may comprise a sterile aqueoussolution.

“Pharmaceutical agent” means a substance that provides a therapeuticeffect when administered to a subject.

“Active pharmaceutical ingredient” means the substance in apharmaceutical composition that provides a desired effect.

“Pharmaceutically acceptable salt” means a physiologically andpharmaceutically acceptable salt of a compound provided herein, i.e., asalt that retains the desired biological activity of the compound anddoes not have undesired toxicological effects when administered to asubject. Nonlimiting exemplary pharmaceutically acceptable salts ofcompounds provided herein include sodium and potassium salt forms. Theterm “compound” as used herein includes pharmaceutically acceptablesalts thereof unless specifically indicated otherwise.

“Improved liver function” means the change in liver function towardnormal limits. In certain embodiments, liver function is assessed bymeasuring molecules found in a subject's blood. For example, in certainembodiments, improved liver function is measured by a reduction in bloodliver transaminase levels.

“Acceptable safety profile” means a pattern of side effects that iswithin clinically acceptable limits.

“Side effect” means a physiological response attributable to a treatmentother than desired effects. In certain embodiments, side effectsinclude, without limitation, injection site reactions, liver functiontest abnormalities, renal function abnormalities, liver toxicity, renaltoxicity, central nervous system abnormalities, and myopathies. Suchside effects may be detected directly or indirectly. For example,increased aminotransferase levels in serum may indicate liver toxicityor liver function abnormality. For example, increased bilirubin mayindicate liver toxicity or liver function abnormality.

“Injection site reaction” means inflammation or abnormal redness of skinat a site of injection in an individual.

“Subject compliance” means adherence to a recommended or prescribedtherapy by a subject.

“Comply” means the adherence with a recommended therapy by a subject.

“Recommended therapy” means a treatment recommended by a medicalprofessional for the treatment, amelioration, or prevention of adisease.

Overview

Metabolic disorders are characterized by one or more abnormalities inmetabolic function in the body. Certain metabolic disorders are relatedto defects in how the body uses blood glucose, resulting in abnormallyhigh levels of blood glucose. Metabolic disorders may also becharacterized by a deficiency in insulin production, or a deficiency insensitivity to insulin. Metabolic disorders affect millions of peopleworldwide, and can be life-threatening disorders. As such, there is aneed for method and compositions to treat, prevent, or delay the onsetof metabolic disorders.

The administration of oligonucleotides complementary to miR-103 and/ormiR-107 resulted in improved blood glucose levels, decreasedgluconeogenesis, enhanced insulin sensitivity, and decreased plasmacholesterol. See, e.g., PCT Publication No. 2010/133970 A1. Theseeffects were observed in animal models of diabetes/insulin resistance.Also observed was a decrease in body weight, which was due to a decreasein body fat. As miR-103 and miR-107 differ by one nucleobase, anoligonucleotide having a sequence complementary to the nucleobasesequence of miR-103 may hybridize to and inhibit the activity of bothmiR-103 and miR-107. Likewise, an oligonucleotide having a sequencecomplementary to the nucleobase sequence of miR-107 may hybridize to andinhibit the activity of both miR-103 and miR-107. As such,oligonucleotides complementary to either one or both of miR-103 andmiR-107 may be used to achieve the phenotypic outcomes described herein.

Administration of a compound comprising an oligonucleotide complementaryto miR-103, miR-107 or a precursor thereof may result in one or moreclinically desirable outcomes. Such clinically desirable outcomesinclude but are not limited to reduced blood glucose levels, reducedhemoglobin Alc (HbAlc) levels, improved glucose tolerance, improvedinsulin resistance, and reduced gluconeogenesis.

Accordingly, provided herein are methods and compositions to reduceblood glucose levels, decrease gluconeogenesis, improve insulinsensitivity, and decrease plasma cholesterol. Also provided herein aremethods to treat, prevent, or delay the onset of metabolic disordersthat are related to elevated blood glucose levels, increasedgluconeogenesis, impaired insulin sensitivity, and increased plasmacholesterol. In certain embodiments, metabolic disorders include, butare not limited to, prediabetes, diabetes, including Type 1 or Type 2diabetes, metabolic syndrome, obesity, diabetic dyslipidemia,hyperglycemia, hypoglycemia, and hyperinsulinemia. In certainembodiments, a subject having a metabolic disorder has a fatty liverdisease. In certain embodiments, fatty liver diseases include, but arenot limited to, non-alcoholic fatty liver disease (NAFLD), alchoholicfatty liver disease, and non-alchoholic steatohepatitis (NASH).

The present invention provides a novel structure that allowsadministration of a single compound, which comprises a modifiedoligonucleotide comprising two or more regions, each of which istargeted to a microRNA (which may be the same or different). Themodified oligonucleotide comprises one or more phosphodiester bondsand/or unmodified nucleosides between the regions, which allow for atleast partial degradation of the modified oligonucleotide into itsseparate regions, e.g., in a target tissue, thereby allowing each regionto target its respective microRNA separately in the target tissue.

The activity of a modified oligonucleotide is based on the specifichybridization event that occurs between a modified oligonucleotide andits target RNA and produces a desired pharmacological endpoint. In orderfor this to occur, certain pharmacokinetic processes must take place,for example, delivery of an intact drug to the target cell or tissue,and entry of the modified oligonucleotide into the cell containing thetarget RNA. Modified oligonucleotides may be conjugated to one or moremoieties which improve delivery to the target cell or tissue and/orcellular uptake of the oligonucleotide, ultimately resulting in enhancedpotency. For example, increased cellular uptake of compounds may beachieved by utilizing conjugates that are ligands for cell-surfacereceptors. The binding of a ligand conjugated to an exogenous molecule(e.g., a drug) to its cell surface receptor leads to receptor-mediatedendocytosis of the conjugated molecule, thereby facilitatingtransmembrane transport of the exogenous molecule. For example, thetargeted delivery to hepatocyte cells may be achieved by covalentlyattaching a conjugate comprising a carbohydrate moiety to a modifiedoligonucleotide. Upon recognition and binding of the carbohydrate moietyby the asialoglycoprotein receptor present on the surface of ahepatocyte cell, the conjugated modified oligonucleotide is transportedacross the cell membrane into the hepatocyte. By improving delivery inthis manner, the potency of the modified oligonucleotide can beenhanced, as a lower does of compound is required to achieve the desiredpharmacological endpoint.

Certain conjugates described herein have the advantage of providingimproved delivery to target cell types and also being cleavable in vivoto produce the unconjugated modified oligonucleotide upon in vivoadministration. As described above, in vivo targeting to a specifictissue or cell type may be enhanced by using a conjugate moiety. Oncethe conjugated modified oligonucleotide reaches its site of action,however, the presence of all or part of the covalently-linked conjugatemoiety may alter the activity of certain conjugated modifiedoligonucleotides or may impact the analyses required to understandcertain pharmacokinetic properties of the modified oligonucleotide, suchas half-life in the target cell. As such, it may be desirable toadminister a compound comprising a modified oligonucleotide attached toa conjugate moiety that is sufficiently stable to improve cellularuptake, but also allows for cleavage of the conjugate moiety once thecompound has been internalized by the target cell. Accordingly, providedherein are compounds comprising a modified oligonucleotide linked to acleavable conjugate moiety, which improve the potency of the modifiedoligonucleotide and permit partial or completed release of the modifiedoligonucleotide in its unconjugated form.

In certain embodiments, provided herein is a compound comprising amodified oligonucleotide having two regions, each of which is targetedto miR-103 and miR-107. The compound is efficacious in experimentalmodels of diabetes, as evidenced by reduced glucose levels, improvedHOMA-IR and improved insulin sensitivity. The compound additionallyresults in decreased liver triglyceride levels. The compound has beenoptimized based on several criteria, including efficacy, safety,viscosity in solution, and cross-reactivity with non-specific microRNAsequences.

In certain embodiments, provided herein are methods for reducing bloodglucose levels in a subject comprising administering to the subject acompound described herein, wherein the compound comprises a modifiedoligonucleotide having at least one region consisting of 7 to 12 linkednucleosides and having a nucleobase sequence complementary to miR-103and/or miR-107. In some embodiments, the compound comprises a modifiedoligonucleotide having two regions, wherein each region consists of 7 to12 linked nucleosides and has a nucleobase sequence complementary tomiR-103 and/or miR-107. In some embodiments, each region consists of 10linked nucleosides and has a nucleobase sequence complementary tomiR-103 and/or miR-107.

In some embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages. In certainembodiments, Y is linked to the 3′ terminus of MO.

In certain embodiments, provided herein are methods for reducing bloodglucose levels in a subject comprising administering to the subject acompound described herein.

In certain embodiments, the methods provided herein comprise measuringblood glucose levels. Blood glucose levels may be measured before and/orafter administration of a compound described herein. Blood glucoselevels may be measured in whole blood, or may be measured in plasma.Blood glucose levels may be measured in a clinical laboratory, or may bemeasured using a blood glucose meter.

In certain embodiments, blood glucose levels are measured in a subjectwhen the subject has fasted for at least 8 hours. In certainembodiments, blood glucose levels are measured at random times, and themeasurement is not timed according to the intake of food or drink. Incertain embodiments, blood glucose levels are measured in thepost-prandial state, i.e. after the subject has eaten a meal. In certainembodiments, blood glucose levels are measured in a subject two hoursafter the subject has eaten a meal. In certain embodiments, bloodglucose levels are measured at timed intervals following administrationof glucose to the subject, in order to determine how quickly thesubject's body clears glucose from the blood. Any measurements of bloodglucose levels may be made in whole blood or in plasma.

In certain embodiments, the subject has elevated blood glucose levels.In certain embodiments, a subject is identified as having elevated bloodglucose levels. Such identification is typically made by a medicalprofessional. In certain embodiments, an elevated blood glucose levelsis a fasting blood glucose level between 100 and 125 mg/dL. In certainembodiments, an elevated blood glucose level is a fasting blood glucoselevel above 126 mg/dL. In certain embodiments, an elevated blood glucoselevel is a two-hour post-prandial glucose level between 140 and 199mg/dL. In certain embodiments, an elevated blood glucose level is atwo-hour post-prandial glucose level at 200 mg/dL or higher.

In certain embodiments, a subject having elevated blood glucose levelshas pre-diabetes. In certain embodiments, a subject is identified ashaving pre-diabetes. In certain such embodiments, the subject has afasting blood glucose level between 100 and 125 mg/dL. In certain suchembodiments, the subject has a two-hour post-prandial blood glucoselevel between 140 and 199 mg/dL. A diagnosis of pre-diabetes istypically made by a medical professional, who may consider factors inaddition to blood glucose levels when determining whether a subject haspre-diabetes.

In certain embodiments, a subject having elevated blood glucose levelshas diabetes. In certain embodiments, a subject is identified as havingdiabetes according to the subject's blood glucose levels. In certainsuch embodiments, the subject has a fasting blood glucose level above126 mg/dL. In certain such embodiments, the subject has a two-hourpost-prandial blood glucose level at or above 200 mg/dL. A diagnosis ofdiabetes is typically made by a medical professional, who may considerfactors in addition to blood glucose levels when determining whether asubject has diabetes.

In certain embodiments, the method provided herein comprises monitoringblood glucose levels before administration of a compound describedherein. In certain embodiments, the methods provided herein comprisemeasuring blood glucose levels after administration of a compounddescribed herein. In certain embodiments, a subject measures bloodglucose levels one or more times daily.

In certain embodiments, methods for reducing blood glucose levelscomprise reducing a subject's blood glucose levels to blood glucoselevels determined as desirable by medical organizations, such as theAmerican Diabetes Association or the World Health Organization. Incertain embodiments, blood glucose levels are reduced below 130 mg/dLwhen measured before a subject has had a meal. In certain embodiments,blood glucose levels are reduced to below 180 mg/dL when measured aftera subject has had a meal.

In certain embodiments, the administration occurs at least once perweek. In certain embodiments, the administration occurs once every twoweeks. In certain embodiments, the administration occurs once everythree weeks. In certain embodiments, the administration occurs onceevery four weeks. The frequency of administration may be set by amedical professional to achieve a desirable blood glucose level in asubject. The frequency of administration may be dependent upon asubject's blood glucose levels. For example, in certain embodiments,administration may be more frequent when a subject has elevated bloodglucose levels.

In certain embodiments, a dosing regimen may include doses during aloading period and/or a maintenance period. During the loading period,which in some embodiments occurs at the initiation of therapy and maylast, for example, one to three weeks or more, a single administrationmay be given or multiple administrations may be given every day, every 2days, every 3 days, every 4 days, every 5 days, every 6 days, or everyweek. During a maintenance period, which in some embodiments follows theloading period and may last for a number of months or years, or for theduration of the lifetime of the subject, doses may be given at afrequency ranging from every day to every 3 months, which is understoodto include every day, every 2 days, every 3 days, every 4 days, every 5days, every 6 days, every week, every 2 weeks, every 3 weeks, every 4weeks, every month, every 2 months, or every 3 months. In someembodiments, the loading period comprises administration of larger dosesand/or more frequent doses than the maintenance period.

Measurements of HbAlc levels may be used to determine how well asubject's blood glucose levels are controlled over time. HbAlc levelsare an indication of the amount of glycated hemoglobin in the blood, andcan provide an estimate of how well a subject's blood glucose levelshave been managed over 2-3 month period prior to the measurement ofHbAlc levels. High HbAlc levels may put a subject at risk for developingcomplications related to diabetes, such as eye disease, heart disease,kidney disease, nerve damage, or stroke. As such, in certain embodimentsit is desirable that a subject's HbAlc levels be within ranges that areconsidered normal by a medical professional. In certain embodiments, anHbAlc level of 6% or less is normal. In certain embodiments, a medicalprofessional may recommend that a subject's HbAlc level be 7% or less.In certain embodiments, the administering results in reduced HbAlclevels. In certain embodiments, the administering reduces the HbAlclevel of a subject to below 8%, to below 7.5%, to below 7%, to below6.5%, to below 6%, to below 5.5%, to below 5%, or to below 4.5%.

In certain embodiments, a subject having elevated blood glucose levelsis insulin resistant. One of the main functions of insulin is to lowerblood glucose levels. A subject whose cells are sensitive to the effectsof insulin needs only a relatively small amount of insulin to keep bloodglucose levels in the normal range. A subject who is insulin resistantrequires more insulin to get the same blood glucose-lowering effects.Insulin resistance may cause hyperinsulinemia. Hyperinsulinemia may beassociated with high blood pressure, heart disease and heart failure,obesity (particularly abdominal obesity), osteoporosis, and certaintypes of cancer, such as colon, breast, and prostate cancer.

Insulin resistance may be detected using a procedure known as thehyperinsulinemic euglycemic clamp, which measures the amount of glucosenecessary to compensate for an increased insulin level without causinghypoglycemia. During the procedure, insulin is infused at 10-120 mU perm2 per minute. In order to compensate for the insulin infusion, a 20%solution of glucose is infused to maintain blood sugar levels between 5and 5.5 mmol/L. The rate of glucose infusion is determined by checkingthe blood sugar levels every 5 to 10 minutes. Low-dose insulin infusionsare more useful for assessing the response of the liver, whereashigh-dose insulin infusions are useful for assessing peripheral (i.e.,muscle and fat) insulin action. The rate of glucose infusion during thelast 30 minutes of the test determines insulin sensitivity. If highlevels (7.5 mg/min or higher) are required, the subject isinsulin-sensitive. Very low levels (4.0 mg/min or lower) indicate thatthe subject is resistant to insulin action. Levels between 4.0 and 7.5mg/min are not definitive and suggest impaired glucose tolerance.Impaired glucose tolerance may be an early sign of insulin resistance.Glucose tracers, such as 3-3H glucose, 6,6 2H-glucose, or 1-13C glucose,may be used in the procedure. Other radioactive forms of glucose may beemployed in a research setting. Prior to beginning the hyperinsulinemicperiod, a 3 hour tracer infusion enables the determination of the basalrate of glucose production. During the clamp procedure, the plasmatracer concentrations enable the calculation of whole-bodyinsulin-stimulated glucose metabolism, as well as the production ofglucose by the body (i.e., endogenous glucose production).

In certain embodiments, provided herein are methods for improvinginsulin resistance in a subject comprising administering to the subjecta compound described herein. In certain embodiments, the subject hasinsulin resistance. In certain embodiments, the methods compriseselecting a subject having insulin resistance. In certain embodiments, asubject having elevated blood glucose levels has insulin resistance. Incertain embodiments, a subject having diabetes has insulin resistance.In certain embodiments, a subject having type 2 diabetes has insulinresistance. In certain embodiments, a subject having type 1 diabetes hasinsulin resistance.

In certain embodiments, provided herein are methods for reducinggluconeogenesis in a subject comprising administering to the subject acompound described herein. In certain embodiments, the subject haselevated gluconeogenesis. In certain embodiments, the subject isidentified as having elevated gluconeogenesis. In certain embodiments,the administering results in a reduction in gluconeogenesis. In certainembodiments, a pyruvate tolerance test is used to measuregluconeogenesis in a subject. In certain embodiments, blood glucoselevels are used to measure gluconeogenesis in a subject. In certainembodiments, the rate of gluconeogenesis is measured in a subject. Incertain embodiments, a reduction in gluconeogenesis is a reduction inthe rate of gluconeogenesis. In certain embodiments, the rate ofgluconeogenesis is measured in the subject prior to administration. Incertain embodiments, the rate of gluconeogenesis is measured in thesubject after administration.

In certain embodiments, provided herein are methods for reducing plasmacholesterol in a subject comprising administering to the subject acompound described herein. In certain embodiments, the subject haselevated plasma cholesterol. In certain embodiments, the subject isidentified as having elevated plasma cholesterol. In certainembodiments, the administering reduces plasma cholesterol. In certainembodiments, the plasma cholesterol is plasma LDL-cholesterol. Incertain embodiments, the plasma cholesterol is plasma VLDL-cholesterol.

In certain embodiments, provided herein are methods for treating ametabolic disorder in a subject comprising administering to the subjecta compound described herein. In certain embodiments, the subject has ametabolic disorder. In certain embodiments, the subject is identified ashaving a metabolic disorder. In certain embodiments, a metabolicdisorder includes, without limitation, prediabetes, diabetes (includingType 1 or Type 2 diabetes), metabolic syndrome, obesity, or diabeticdyslipidemia, hyperglycemia, hypoglycemia, and hyperinsulinemia. Incertain embodiments, the subject is diagnosed with one or more metabolicdisorders. A subject may be diagnosed with a metabolic disorderfollowing the administration of medical tests well-known to those in themedical profession.

Fatty liver diseases are often associated with metabolic disorders. Incertain embodiments, a subject having a metabolic disorder has a fattyliver disease. In certain embodiments, a fatty liver disease isnon-alcoholic fatty liver disease (NAFLD). In certain embodiments, afatty liver disease is alcoholic fatty liver disease. In certainembodiments, a fatty liver disease is alcoholic steatohepatitis. Incertain embodiments, a fatty liver disease is non-alcoholicsteatohepatitis (NASH).

In certain embodiments, provided herein are methods for treating fattyliver disease in a subject comprising administering to the subject acompound described herein. In certain embodiments, the fatty liverdisease is selected from non-alcoholic fatty liver disease (NAFLD),alcoholic fatty liver disease, alcoholic steatohepatitis, andnon-alcoholic steatohepatitis (NASH). In certain embodiments, the fattyliver disease is selected from non-alcoholic fatty liver disease (NAFLD)and non-alcoholic steatohepatitis (NASH). In certain embodiments,provided herein are methods for treating a subject having NAFLD and type2 diabetes. In certain embodiments, provided herein are methods fortreating a subject having NASH and type 2 diabetes.

In certain embodiments, provided herein are methods of reducing livertriglycerides comprising administering to the subject a compounddescribed herein. In some embodiments, the subject has fatty liverdisease. In certain embodiments, the fatty liver disease is selectedfrom non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liverdisease, alcoholic steatohepatitis, and non-alcoholic steatohepatitis(NASH). In certain embodiments, the fatty liver disease is selected fromnon-alcoholic fatty liver disease (NAFLD) and non-alcoholicsteatohepatitis (NASH).

In certain embodiments, provided herein are methods for preventing theonset of a metabolic disorder in a subject comprising administering tothe subject a compound described herein. In certain embodiments, thesubject is at risk for developing a metabolic disorder. In certainembodiments, the subject is identified being at risk for developing ametabolic disorder. In certain embodiments, a metabolic disorder isprediabetes, diabetes (including Type 1 or Type 2 diabetes), metabolicsyndrome, obesity, or diabetic dyslipidemia, hyperglycemia,hypoglycemia, hyperinsulinemia, ketoacidosis and celiac disease.

In certain embodiments, provided herein are methods for delaying theonset of a metabolic disorder in a subject comprising administering tothe subject a compound described herein. In certain embodiments, thesubject is at risk for developing a metabolic disorder. In certainembodiments, the subject is identified being at risk for developing ametabolic disorder. In certain embodiments, a metabolic disorderincludes, without limitation, prediabetes, diabetes (including Type 1 orType 2 diabetes), metabolic syndrome, obesity, or diabetic dyslipidemia,hyperglycemia, hypoglycemia, and hyperinsulinemia.

In certain embodiments, a subject has one or more metabolic disorders.In certain embodiments, a subject has been diagnosed with one or moremetabolic disorders. A subject may be diagnosed with a metabolicdisorder following the administration of medical tests well-known tothose in the medical profession.

A subject's response to treatment may be evaluated by tests similar tothose used to diagnosis the metabolic disorder, including blood glucoselevel tests, glucose tolerance tests, and HbAlc tests. Response totreatment may also be assessed by comparing post-treatment test resultsto pre-treatment test results.

Fatty liver diseases may be associated with metabolic disorders. Incertain embodiments, a fatty liver disease is non-alcoholic fatty liverdisease (NAFLD). In certain embodiments, a fatty liver disease isalcoholic fatty liver disease. In certain embodiments, a fatty liverdisease is alcoholic steatohepatitis. In certain embodiments, a fattyliver disease is non-alcoholic steatohepatitis (NASH).

In certain embodiments, provided herein are methods for treating fattyliver disease in a subject comprising administering to the subject acompound described herein.

In certain embodiments, provided herein are methods for preventing afatty liver disease in a subject comprising administering to the subjecta compound described herein. In certain such embodiments, the subject isat risk for developing a fatty liver disease.

In certain embodiments, provided herein are methods for delaying theonset of a fatty liver disease in a subject comprising administering tothe subject a compound described herein. In certain such embodiments,the subject is at risk for developing a fatty liver disease.

Certain Compounds and Modified Oligonucleotides and Regions of ModifiedOligonucleotides

In some embodiments, a compound comprising a modified oligonucleotidehaving the structure:

[oligo1]-[x-N]_(m)-x-[oligo2]

is provided. In some embodiments, a compound comprising a modifiedoligonucleotide consisting of the structure[oligo1]-[x-N]_(m)-x-[oligo2] is provided. In some embodiments, oligo1consists of 7 to 15 linked nucleosides and has a nucleobase sequencethat is complementary to the nucleobase sequence of miR-103 and/ormiR-107 with no more than 1 mismatch; oligo2 consists of 7 to 15 linkednucleosides and has a nucleobase sequence that is complementary to thenucleobase sequence of miR-103 and/or miR-107 with no more than 1mismatch; each x is independently selected from a phosphodiester bondand a phosphorothioate bond; each N is independently selected from amodified nucleoside and an unmodified nucleoside; m is an integer from 1to 5; and at least one x is a phosphodiester bond. In some embodiments,the modified oligonucleotide consists of 15 to 32, 15 to 30, 15 to 28,15 to 26, 15 to 24, or 15 to 22, or 15 to 20 nucleosides. In someembodiments, oligo1 has a nucleobase sequence that is at least 80%, atleast 90%, or 100% complementary to the nucleobase sequence of miR-103and/or miR-107. In some embodiments, oligo1 has a nucleobase sequencethat is at least 80%, at least 90%, or 100% complementary to thenucleobase sequence of miR-103 and miR-107. In some embodiments, oligo1has a nucleobase sequence that is complementary to at least 6, at least7, or 8 nucleotides of the seed region of miR-103 and/or miR-107. Insome embodiments, oligo1 has a nucleobase sequence that is complementaryto at least 6, at least 7, or 8 nucleotides of the seed region ofmiR-103 and miR-107. In some embodiments, oligo2 has a nucleobasesequence that is at least 80%, at least 90%, or 100% complementary tothe nucleobase sequence of miR-103 and/or miR-107. In some embodiments,oligo2 has a nucleobase sequence that is at least 80%, at least 90%, or100% complementary to the nucleobase sequence of miR-103 and miR-107. Insome embodiments, oligo2 has a nucleobase sequence that is complementaryto at least 6, at least 7, or 8 nucleotides of the seed region ofmiR-103 and/or miR-107. In some embodiments, oligo2 has a nucleobasesequence that is complementary to at least 6, at least 7, or 8nucleotides of the seed region of miR-103 and miR-107.

In some embodiments, at least 2× are phosphodiester bonds. In someembodiments, each x is a phosphodiester bond. In some embodiments, atleast one N is an unmodified nucleoside. In some embodiments, at leastone N is an unmodified deoxyribonucleoside. In some embodiments, atleast one N is an unmodified ribonucleoside. In some embodiments, each Nis an unmodified nucleoside. In some embodiments, each N is anunmodified deoxyribonucleoside. In some embodiments, each N is anunmodified ribonucleoside. In some embodiments, m is 1, 2, 3, 4, or 5.In some embodiments, m is 1, 2, or 3. In some embodiments, m is 1, N isan unmodified deoxyribonucleoside, and each x is a phosphodiester bond.In some embodiments, m is 2, each N is an unmodifieddeoxyribonucleoside, and each x is a phosphodiester bond.

In some embodiments, oligo1 and oligo2 have the same nucleobasesequence. In such embodiments, the pattern and/or number of nucleosidemodifications in oligo1 and oligo2 may be the same or different. In someembodiments, oligo1 and oligo2 have different nucleobase sequences. Insome such embodiments, oligo1 and oligo2 may target overlapping ornon-overlapping regions of the microRNAs.

In some embodiments, a compound comprising a modified oligonucleotidehaving the structure:

[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3]

is provided. In some embodiments, a compound comprising a modifiedoligonucleotide consisting of the structure:[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3] is provided. In someembodiments, oligo1 consists of 7 to 15 linked nucleosides and has anucleobase sequence that is complementary to the nucleobase sequence ofmiR-103 and/or miR-107 with no more than 1 mismatch; oligo2 consists of7 to 15 linked nucleosides and has a nucleobase sequence that iscomplementary to the nucleobase sequence of miR-103 and/or miR-107 withno more than 1 mismatch; oligo3 consists of 7 to 15 linked nucleosidesand has a nucleobase sequence that is complementary to the nucleobasesequence of a third microRNA with no more than 1 mismatch; each x isindependently selected from a phosphodiester bond and a phosphorothioatebond; each N is independently selected from a modified nucleoside and anunmodified nucleoside; each m is independently an integer from 1 to 5;and at least one x is a phosphodiester bond. In some embodiments, thethird microRNA is miR-103 and/or miR-107.

In some embodiments, at least one x between oligo1 and oligo2 is aphosphodiester bond and at least one x between oligo2 and oligo3 is aphosphodiester bond. In some embodiments, each x is a phosphodiesterbond. In some embodiments, the modified oligonucleotide consists of 23to 55, 23 to 50, 23 to 45, 23 to 40, 23 to 35, 23 to 30, or 23 to 26nucleosides. In some embodiments, oligo1 has a nucleobase sequence thatis at least 80%, at least 90% or 100% complementary to the nucleobasesequence of miR-103 and/or miR-107. In some embodiments, oligo1 has anucleobase sequence that is complementary to at least 6, at least 7, or8 nucleotides of the seed region of miR-103 and/or miR-107. In someembodiments, oligo2 has a nucleobase sequence that is at least 80%, atleast 90% or 100% complementary to the nucleobase sequence of miR-103and/or miR-107. In some embodiments, oligo2 has a nucleobase sequencethat is complementary to at least 6, at least 7, or 8 nucleotides of theseed region of miR-103 and/or miR-107. In some embodiments, oligo3 has anucleobase sequence that is at least 80%, at least 90% or 100%complementary to the nucleobase sequence of the third microRNA. In someembodiments, oligo3 has a nucleobase sequence that is complementary toat least 6, at least 7, or 8 nucleotides of the seed region of the thirdmicroRNA.

In some embodiments, at least 4× are phosphodiester bonds. In someembodiments, at least 2× between oligo1 and oligo2 are phosphodiesterbonds and at least 2× between oligo2 and oligo3 are phosphodiesterbonds. In some embodiments, each x is a phosphodiester bond. In someembodiments, at least one N is an unmodified nucleoside. In someembodiments, at least one N between oligo1 is an unmodified nucleoside,and at least one N between oligo2 and oligo3 is an unmodifiednucleoside. In some embodiments, each N is an unmodified nucleoside. Insome embodiments, each m is independently selected from 1, 2, 3, 4, and5. In some embodiments, each m is independently selected from 1, 2, or3. In some embodiments, each m is 1, each N is an unmodifieddeoxyribonucleoside, and each x is a phosphodiester bond. In someembodiments, one or both m is 2, each N is an unmodifieddeoxyribonucleoside, and each x is a phosphodiester bond.

In some embodiments, at least two or all three of the first microRNA,the second microRNA, and the third microRNA are the same. In someembodiments, the first microRNA, the second microRNA, and the thirdmicroRNA are each different from one another. In some embodiments whenat least two of the microRNA are the same, the corresponding oligos havethe same nucleobase sequence. In such embodiments, the pattern and/ornumber of nucleoside modifications in the oligos with the samenucleobase sequence may be the same or different. In some embodimentswhen at least two microRNAs are the same, the corresponding oligos havedifferent nucleobase sequences. In some such embodiments, the oligostargeted to the same microRNA may target overlapping or non-overlappingregions of the microRNA.

In some embodiments, oligo1 consists of 7 to 15 linked nucleosides, 7 to14 linked nucleosides, 7 to 13 linked nucleosides, 7 to 12 linkednucleosides, 7 to 11 linked nucleosides, 7 to 10 linked nucleosides, 8to 15 linked nucleosides, 8 to 14 linked nucleosides, 8 to 13 linkednucleosides, 8 to 12 linked nucleosides, 8 to 11 linked nucleosides, or8 to 10 linked nucleosides. In some embodiments, oligo1 consists of 9linked nucleosides. In some embodiments, oligo1 consists of 10 linkednucleosides.

In some embodiments, oligo1 comprises at least one nucleoside with amodified sugar moiety. In some embodiments, oligo1 comprises at leastone nucleoside with an unmodified sugar moiety. In some embodiments,oligo1 comprises a plurality of nucleosides with a modified sugarmoiety, and a plurality of nucleosides with an unmodified sugar moiety.In some embodiments, at least 4, at least 5, at least 6, at least 7, orat least 8 nucleosides of oligo1 have a modified sugar moiety. In someembodiments, each nucleoside of oligo1 has a modified sugar moiety. Insome embodiments, each modified nucleoside is independently selectedfrom a 2′-O-methyl sugar moiety, a 2′-O-methoxyethyl sugar moiety, a2′-fluoro sugar moiety, and a bicyclic sugar moiety. In someembodiments, each bicyclic sugar moiety is independently selected from acEt sugar moiety and an LNA sugar moiety. In some embodiments, eachunmodified sugar moiety is independently selected from a β-D-deoxyriboseand a β-D-ribose. In some embodiments, oligo1 comprises at least atleast 4, at least 5, at least 6, at least 7, or at least 8 bicyclicnucleosides. In some embodiments, oligo1 comprises at least 4, at least5, at least 6, at least 7, or at least 8 cEts. In some embodiments,oligo1 comprises at least 4, at least 5, at least 6, at least 7, or atleast 8 LNAs. In some embodiments, oligo1 consists of 10 linked bicyclicnucleosides. In some such embodiments, each bicyclic nucleoside isindependently selected from cEt and LNA. In some embodiments, eachbicyclic nucleoside is cEt.

In some embodiments, oligo2 consists of 7 to 15 linked nucleosides, 7 to14 linked nucleosides, 7 to 13 linked nucleosides, 7 to 12 linkednucleosides, 7 to 11 linked nucleosides, 7 to 10 linked nucleosides, 8to 15 linked nucleosides, 8 to 14 linked nucleosides, 8 to 13 linkednucleosides, 8 to 12 linked nucleosides, 8 to 11 linked nucleosides, or8 to 10 linked nucleosides. In some embodiments, oligo2 consists of 9linked nucleosides. In some embodiments, oligo2 consists of 10 linkednucleosides.

In some embodiments, oligo2 comprises at least one nucleoside with amodified sugar moiety. In some embodiments, oligo2 comprises at leastone nucleoside with an unmodified sugar moiety. In some embodiments,oligo2 comprises a plurality of nucleosides with a modified sugarmoiety, and a plurality of nucleosides with an unmodified sugar moiety.In some embodiments, at least 4, at least 5, at least 6, at least 7, orat least 8 nucleosides of oligo2 have a modified sugar moiety. In someembodiments, each nucleoside of oligo2 has a modified sugar moiety. Insome embodiments, each modified nucleoside is independently selectedfrom a 2′-O-methyl sugar moiety, a 2′-O-methoxyethyl sugar moiety, a2′-fluoro sugar moiety, and a bicyclic sugar moiety. In someembodiments, each bicyclic sugar moiety is independently selected from acEt sugar moiety and an LNA sugar moiety. In some embodiments, eachunmodified sugar moiety is independently selected from a β-D-deoxyriboseand a β-D-ribose. In some embodiments, oligo2 comprises at least atleast 4, at least 5, at least 6, at least 7, or at least 8 bicyclicnucleosides. In some embodiments, oligo2 comprises at least at least 4,at least 5, at least 6, at least 7, or at least 8 cEts. In someembodiments, oligo2 comprises at least at least 4, at least 5, at least6, at least 7, or at least 8 LNAs. In some embodiments, oligo2 consistsof 10 linked bicyclic nucleosides. In some such embodiments, eachbicyclic nucleoside is independently selected from cEt and LNA. In someembodiments, each bicyclic nucleoside is cEt. In some embodiments,oligo1 and oligo2 have the same nucleobase sequence and each consists of10 linked cEt nucleosides.

In some embodiments, oligo3 consists of 7 to 15 linked nucleosides, 7 to14 linked nucleosides, 7 to 13 linked nucleosides, 7 to 12 linkednucleosides, 7 to 11 linked nucleosides, 7 to 10 linked nucleosides, 8to 15 linked nucleosides, 8 to 14 linked nucleosides, 8 to 13 linkednucleosides, 8 to 12 linked nucleosides, 8 to 11 linked nucleosides, or8 to 10 linked nucleosides.

In some embodiments, oligo3 comprises at least one nucleoside with amodified sugar moiety. In some embodiments, oligo3 comprises at leastone nucleoside with an unmodified sugar moiety. In some embodiments,oligo3 comprises a plurality of nucleosides with a modified sugarmoiety, and a plurality of nucleosides with an unmodified sugar moiety.In some embodiments, at least 4, at least 5, at least 6, at least 7, orat least 8 nucleosides of oligo3 have a modified sugar moiety. In someembodiments, each nucleoside of oligo3 has a modified sugar moiety. Insome embodiments, each modified nucleoside is independently selectedfrom a 2′-O-methyl sugar moiety, a 2′-O-methoxyethyl sugar moiety, a2′-fluoro sugar moiety, and a bicyclic sugar moiety. In someembodiments, each bicyclic sugar moiety is independently selected from acEt sugar moiety and an LNA sugar moiety. In some embodiments, eachunmodified sugar moiety is independently selected from a β-D-deoxyriboseand a β-D-ribose. In some embodiments, oligo3 comprises at least atleast 4, at least 5, at least 6, at least 7, or at least 8 bicyclicnucleosides. In some embodiments, oligo3 comprises at least at least 4,at least 5, at least 6, at least 7, or at least 8 cEts. In someembodiments, oligo3 comprises at least at least 4, at least 5, at least6, at least 7, or at least 8 LNAs.

In some embodiments, the first microRNA and second microRNA, and, whenpresent, the third microRNA, are each miR-103/107. In some embodiments,oligo1 and/or oligo2 has the nucleobase sequence 5′-CAAUGCUGCA-3′ (SEQID NO: 6). In some embodiments, oligo1 and oligo2 each has thenucleobase sequence 5′-CAAUGCUGCA-3′ (SEQ ID NO: 6). In someembodiments, the compound comprises a modified oligonucleotideconsisting of the sequence5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein oligo 1 is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 6),oligo 2 is 5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQID NO: 6), and oligo1 and oligo2 are linked by AA, wherein eachnucleoside followed by a subscript “S” is a S-cEt nucleoside and eachnucleoside not followed by a subscript is a deoxynucleoside.

In some embodiments, oligo1 and/or oligo2 has the nucleobase sequence5′-CAAUGCUGCC-3′ (SEQ ID NO: 8). In some embodiments, oligo1 and oligo2each has the nucleobase sequence 5′-CAAUGCUGCC′ (SEQ ID NO: 8). In someembodiments, the compound comprises a modified oligonucleotideconsisting of the sequence5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)C_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)C_(S)-3′(SEQ ID NO: 9), wherein oligo 1 is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)C_(S)-3′ (SEQ ID NO: 8),oligo 2 is 5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)C_(S)-3′ (SEQID NO: 8), and oligo1 and oligo2 are linked by AA, wherein eachnucleoside followed by a subscript “S” is a S-cEt nucleoside and eachnucleoside not followed by a subscript is a deoxynucleoside. In someembodiments, oligo1 and/or oligo2 has the nucleobase sequence5′-CAAUGCUGCG-3′ (SEQ ID NO: 10). In some embodiments, oligo1 and oligo2each has the nucleobase sequence 5′-CAAUGCUGCAG-3′ (SEQ ID NO: 10). Insome embodiments, the compound comprises a modified oligonucleotideconsisting of the sequence5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)G_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)G_(S)-3′(SEQ ID NO: 11), wherein oligo 1 is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)G_(S)-3′ (SEQ ID NO:10), oligo 2 is 5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)G_(S)-3′(SEQ ID NO: 10), and oligo1 and oligo2 are linked by AA, wherein eachnucleoside followed by a subscript “S” is a S-cEt nucleoside and eachnucleoside not followed by a subscript is a deoxynucleoside.

In some embodiments, the internucleoside linkages between the 3′ end ofoligo1 and the AA linker and between the AA linker and the 5′ end ofoligo2 are phosphodiester internucleoside linkages. In some embodiments,the internucleoside linkage between the As of the AA linker is also aphosphodiester internucleoside linkage. In some embodiments, all of theinternucleoside linkages between nucleosides within oligo1 and oligo2are phosphorothioate linkages (i.e., all of the internucleoside linkagesbetween two S-cEt nucleosides are phosphorothioate linkages). In someembodiments, the 3′ end of oligo2 is attached to a conjugate moietythrough a linker. In some embodiments, the conjugate moiety is GalNAc.In some embodiments, the linker is an AA linker, wherein each A is adeoxyadenosine and the internucleoside linkages between oligo2 and thelinker, and between the A's of the AA linker, and between the linker andthe conjugate moiety, are phosphodiester linkages.

In certain embodiments, the nucleobase sequence of a region (i.e.,oligo1, oligo2, or oligo3 in the structures shown herein) of a modifiedoligonucleotide is at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 95%, at least 96%, or 100% complementary tothe nucleobase sequence of the target RNA. In certain embodiments, aregion (i.e., oligo1, oligo2, or oligo3 in the structures shown herein)of a modified oligonucleotide is at least 90%, at least 93%, at least94%, at least 95%, or 100% complementary to a target RNA.

In certain embodiments, a region (i.e., oligo1, oligo2, or oligo3 in thestructures shown herein) of a modified oligonucleotide comprises atleast one nucleoside with a modified sugar moiety. In certainembodiments, a region (i.e., oligo1, oligo2, or oligo3 in the structuresshown herein) of a modified oligonucleotide comprises a plurality ofnon-bicyclic nucleosides and a plurality of bicyclic nucleosides.

In certain embodiments, at least 70% of the nucleosides of a region(i.e., oligo1, oligo2, or oligo3 in the structures shown herein) of amodified oligonucleotide comprise a modified sugar moiety. In certainembodiments, at least 80% of the nucleosides of a region (i.e., oligo1,oligo2, or oligo3 in the structures shown herein) of a modifiedoligonucleotide comprise a modified sugar moiety. In certainembodiments, at least 90% of the nucleosides of a region (i.e., oligo1,oligo2, or oligo3 in the structures shown herein) of a modifiedoligonucleotide comprise a modified sugar moiety. In certainembodiments, at least 95% of the nucleosides of a region (i.e., oligo1,oligo2, or oligo3 in the structures shown herein) of a modifiedoligonucleotide comprise a modified sugar moiety. In some embodiments,100% of the nucleosides of a region (i.e., oligo1, oligo2, or oligo3 inthe structures shown herein) of a modified oligonucleotide comprise amodified sugar moiety. In some embodiments, 100% of the nucleosides of aregion (i.e., oligo1, oligo2, or oligo3 in the structures shown herein)of a modified oligonucleotide are bicyclic nucleosides. In someembodiments, 100% of the nucleosides of a region (i.e., oligo1, oligo2,or oligo3 in the structures shown herein) of a modified oligonucleotideare cEt nucleosides.

In certain embodiments, at least two bicyclic nucleosides comprise sugarmoieties that are different from one another. In certain embodiments,each bicyclic nucleoside has the same type of sugar moiety. In certainembodiments, at least two non-bicyclic nucleosides comprise sugarmoieties that are different from one another. In certain embodiments,each non-bicyclic nucleoside has the same type of sugar moiety.

In certain embodiments, each non-bicyclic nucleoside is independentlyselected from a β-D-deoxyribonucleoside, a β-D-ribonucleoside,2′-O-methyl nucleoside, a 2′-O-methoxyethyl nucleoside, and a2′-fluoronucleoside. In certain embodiments, each non-bicyclicnucleoside is independently selected from a β-D-deoxyribonucleoside, anda 2′-O-methoxyethyl nucleoside. In certain embodiments, eachnon-bicyclic nucleoside is a β-D-deoxyribonucleoside.

In certain embodiments, the bicyclic nucleoside is selected from a cEtnucleoside, and LNA nucleoside, and an ENA nucleoside. In certainembodiments, the cEt nucleoside is an S-cEt nucleoside. In certainembodiments, the cEt nucleoside is an R-cEt nucleoside.

In certain embodiments, a region (i.e., oligo1, oligo2, or oligo3 in thestructures shown herein) of the modified oligonucleotide comprises aplurality of modified nucleosides and a plurality ofβ-D-deoxyribonucleoside, wherein each β-D-deoxyribonucleoside maycomprise a modified or unmodified nucleobase. In certain embodiments, aregion (i.e., oligo1, oligo2, or oligo3 in the structures shown herein)of the modified oligonucleotide is a gapmer. In certain embodiments, thesugar moiety of each nucleoside is a modified sugar moiety. In certainembodiments, a modified nucleoside is a 2′-O-methoxyethyl nucleoside. Incertain embodiments, a modified nucleoside is an S-cEt nucleoside.

In certain embodiments, a modified oligonucleotide comprising tworegions (i.e., comprising oligo1 and oligo2 in the structures shownherein) consists of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,28, 29, 30, 31, or 32 linked nucleosides. In some embodiments, themodified oligonucleotide consists of 15 to 32 linked nucleosides. Insome embodiments, the modified oligonucleotide consists of 15 to 30linked nucleosides. In some embodiments, the modified oligonucleotideconsists of 15 to 28 linked nucleosides. In some embodiments, themodified oligonucleotide consists of 15 to 26 linked nucleosides. Insome embodiments, the modified oligonucleotide consists of 15 to 24linked nucleosides. In some embodiments, the modified oligonucleotideconsists of 15 to 22 linked nucleosides. In some embodiments, themodified oligonucleotide consists of 15 to 20 linked nucleosides. Insome embodiments, the modified oligonucleotide consists of 22 linkednucleosides. In some embodiments, the modified oligonucleotide consistsof 24 linked nucleosides.

In certain embodiments, a modified oligonucleotide comprising threeregions (i.e., comprising oligo1, oligo2, and oligo3 in the structuresshown herein) consists of 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, or 55 linked nucleosides. In some embodiments, the modifiedoligonucleotide consists of 23 to 55 linked nucleosides. In someembodiments, the modified oligonucleotide consists of 23 to 50 linkednucleosides. In some embodiments, the modified oligonucleotide consistsof 24 to 45 linked nucleosides. In some embodiments, the modifiedoligonucleotide consists of 23 to 40 linked nucleosides. In someembodiments, the modified oligonucleotide consists of 23 to 35 linkednucleosides. In some embodiments, the modified oligonucleotide consistsof 23 to 30 linked nucleosides. In some embodiments, the modifiedoligonucleotide consists of 23 to 26 linked nucleosides.

In certain embodiments, a region (i.e., oligo1, oligo2, or oligo3 in thestructures shown herein) of a modified oligonucleotide consists of 7 to15 linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 7 to 14 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 7 to 13linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 7 to 12 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 7 to 11linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 7 to 10 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 8 to 15linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 8 to 14 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 8 to 13linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 8 to 12 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 8 to 11linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 8 to 10 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 7 linkednucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 8 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 9 linkednucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 10 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 11linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 12 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 13linked nucleosides. In certain embodiments, a region of a modifiedoligonucleotide consists of 14 linked nucleosides. In certainembodiments, a region of a modified oligonucleotide consists of 15linked nucleosides.

In certain embodiments, at least one internucleoside linkage of a region(i.e., oligo1, oligo2, and/or oligo3) of a modified oligonucleotide is amodified internucleoside linkage. In certain embodiments, eachinternucleoside linkage of a region (i.e., oligo1, oligo2, and/oroligo3) of a modified oligonucleotide is a modified internucleosidelinkage. In certain embodiments, the modified internucleoside linkage isa phosphorothioate internucleoside linkage. In certain embodiments, atleast one nucleoside of a modified oligonucleotide comprises a modifiednucleobase. In certain embodiments, at least one pyrimidine of themodified oligonucleotide comprises a 5-methyl group. In certainembodiments, at least one nucleoside of a modified oligonucleotidecomprises a 5-methylcytosine. In certain embodiments, each cytosine of amodified oligonucleotide is a 5-methylcytosine.

In certain embodiments, where a region (i.e., oligo1, oligo2, and/oroligo3 of the structures shown herein) of a modified oligonucleotide isbetween 7 and 12 linked nucleosides in length, each nucleoside of themodified oligonucleotide comprises a modified sugar moiety. In certainembodiments, where a region of modified oligonucleotide is between 7 and10 linked nucleosides in length, each nucleoside of the modifiedoligonucleotide comprises a modified sugar moiety. In certainembodiments, where a region of a modified oligonucleotide is between 8and 12 linked nucleosides, each nucleoside of the modifiedoligonucleotide comprises a modified sugar moiety.

In certain embodiments, a region of modified oligonucleotide consists of7 linked nucleosides, wherein each nucleoside of the region comprises amodified sugar moiety. In certain embodiments, a region of a modifiedoligonucleotide consists of 8 linked nucleosides, wherein eachnucleoside of the region comprises a modified sugar moiety. In certainembodiments, a region of a modified oligonucleotide consists of 9 linkednucleosides, wherein each nucleoside of the region comprises a modifiedsugar moiety. In certain embodiments, a region of a modifiedoligonucleotide consists of 10 linked nucleosides, wherein eachnucleoside of the region comprises a modified sugar moiety. In certainembodiments, a region of a modified oligonucleotide consists of 11linked nucleosides, wherein each nucleoside of the region comprises amodified sugar moiety. In certain embodiments, a region of a modifiedoligonucleotide consists of 12 linked nucleosides, wherein eachnucleoside of the region comprises a modified sugar moiety. In certainembodiments, each nucleoside of the region comprises a bicyclic sugarmoiety. In certain embodiments, the bicyclic sugar moiety is a cEt sugarmoiety. In certain embodiments, the cEt sugar moiety is an S-cEt sugarmoiety. In certain embodiments, the bicyclic sugar moiety is an LNAsugar moiety.

In certain embodiments, a region of a modified oligonucleotide is fullymodified. In certain embodiments, a fully modified region of anoligonucleotides comprise a sugar modification at each nucleoside. Incertain embodiments, a fully modified region of an oligonucleotidecomprises at least one modified internucleoside linkage. In certainembodiments, a fully modified region of an oligonucleotide comprises asugar modification at each nucleoside, and each internucleoside linkageis a modified internucleoside linkage. In certain embodiments, a fullymodified region of an oligonucleotide comprises a sugar modification ateach nucleoside, and comprise at least one phosphorothioateinternucleoside linkage. In certain embodiments, a fully modified regionof an oligonucleotide comprises a sugar modification at each nucleoside,and each internucleoside linkage is a phosphorothioate internucleosidelinkage. In certain embodiments, each nucleoside of a fully modifiedregion of an oligonucleotide comprises the same modified sugar moiety.

In certain embodiments, a region of a modified oligonucleotide is auniformly modified oligonucleotide. In certain embodiments, eachnucleoside of a uniformly modified region of an oligonucleotidecomprises the same sugar modified moiety. In certain embodiments, eachinternucleoside linkage of a uniformly modified region of anoligonucleotide comprises the same modified internucleotide linkage.

In certain embodiments, a region of a modified oligonucleotide is agapmer.

In certain embodiments, provided herein are compounds comprising amodified oligonucleotide consisting of a single region of 8 to 25 linkednucleosides, wherein the nucleobase sequence of the single region iscomplementary to miR-103 and/or miR-107, and wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus or the 3′terminus of the modified oligonucleotide, and wherein the conjugatemoiety comprises a ligand that improves cellular uptake in a liver cell.In certain embodiments, provided herein are compounds comprising amodified oligonucleotide consisting of 8 to 25 linked nucleosides,wherein the nucleobase sequence of the modified oligonucleotide iscomplementary to miR-103 and/or miR-107, and wherein the compoundcomprises a conjugate moiety linked to the 5′ terminus or the 3′terminus of the modified oligonucleotide, and wherein the conjugatemoiety comprises a ligand that improves cellular uptake in a liver cell.In certain embodiments, the conjugate moiety comprises a ligand havingaffinity for the asialoglycoprotein receptor. In certain embodiments,the ligand is selected from N-acetylgalactosamine, galactose,galactosamine, N-formylgalactosamine, N-propionyl-galactosamine,N-n-butanoylgalactosamine, and N-iso-butanoyl-galactosamine. In certainembodiments, a modified oligonucleotide consists of 8 to 25 linkednucleosides. In certain embodiments, a modified oligonucleotide consistsof 12 to 25 linked nucleosides. In certain embodiments, a modifiedoligonucleotide consists of 15 to 30 linked nucleosides. In certainembodiments, a modified oligonucleotide consists of 15 to 25 linkednucleosides. In certain embodiments, a modified oligonucleotide consistsof 15 to 19 linked nucleosides. In certain embodiments, a modifiedoligonucleotide consists of 15 to 16 linked nucleosides. In certainembodiments, a modified oligonucleotide consists of 19 to 24 linkednucleosides. In certain embodiments, a modified oligonucleotide consistsof 21 to 24 linked nucleosides.

In certain embodiments, the nucleobase sequence of the single region hasat least 90%, at least 95%, or has 100% complementarity to thenucleobase sequence of miR-103 and/or miR-107. In certain embodiments,the nucleobase sequence of the modified oligonucleotide has at least90%, at least 95%, or has 100% complementarity to the nucleobasesequence of miR-103 and/or miR-107.

In certain embodiments, the modified oligonucleotide consisting of asingle region has at least one modified sugar moiety, at least onemodified internucleoside linkage, and/or at least one modifiednucleobase, each of which may be selected from any of those describedherein. In certain embodiments, the modified oligonucleotide has atleast one modified sugar moiety, at least one modified internucleosidelinkage, and/or at least one modified nucleobase, each of which may beselected from any of those described herein. The conjugate moiety may beselected from any of the structures described herein.

Certain Conjugated Compounds

In certain embodiments, a compound provided herein comprises a conjugatemoiety linked to the 5′ terminus or the 3′ terminus of a modifiedoligonucleotide. In certain embodiments, the compound comprises aconjugate moiety linked to the 3′ terminus of a modifiedoligonucleotide. In certain embodiments, the compound comprises aconjugate moiety linked to the 5′ terminus of a modifiedoligonucleotide. In certain embodiments, the compound comprises a firstconjugate moiety linked to a 3′ terminus of the modified oligonucleotideand a second conjugate moiety linked to the 5′ terminus of a modifiedoligonucleotide.

In certain embodiments, a conjugate moiety comprises at least one ligandselected from a carbohydrate, cholesterol, a lipid, a phospholipid, anantibody, a lipoprotein, a hormone, a peptide, a vitamin, a steroid, ora cationic lipid.

Ligands may be covalently attached to a modified oligonucleotide by anysuitable linker Various linkers are known in the art, and certainnonlimiting exemplary linkers are described, e.g., in PCT PublicationNo. WO 2013/033230 and U.S. Pat. No. 8,106,022 B2. In some embodiments,a linker may be selected that is resistant to enzymatic cleavage invivo. In some embodiments, a linker may be selected that is resistant tohydrolytic cleavage in vivo. In some embodiments, a linker may beselected that will undergo enzymatic cleavage in vivo. In someembodiments, a linker may be selected that will undergo hydrolyticcleavage in vivo.

In certain embodiments, a compound comprising a conjugated modifiedoligonucleotide described herein has the structure:

L-X₁—N_(m)—X₂-MO;

wherein each L is a ligand; each N of N_(m) is, independently, amodified or unmodified nucleoside and m is from 1 to 5; X₁ and X₂ areeach, independently, a phosphodiester linkage or a phosphorothioatelinkage; and MO is a modified oligonucleotide. In certain embodiments, mis 1. In certain embodiments, m is 2. In certain embodiments, m is 2, 3,4, or 5. In certain embodiments, m is 3, 4, or 5. In certainembodiments, when m is greater than 1, each modified or unmodifiednucleoside of N_(m) may be connected to adjacent modified or unmodifiednucleosides of N_(m) by a phosphodiester internucleoside linkage or aphosphorothioate internucleoside linkage. In certain embodiments, m is 1and X₁ and X₂ are each phosphodiester.

In certain embodiments, a compound comprising a conjugated modifiedoligonucleotide described herein has Structure A:

L_(n)-linker-MO;

wherein each L is, independently, a ligand and n is from 1 to 10; and MOis a modified oligonucleotide.

In certain embodiments, a compound comprising a conjugated modifiedoligonucleotide described herein has Structure B:

L_(n)-linker-X₁-N_(m)-X₂-MO

wherein each L is, independently, a ligand and n is from 1 to 10; each Nof N_(m) is, independently, a modified or unmodified nucleoside and m isfrom 1 to 5; X₁ and X₂ are each, independently, a phosphodiester linkageor a phosphorothioate linkage; and MO is a modified oligonucleotide. Incertain embodiments, m is 1. In certain embodiments, m is 2. In certainembodiments, m is 3, 4, or 5. In certain embodiments, m is 2, 3, 4, or5. In certain embodiments, when m is greater than 1, each modified orunmodified nucleoside of N_(m) may be connected to adjacent modified orunmodified nucleosides of N_(m) by a phosphodiester internucleosidelinkage or phosphorothioate internucleoside linkage.

In certain embodiments, a compound comprising a conjugated modifiedoligonucleotide described herein has Structure C:

L_(n)-linker-X—N_(m)—Y-MO;

wherein each L is, independently, a ligand and n is from 1 to 10; each Nof N_(m) is, independently, a modified or unmodified nucleoside and m isfrom 1 to 5; X is a phosphodiester linkage or a phosphorothioatelinkage; Y is a phosphodiester linkage; and MO is a modifiedoligonucleotide. In certain embodiments, m is 1. In certain embodiments,m is 2. In certain embodiments, m is 3, 4, or 5. In certain embodiments,m is 2, 3, 4, or 5. In certain embodiments, when m is greater than 1,each modified or unmodified nucleoside of N_(m) may be connected toadjacent modified or unmodified nucleosides of N_(m) by a phosphodiesterinternucleoside linkage or phosphorothioate internucleoside linkage.

In certain embodiments, a compound comprising a conjugated modifiedoligonucleotide described herein has Structure D:

L_(n)-linker-Y—N_(m)—Y-MO;

wherein each L is, independently, a ligand and n is from 1 to 10; each Nof N_(m) is, independently, a modified or unmodified nucleoside and m isfrom 1 to 5; each Y is a phosphodiester linkage; and MO is a modifiedoligonucleotide. In certain embodiments, m is 1. In certain embodiments,m is 2. In certain embodiments, m is 3, 4, or 5. In certain embodiments,m is 2, 3, 4, or 5. In certain embodiments, when m is greater than 1,each modified or unmodified nucleoside of N_(m) may be connected toadjacent modified or unmodified nucleosides of N_(m) by a phosphodiesterinternucleoside linkage or phosphorothioate internucleoside linkage.

In certain embodiments, when n is greater than 1, the linker comprises ascaffold capable of linking more than one L to the remainder of thecompound (i.e., to the modified oligonucleotide (MO), to X₁—N_(m)—X₂-MO,to X—N_(m)—Y-MO, etc.). In some such embodiments, the L_(n)-linkerportion of the compound (such as a compound of Structure A, B, C, or D)comprises Structure E:

wherein each L is, independently, a ligand; n is from 1 to 10; S is ascaffold; and Q′ and Q″ are, independently, linking groups.

In some embodiments, each Q′ and Q″ is independently selected from apeptide, an ether, polyethylene glycol, an alkyl, a C₁-C₂₀ alkyl, asubstituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, a substituted C₂-C₂₀alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀ alkynyl, a C₁-C₂₀alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, a pyrrolidine,8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid.

In some embodiments, a scaffold is capable of linking 2, 3, 4, or 5ligands to a modified oligonucleotide. In some embodiments, a scaffoldis capable of linking 3 ligands to a modified oligonucleotide.

A nonlimiting exemplary Structure E is Structure E(i):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; and R₁, R₂, R₃, and R₄are each, independently, selected from H, C₁-C₆ alkyl, and substitutedC₁-C₆ alkyl.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁, R₂, R₃, and R₄ are each, independently,selected from H, methyl, ethyl, propyl, isopropyl, and butyl. In someembodiments, R₁, R₂, R₃, and R₄ are each selected from H and methyl.

A further nonlimiting exemplary Structure E is Structure E(ii):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; and R₁ is selected fromH, C₁-C₆ alkyl, and substituted C₁-C₆ alkyl.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁ is selected from H, methyl, ethyl, propyl,isopropyl, and butyl. In some embodiments, R₁ is H or methyl.

A further nonlimiting exemplary Structure E is Structure E(iii):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; and R₁, R₂, R₃, R₄, andR₅ are each, independently, selected from H, C₁-C₆ alkyl, andsubstituted C₁-C₆ alkyl.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁, R₂, R₃, R₄, and R₅ are each,independently, selected from H, methyl, ethyl, propyl, isopropyl, andbutyl. In some embodiments R₁, R₂, R₃, R₄, and R₅ are each selected fromH and methyl.

A further nonlimiting exemplary Structure E is Structure E(iv):

wherein L₁ and L₂ are each, independently, a ligand; Q′₁, Q′₂, and Q″are each, independently, a linking group; and R₁, R₂, and R₃ are each,independently, selected from H, C₁-C₆ alkyl, and substituted C₁-C₆alkyl.

In some embodiments, Q′₁, Q′₂, and Q″ are each, independently, selectedfrom a peptide, an ether, polyethylene glycol, an alkyl, a C₁-C₂₀ alkyl,a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, a substituted C₂-C₂₀alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀ alkynyl, a C₁-C₂₀alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, a pyrrolidine,8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid. In someembodiments, R₁, R₂, and R₃ are each, independently, selected from H,methyl, ethyl, propyl, isopropyl, and butyl. In some embodiments R₁, R₂,and R₃ are each selected from H and methyl.

A further nonlimiting exemplary Structure E is Structure E(v):

wherein L₁ and L₂ are each, independently, a ligand; Q′₁, Q′₂, and Q″are each, independently, a linking group; and R₁, R₂, and R₃ are each,independently, selected from H, C₁-C₆ alkyl, and substituted C₁-C₆alkyl.

In some embodiments, Q′₁, Q′₂, and Q″ are each, independently, selectedfrom a peptide, an ether, polyethylene glycol, an alkyl, a C₁-C₂₀ alkyl,a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, a substituted C₂-C₂₀alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀ alkynyl, a C₁-C₂₀alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, a pyrrolidine,8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid. In someembodiments, R₁, R₂, and R₃ are each, independently, selected from H,methyl, ethyl, propyl, isopropyl, and butyl. In some embodiments R₁, R₂,and R₃ are each selected from H and methyl.

A further nonlimiting exemplary Structure E is Structure E(vi):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; and R₁, R₂, and R₃ areeach, independently, selected from H, C₁-C₆ alkyl, and substituted C₁-C₆alkyl.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁, R₂, and R₃ are each, independently,selected from H, methyl, ethyl, propyl, isopropyl, and butyl. In someembodiments R₁, R₂, and R₃ are each selected from H and methyl.

A further nonlimiting exemplary Structure E is Structure E(vii):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; R₁, R₂, and R₃ areeach, independently, selected from H, C₁-C₆ alkyl, and substituted C₁-C₆alkyl; and Z and Z′ are each independently selected from O and S.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁, R₂, and R₃ are each, independently,selected from H, methyl, ethyl, propyl, isopropyl, and butyl. In someembodiments R₁, R₂, and R₃ are each selected from H and methyl. In someembodiments, Z or Z′ on at least one P atom is S, and the other Z or Z′is O (i.e., a phosphorothioate linkage). In some embodiments, each—OP(Z)(Z′)O— is a phosphorothioate linkage. In some embodiments, Z andZ′ are both O on at least one P atom (i.e., a phosphodiester linkage).In some embodiments, each —OP(Z)(Z′)O— is a phosphodiester linkage.

A further nonlimiting exemplary Structure E is Structure E(viii):

wherein L₁, L₂, and L₃ are each, independently, a ligand; Q′₁, Q′₂, Q′₃,and Q″ are each, independently, a linking group; and R₁, R₂, R₃, and R₄are each, independently, selected from H, C₁-C₆ alkyl, and substitutedC₁-C₆ alkyl.

In some embodiments, Q′₁, Q′₂, Q′₃, and Q″ are each, independently,selected from a peptide, an ether, polyethylene glycol, an alkyl, aC₁-C₂₀ alkyl, a substituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, asubstituted C₂-C₂₀ alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀alkynyl, a C₁-C₂₀ alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, apyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate, and 6-aminohexanoicacid. In some embodiments, R₁, R₂, R₃, and R₄ are each, independently,selected from H, methyl, ethyl, propyl, isopropyl, and butyl. In someembodiments R₁, R₂, R₃, and R₄ are each selected from H and methyl.

Nonlimiting exemplary scaffolds and/or linkers comprising scaffolds, andsynthesis thereof, are described, e.g., PCT Publication No. WO2013/033230, U.S. Pat. No. 8,106,022 B2, U.S. Publication No.2012/0157509 A1; U.S. Pat. No. 5,994,517; U.S. Pat. No. 7,491,805 B2;U.S. Pat. No. 8,313,772 B2; Manoharan, M., Chapter 16, Antisense DrugTechnology, Crooke, S. T., Marcel Dekker, Inc., 2001, 391-469.

In some embodiments, the L_(n)-linker portion of the compound comprisesStructure F:

wherein:

B is selected from —O—, —S—, —N(R^(N))—, —Z—P(Z′)(Z″)O—,—Z—P(Z′)(Z″)O—N_(m)—X—, and —Z—P(Z′)(Z″)O—N_(m)—Y—;

MO is a modified oligonucleotide;

R^(N) is selected from H, methyl, ethyl, propyl, isopropyl, butyl, andbenzyl;

Z, Z′, and Z″ are each independently selected from O and S;

each N of N_(m) is, independently, a modified or unmodified nucleoside;

m is from 1 to 5;

X is selected from a phosphodiester linkage and a phosphorothioatelinkage;

Y is a phosphodiester linkage; and

the wavy line indicates the connection to the rest of the linker andligand(s).

In certain embodiments, the wavy line indicates a connection toStructure E, above.

In certain embodiments, n is from 1 to 5, 1 to 4, 1 to 3, or 1 to 2. Incertain embodiments, n is 1. In certain embodiments, n is 2. In certainembodiments, n is 3. In certain embodiments, n is 4. In certainembodiments, n is 5.

In some embodiments, the L_(n)-linker portion of the compound comprisesStructure G:

wherein:B is selected from —O—, —S—, —N(R^(N))—, —Z—P(Z′)(Z″)O—,—Z—P(Z′)(Z″)O—N_(m)—X—, and —Z—P(Z′)(Z″)O—N_(m)—Y—;

MO is a modified oligonucleotide;

R^(N) is selected from H, methyl, ethyl, propyl, isopropyl, butyl, andbenzyl;

Z, Z′, and Z″ are each independently selected from O and S;

each N of N_(m) is, independently, a modified or unmodified nucleoside;

m is from 1 to 5;

X is selected from a phosphodiester linkage and a phosphorothioatelinkage;

Y is a phosphodiester linkage;

each L is, independently, a ligand; n is from 1 to 10; S is a scaffold;and Q′ and Q″ are, independently, linking groups.

In some embodiments, each Q′ and Q″ are independently selected from apeptide, an ether, polyethylene glycol, an alkyl, a C₁-C₂₀ alkyl, asubstituted C₁-C₂₀ alkyl, a C₂-C₂₀ alkenyl, a substituted C₂-C₂₀alkenyl, a C₂-C₂₀ alkynyl, a substituted C₂-C₂₀ alkynyl, a C₁-C₂₀alkoxy, a substituted C₁-C₂₀ alkoxy, amino, amido, a pyrrolidine,8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and 6-aminohexanoic acid.

A nonlimiting exemplary L_(n)-linker portion (e.g., of Structure F or G)of a compound is shown in Structure H below:

wherein the wavy line indicates attachment to the modifiedoligonucleotide (MO), to X₁, e.g. in Structure B, or to X or Y, e.g., inStructure C, or D.

Additional nonlimiting exemplary L_(n)-linker portion of a compound areillustrated in the structures below, wherein the wavy bond indicatesattachment to the modified oligonucleotide (MO), e.g., in Structure A;to X₁, e.g. in Structure B; to X, e.g., in Structure C; or to Y, e.g.,in Structure D.

In certain embodiments, each ligand is a carbohydrate. A compoundcomprising a carbohydrate-conjugated modified oligonucleotide, whenrecognized by a cell surface lectin, is transported across the cellmembrane into the cell. In certain embodiments, a cell surface lectin isa C-type lectin. In certain embodiments, the C-type lectin is present ona Kuppfer cell. In certain embodiments, a C-type lectin is present on amacrophage. In certain embodiments, a C-type lectin is present on anendothelial cell. In certain embodiments, a C-type lectin is present ona monocyte. In certain embodiments, a C-type lectin is present on aleukocyte. In certain embodiments, a C-type lectin is present on adendritic cell. In certain embodiments, a C-type lectin is present on aB cell. A conjugate may facilitate uptake of an anti-miR-122 compoundinto any cell type that expresses a C-type lectin.

In certain embodiments, a C-type lectin is the asialoglycoproteinreceptor (ASGPR). In certain embodiments, a conjugate comprises one ormore ligands having affinity for the ASGPR, including but not limited togalactose or a galactose derivative. In certain embodiments, a ligandhaving affinity for the ASGPR is N-acetylgalactosamine, galactose,galactosamine, N-formylgalactosamine, N-propionyl-galactosamine,N-n-butanoylgalactosamine, or N-iso-butanoyl-galactosamine. Suchconjugates facilitate the uptake of compounds into cells that expressthe ASGPR, for example, hepatocytes and dendritic cells.

In certain embodiments, a ligand is a carbohydrate selected frommannose, glucose, galactose, ribose, arabinose, fructose, fucose,xylose, D-mannose, L-mannose, D-galactose, L-galactose, D-glucose,L-glucose, D-ribose, L-ribose, D-arabinose, L-arabinose, D-fructose,L-fructose, D-fucose, L-fucose, D-xylose, L-xylose,alpha-D-mannofuranose, beta-D-mannofuranose, alpha-D-mannopyranose,beta-D-mannopyranose, alpha-D-glucofuranose, Beta-D-glucofuranose,alpha-D-glucopyranose, beta-D-glucopyranose, alpha-D-galactofuranose,beta-D-galactofuranose, alpha-D-galactopyranose, beta-D-galactopyranose,alpha-D-ribofuranose, beta-D-ribofuranose, alpha-D-ribopyranose,beta-D-ribopyranose, alpha-D-fructofuranose, alpha-D-fructopyranose,glucosamine, galactosamine, sialic acid, and N-acetylgalactosamine.

In certain embodiments, a ligand is selected from N-acetylgalactosamine,galactose, galactosamine, N-formylgalactosamine,N-propionyl-galactosamine, N-n-butanoylgalactosamine, andN-iso-butanoyl-galactosamine.

In certain embodiments, a ligand is N-acetylgalactosamine.

In certain embodiments, a compound comprises the structure:

wherein each N of N_(m) is, independently, a modified or unmodifiednucleoside and m is from 1 to 5; X₁ and X₂ are each, independently, aphosphodiester linkage or a phosphorothioate linkage; and MO is amodified oligonucleotide. In certain embodiments, m is 1. In certainembodiments, m is 2. In certain embodiments, m is 3, 4, or 5. In certainembodiments, m is 2, 3, 4, or 5. In certain embodiments, when m isgreater than 1, each modified or unmodified nucleoside of N_(m) may beconnected to adjacent modified or unmodified nucleosides of N_(m) by aphosphodiester internucleoside linkage or phosphorothioateinternucleoside linkage.

In certain embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage or a phosphorothioate linkage;each N of N_(m) is, independently, a modified or unmodified nucleosideand m is from 1 to 5; Y is a phosphodiester linkage; and MO is amodified oligonucleotide. In certain embodiments, m is 1. In certainembodiments, m is 2. In certain embodiments, m is 3, 4, or 5. In certainembodiments, m is 2, 3, 4, or 5. In certain embodiments, when m isgreater than 1, each modified or unmodified nucleoside of N_(m) may beconnected to adjacent modified or unmodified nucleosides of N_(m) by aphosphodiester internucleoside linkage or phosphorothioateinternucleoside linkage.

In certain embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is,independently, a modified or unmodified nucleoside and m is from 1 to 5;Y is a phosphodiester linkage; and MO is a modified oligonucleotide. Incertain embodiments, m is 1. In certain embodiments, m is 2. In certainembodiments, m is 3, 4, or 5. In certain embodiments, m is 2, 3, 4, or5. In certain embodiments, when m is greater than 1, each modified orunmodified nucleoside of N_(m) may be connected to adjacent modified orunmodified nucleosides of N_(m) by a phosphodiester internucleosidelinkage or phosphorothioate internucleoside linkage.

In some embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages. In someembodiments, Y is linked to the 3′ terminus of MO.

In some embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages; and wherein Y islinked to the 3′ terminus of MO.

In some embodiments, a compound consists of the structure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′ (SEQ ID NO: 7),wherein each nucleoside followed by a subscript “S” is a S-cEtnucleoside, each nucleoside not followed by a subscript is adeoxynucleoside, and each internucleoside linkage between two S-cEtnucleosides is a phosphorothioate linkage, and the remaininginternucleoside linkages are phosphodiester linkages; and wherein Y islinked to the 3′ terminus of MO; or a pharmaceutically acceptable saltthereof.

In some embodiments, a compound has the structure:

wherein each N of N_(m) is, independently, a modified or unmodifiednucleoside and m is from 1 to 5; X₁ and X₂ are each, independently, aphosphodiester linkage or a phosphorothioate linkage; and MO is amodified oligonucleotide.

In certain embodiments, at least one of X₁ and X₂ is a phosphodiesterlinkage. In certain embodiments, each of X₁ and X₂ is a phosphodiesterlinkage.

In certain embodiments, m is 1. In certain embodiments, m is 2. Incertain embodiments, m is 2, 3, 4, or 5. In certain embodiments, m is 3,4, or 5. In certain embodiments, when m is greater than 1, each modifiedor unmodified nucleoside of N_(m) may be connected to adjacent modifiedor unmodified nucleosides of N_(m) by a phosphodiester internucleosidelinkage or a phosphorothioate internucleoside linkage. In certainembodiments, when m is 2, the nucleosides of N_(m) are linked by aphosphodiester internucleoside linkage.

In any of the embodiments described herein, N_(m) may be N′_(p)N“, whereeach N′ is, independently, a modified or unmodified nucleoside and p isfrom 0 to 4; and N” is a nucleoside comprising an unmodified sugarmoiety.

In certain embodiments, p is 0. In certain embodiments, p is 1, 2, 3, or4. In certain embodiments, when p is 1, 2, 3, or 4, each N′ comprises anunmodified sugar moiety.

In certain embodiments, an unmodified sugar moiety is a β-D-ribose or aβ-D-deoxyribose.

In certain embodiments, where p is 1, 2, 3, or 4, N′ comprises a purinenucleobase. In certain embodiments, N″ comprises a purine nucleobase. Incertain embodiments, a purine nucleobase is selected from adenine,guanine, hypoxanthine, xanthine, and 7-methylguanine. In certainembodiments, N is a β-D-deoxyriboadenosine or a β-D-deoxyriboguanosine.In certain embodiments, N″ is a β-D-deoxyriboadenosine or aβ-D-deoxyriboguanosine. In some embodiments, p is 1 and N′ and N″ areeach a β-D-deoxyriboadenosine.

In certain embodiments, where p is 1, 2, 3, or 4, N′ comprises apyrimidine nucleobase. In certain embodiments, N″ comprises a pyrimidinenucleobase. In certain embodiments, a pyrimidine nucleobase is selectedfrom cytosine, 5-methylcytosine, thymine, uracil, and 5,6-dihydrouracil.

In any of the embodiments described herein, the sugar moiety of each Nis independently selected from a β-D-ribose, a β-D-deoxyribose, a2′-O-methoxy sugar, a 2′-O-methyl sugar, a 2′-fluoro sugar, and abicyclic sugar moiety. In certain embodiments, each bicyclic sugarmoiety is independently selected from a cEt sugar moiety, an LNA sugarmoiety, and an ENA sugar moiety. In certain embodiments, the cEt sugarmoiety is an S-cEt sugar moiety. In certain embodiments, the cEt sugarmoiety is an R-cEt sugar moiety. In any embodiments described herein,the sugar moiety of each N may be independently selected fromβ-D-ribose, a β-D-deoxyribose, and a 2′-fluoro sugar.

In certain embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; m is 1; N of N_(m) is aβ-D-deoxyriboadenosine; Y is a phosphodiester linkage; and MO is amodified oligonucleotide.

In certain embodiments, a compound comprises the structure:

wherein X is a phosphodiester linkage; m is 2; each N of N_(m) is aβ-D-deoxyriboadenosine; the nucleosides of N are linked by aphosphodiester internucleoside linkage; Y is a phosphodiester linkage;and MO is a modified oligonucleotide.

Additional moieties for conjugation to a modified oligonucleotideinclude phenazine, phenanthridine, anthraquinone, acridine,fluoresceins, rhodamines, coumarins, and dyes. In certain embodiments, aconjugate group is attached directly to a modified oligonucleotide.

Certain Metabolic Products

Upon exposure to exonucleases and/or endonucleases in vitro or in vivo,compounds may undergo cleavage at various positions throughout thecompound. The products of such cleavage may retain some degree of theactivity of the parent compound, and as such are considered activemetabolites. As such, a metabolic product of a compound may be used inthe methods described herein. In certain embodiments, a modifiedoligonucleotide (unconjugated or conjugated) undergoes cleavage at the5′ end and/or the 3′ end, resulting in a metabolic product that has 1,2, or 3 fewer nucleotides at the 5′ end and/or the 3′ end, relative tothe parent modified oligonucleotide. In certain embodiments, a modifiedoligonucleotide undergoes cleavage at the 5′ end, releasing the5′-terminal nucleotide and resulting in a metabolic product that has 1less nucleotide at the 5′ end, relative to the parent modifiedoligonucleotide. In certain embodiments, a modified oligonucleotideundergoes cleavage at the 5′ end, releasing two 5′-terminal nucleosidesand resulting in a metabolic product that has two fewer nucleotides atthe 5′ end, relative to the parent modified oligonucleotide. In certainembodiments, a modified oligonucleotide undergoes cleavage at the 3′end, releasing the 3′-terminal nucleotide and resulting in a metabolicproduct that has one less nucleotide at the 3′ end, relative to theparent modified oligonucleotide. In certain embodiments, a modifiedoligonucleotide undergoes cleavage at the 3′ end, releasing two3′-terminal nucleosides and resulting in a metabolic product that hastwo fewer nucleotides at the 3′ end, relative to the parent modifiedoligonucleotide.

In some embodiments, the modified oligonucleotides described hereinundergo cleavage between the regions (i.e., oligo1, oligo2, and/oroligo3 in the structures described herein) such that the regions areseparated from one another. For example, where a modifiedoligonucleotide has the structure [oligo1]-[x-N]_(m)-x-[oligo2], in someembodiments, cleavage yields the oligo1 and oligo2, wherein one or botholigos may comprise one or more nucleotides of [x-N]_(m), or one or botholigos may not comprise any nucleotides of [x-N]_(m). Similarly, where amodified oligonucleotide has the structure[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3], in some embodiments,cleavage yields the oligo1, oligo2, and oligo3, wherein one or more ofthe oligos may comprise one or more nucleotides of [x-N]_(m), or one ormore oligos may not comprise any nucleotides of [x-N]_(m). In someembodiments, cleavage may be partial, and yield[oligo1]-[x-N]_(m)-x-[oligo2] and oligo3, or oligo1 and-[oligo2]-[x-N]_(m)-x-[oligo3], again where one or both portions maycomprise one or more nucleotides of [x-N]_(m). In some embodiments, thecleavage occurs in a target tissue. In some embodiments, each region ofthe modified oligonucleotide is more stable than the modified nucleotideas a whole.

Compounds comprising modified oligonucleotide linked to a conjugatemoiety may also undergo cleavage at a site within the linker between themodified oligonucleotide and the ligand. In certain embodiments,cleavage yields the parent modified oligonucleotide comprising a portionof the conjugate moiety. In certain embodiments, cleavage yields theparent modified oligonucleotide comprising one or more subunits of thelinker between the modified oligonucleotide and the ligand. For example,where a compound has the structure L_(n)-linker-N_(m)—P-MO, in someembodiments, cleavage yields the parent modified oligonucleotidecomprising one or more nucleotides of N_(m). In some embodiments,cleavage of a conjugated modified oligonucleotide yields the parentmodified oligonucleotide. In some such embodiments, for example, where acompound has the structure L_(n)-linker-N_(m)—P-MO, in some embodiments,cleavage yields the parent modified oligonucleotide without any of thenucleotides of N_(m).

Certain MicroRNA Targets

In certain embodiments, each nucleobase of a region of a modifiedoligonucleotide targeted to a microRNA is capable of undergoingbase-pairing with a nucleobase at each corresponding position in thenucleobase sequence of the microRNA, or a precursor thereof. In certainembodiments the nucleobase sequence of a region of a modifiedoligonucleotide may have one or more mismatched basepairs with respectto its target microRNA or precursor sequence, and remains capable ofhybridizing to its target sequence.

In certain embodiments, a region of a modified oligonucleotide has anucleobase sequence that is complementary to the nucleobase sequence ofa microRNA precursor, such as a microRNA stem-loop sequence. As a maturemicroRNA is contained within a microRNA precursor sequence, a region ofa modified oligonucleotide having a nucleobase sequence complementary toa microRNA is also complementary to a region of a the correspondingmicroRNA precursor.

In certain embodiments, the number of linked nucleosides of a region ofa modified oligonucleotide is less than the length of a microRNA, or aprecursor thereof. In certain embodiments, the region of the modifiedoligonucleotide has a nucleobase sequence that is complementary to aregion of the microRNA, or the precursor thereof. A region of a modifiedoligonucleotide having a number of linked nucleosides that is less thanthe length of the microRNA, wherein each nucleobase of a modifiedoligonucleotide is complementary to each nucleobase at a correspondingposition in a microRNA nucleobase sequence, is considered to have anucleobase sequence that is fully complementary to a region of amicroRNA nucleobase sequence. For example, a region of a modifiedoligonucleotide consisting of 12 linked nucleosides, where thenucleobases of nucleosides 1 through 12 are each complementary to acorresponding position of a microRNA that is 23 nucleobases in length,is fully complementary to a 12 nucleobase region of the nucleobasesequence of the microRNA. Such a region of a modified oligonucleotidehas a nucleobase sequence that is 100% complementarity to a 22nucleobase portion of the microRNA. Further, such a region of a modifiedoligonucleotide is considered to be 100% complementary to the microRNA.

In certain embodiments, a region of the nucleobase sequence of amodified oligonucleotide is fully complementary to a region of thenucleobase sequence of a microRNA. In certain embodiments, 8 contiguousnucleobases of a modified oligonucleotide are each complementary to 8contiguous nucleobases of a microRNA. In certain embodiments, 9contiguous nucleobases of a modified oligonucleotide are eachcomplementary to 9 contiguous nucleobases of a microRNA. In certainembodiments, 10 contiguous nucleobases of a modified oligonucleotide areeach complementary to 10 contiguous nucleobases of a microRNA. Incertain embodiments, 11 contiguous nucleobases of a modifiedoligonucleotide are each complementary to 11 contiguous nucleobases of amicroRNA. In certain embodiments, 12 contiguous nucleobases of amodified oligonucleotide are each complementary to 12 contiguousnucleobases of a microRNA. In certain embodiments, 13 contiguousnucleobases of a modified oligonucleotide are each complementary to 13contiguous nucleobases of a microRNA. In certain embodiments, 14contiguous nucleobases of a modified oligonucleotide are eachcomplementary to 14 contiguous nucleobases of a microRNA. In certainembodiments, 15 contiguous nucleobases of a modified oligonucleotide areeach complementary to 15 contiguous nucleobases of a microRNA.

In certain embodiments, a region of a modified oligonucleotide comprisesa nucleobase sequence that is complementary to a seed sequence, i.e. theregion comprises a seed-match sequence. In certain embodiments, a seedsequence is a hexamer seed sequence. In certain embodiments, a hexamerseed sequence is nucleobases 1-6 of a microRNA. In certain embodiments,a hexamer seed sequence is nucleobases 2-7 of a microRNA. In certainembodiments, a hexamer seed sequence is nucleobases 3-8 of a microRNA.In certain embodiments, a seed sequence is a heptamer seed sequence. Incertain embodiments, a heptamer seed sequence is nucleobases 1-7 of amicroRNA. In certain embodiments, a heptamer seed sequence isnucleobases 2-8 of a microRNA. In certain embodiments, the seed sequenceis an octamer seed sequence. In certain embodiments, an octamer seedsequence is nucleobases 1-8 of a microRNA. In certain embodiments, anoctamer seed sequence is nucleobases 2-9 of a microRNA.

In certain embodiments, a nucleobase sequence of a region of a modifiedoligonucleotide is 100% complementary to a microRNA nucleobase sequencelisted herein, or a precursor thereof. In certain embodiments, a regionof a modified oligonucleotide has a nucleobase sequence having onemismatch with respect to the nucleobase sequence of a microRNA, or aprecursor thereof. In certain embodiments, a region of a modifiedoligonucleotide has a nucleobase sequence having two mismatches withrespect to the nucleobase sequence of a microRNA, or a precursorthereof. In certain embodiments, a region of a modified oligonucleotidehas a nucleobase sequence having no more than two mismatches withrespect to the nucleobase sequence of a microRNA, or a precursorthereof. In certain embodiments, the mismatched nucleobases arecontiguous. In certain embodiments, the mismatched nucleobases are notcontiguous.

Certain Nucleobase Sequences

Any nucleobase sequences set forth herein, including but not limited tothose found in the Examples and in the sequence listing, are independentof any modification to the nucleic acid. As such, nucleic acids definedby a SEQ ID NO may comprise, independently, one or more modifications toone or more sugar moieties, to one or more internucleoside linkages,and/or to one or more nucleobases.

Although the sequence listing accompanying this filing identifies eachnucleobase sequence as either “RNA” or “DNA” as required, in practice,those sequences may be modified with any combination of chemicalmodifications. One of skill in the art will readily appreciate that suchdesignation as “RNA” or “DNA” to describe modified oligonucleotides issomewhat arbitrary. For example, an oligonucleotide comprising anucleoside comprising a 2′-OH sugar moiety and a thymine base could bedescribed as a DNA having a modified sugar (2′-OH for the natural 2′-Hof DNA) or as an RNA having a modified base (thymine (methylated uracil)for natural uracil of RNA).

Accordingly, nucleic acid sequences provided herein, including, but notlimited to those in the sequence listing, are intended to encompassnucleic acids containing any combination of natural or modified RNAand/or DNA, including, but not limited to such nucleic acids havingmodified nucleobases. By way of further example and without limitation,an oligomeric compound having the nucleobase sequence “ATCGATCG”encompasses any oligomeric compounds having such nucleobase sequence,whether modified or unmodified, including, but not limited to, suchcompounds comprising RNA bases, such as those having sequence “AUCGAUCG”and those having some DNA bases and some RNA bases such as “AUCGATCG”and oligomeric compounds having other modified bases, such as“AT^(me)CGAUCG,” wherein ^(me)C indicates a cytosine base comprising amethyl group at the 5-position.

Certain Synthesis Methods

Modified oligonucleotides may be made with automated, solid phasesynthesis methods known in the art. During solid phase synthesis,phosphoramidite monomers are sequentially coupled to a nucleoside thatis covalently linked to a solid support. This nucleoside is the 3′terminal nucleoside of the modified oligonucleotide. Typically, thecoupling cycle comprises four steps: detritylation (removal of a5′-hydroxyl protecting group with acid), coupling (attachment of anactivated phosphoroamidite to the support bound nucleoside oroligonucleotide), oxidation or sulfurization (conversion of a newlyformed phosphite trimester with an oxidizing or sulfurizing agent), andcapping (acetylation of unreacted 5′-hydroxyl groups). After the finalcoupling cycle, the solid support-bound oligonucleotide is subjected toa detritylation step, followed by a cleavage and deprotection step thatsimultaneously releases the oligonucleotide from the solid support andremoves the protecting groups from the bases. The solid support isremoved by filtration, the filtrate is concentrated and the resultingsolution is tested for identity and purity. The oligonucleotide is thenpurified, for example using a column packed with anion-exhange resin.

GalNAc-conjugated modified oligonucleotides may be made with automatedsolid phase synthesis, similar to the solid phase synthesis thatproduced unconjugated oligonucleotides. During the synthesis ofGalNAc-conjugated oligonucleotides, the phosphoramidite monomers aresequentially coupled to a GalNAc conjugate which is covalently linked toa solid support. The synthesis of GalNAc conjugates and GalNAc conjugatesolid support is described, for example in U.S. Pat. No. 8,106,022,which is herein incorporated by reference in its entiretly for thedescription of the synthesis of carbohydrate-containing conjugates,including conjugates comprising one or more GalNAc moieties, and of thesynthesis of conjugate covalently linked to solid support.

Provided herein are processes of making a GalNAc-conjugated modifiedoligonucleotide having the structure shown in formula (I):

wherein each N of N_(m) is, independently, a modified or unmodifiednucleoside and m is from 1 to 5; X₁ and X₂ are each, independently, aphosphodiester linkage or a phosphorothioate linkage; and MO is amodified oligonucleotide; comprising the steps of:providing a solid support comprising a conjugate as shown in formula IV;deprotecting the DMT group under conditions effective to produce areactive hydroxyl;

performing sequential phosphoramidite coupling steps to form N_(m);performing sequential phosphoramidite coupling steps to form MO;and releasing the conjugated modified oligonucleotide from the solidsupport.

Certain Modifications

Provided herein are compounds comprising modified oligonucleotideshaving the structure [oligo1]-[x-N]_(m)-x-[oligo2] or[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3]. Also provided hereinare compounds comprising a modified oligonucleotide consisting of thestructure [oligo1]-[x-N]_(m)-x-[oligo2.] or[oligo1]-[x-N]_(m)-x-[oligo2]-[x-N]_(m)-x-[oligo3]. In some embodiments,the modified oligonucleotide is attached to a conjugate moiety. Amodified oligonucleotide may comprise one or more modifications to anucleobase, sugar, and/or internucleoside linkage. A modifiednucleobase, sugar, and/or internucleoside linkage may be selected overan unmodified form because of desirable properties such as, for example,enhanced cellular uptake, enhanced affinity for other oligonucleotidesor nucleic acid targets and increased stability in the presence ofnucleases.

In certain embodiments, a modified oligonucleotide comprises one or moremodified nucleosides. In certain embodiments, a modified nucleoside is astabilizing nucleoside. An example of a stabilizing nucleoside is asugar-modified nucleoside.

In certain embodiments, a modified nucleoside comprises a modified sugarmoiety. In certain embodiments, a modified nucleoside comprising amodified sugar moiety comprises an unmodified nucleobase. In certainembodiments, a modified sugar comprises a modified nucleobase. Incertain embodiments, a modified nucleoside is a 2′-modified nucleoside.

In certain embodiments, a 2′-modified nucleoside comprises a bicyclicsugar moiety. In certain embodiments, the bicyclic sugar moiety is a Dsugar in the alpha configuration. In certain embodiments, the bicyclicsugar moiety is a D sugar in the beta configuration. In certainembodiments, the bicyclic sugar moiety is an L sugar in the alphaconfiguration. In certain embodiments, the bicyclic sugar moiety is an Lsugar in the beta configuration.

In certain embodiments, the bicyclic sugar moiety comprises a bridgegroup between the 2′ and the 4′-carbon atoms. In certain embodiments,the bridge group comprises from 1 to 8 linked biradical groups. Incertain embodiments, the bicyclic sugar moiety comprises from 1 to 4linked biradical groups. In certain embodiments, the bicyclic sugarmoiety comprises 2 or 3 linked biradical groups. In certain embodiments,the bicyclic sugar moiety comprises 2 linked biradical groups. Examplesof such 4′ to 2′ sugar substituents, include, but are not limited to:—[C(R_(a))(R_(b))]_(n)—, —[C(R_(a))(R_(b))]_(n)—O—,—C(R_(a)R_(b))—N(R)—O— or, C(R_(a)R_(b))—O—N(R)—; 4′-CH₂-2′,4′—(CH₂)₂-2′, 4′—(CH₂)₃-2′; 4′—(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2′;4′—(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (cEt) and 4′-CH(CH₂OCH₃)—O-2′, andanalogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul. 15,2008); 4′-C(CH₃)(CH₃)—O-2′ and analogs thereof, (see, e.g.,WO2009/006478, published Jan. 8, 2009); 4′-CH₂—N(OCH₃)-2′ and analogsthereof (see, e.g., WO2008/150729, published Dec. 11, 2008);4′-CH₂—O—N(CH₃)-2′ (see, e.g., US2004/0171570, published Sep. 2, 2004);4′-CH₂—O—N(R)-2′, and 4′-CH₂—N(R)—O-2′-, wherein each R is,independently, H, a protecting group, or C₁-C₁₂ alkyl; 4′-CH₂—N(R)—O-2′,wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see, U.S. Pat. No.7,427,672, issued on Sep. 23, 2008); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g.,Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and4′-CH₂—C(═CH₂)-2′ and analogs thereof (see, published PCT InternationalApplication WO 2008/154401, published on Dec. 8, 2008).

In certain embodiments, such 4′ to 2′ bridges independently comprise 1or from 2 to 4 linked groups independently selected from—[C(R_(a))(R_(b))]_(n)—, —C(R_(a))═C(R_(b))—, —C(R_(a))═N—,—C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—, —Si(R_(a))₂—, —S(═O)_(x)—, and—N(R_(a))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl,C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substitutedC₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl,substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycleradical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical,substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃,COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), orsulfoxyl (S(═O)-J₁); and each J₁ and J₂ is, independently, H, C₁-C₁₂alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl,substituted C₅-C₂₀ aryl, acyl (C(═O)—H), substituted acyl, a heterocycleradical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl,substituted C₁-C₁₂ aminoalkyl, or a protecting group.

Nucleosides comprising bicyclic sugar moieties are referred to asbicyclic nucleosides or BNAs. In certain embodiments, bicyclicnucleosides include, but are not limited to, (A) α-L-Methyleneoxy(4′-CH₂—O-2′) BNA; (B) β-D-Methyleneoxy (4′-CH₂—O-2′) BNA; (C)Ethyleneoxy (4′-(CH₂)₂—O-2′) BNA; (D) Aminooxy (4′-CH₂—O—N(R)-2′) BNA;(E) Oxyamino (4′-CH₂—N(R)—O-2′) BNA; (F) Methyl(methyleneoxy)(4′-CH(CH₃)—O-2′) BNA (also referred to as constrained ethyl or cEt);(G) methylene-thio (4′-CH₂—S-2′) BNA; (H) methylene-amino(4′-CH₂—N(R)-2′) BNA; (I) methyl carbocyclic (4′-CH₂—CH(CH₃)-2′) BNA;(J) c-MOE (4′-CH₂—OMe-2′) BNA and (K) propylene carbocyclic(4′-(CH₂)₃-2′) BNA as depicted below.

wherein Bx is a nucleobase moiety and R is, independently, H, aprotecting group, or C₁-C₁₂ alkyl.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from halo, allyl, amino, azido, SH, CN,OCN, CF₃, OCF₃, O—, S—, or N(R_(m))-alkyl; O—, S—, or N(R_(m))-alkenyl;O—, S— or N(R_(m))-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl,aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n))or O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,independently, H, an amino protecting group or substituted orunsubstituted C₁-C₁₀ alkyl. These 2′-substituent groups can be furthersubstituted with one or more substituent groups independently selectedfrom hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂),thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, NH₂, N₃, OCF₃, O—CH₃, O(CH₂)₃NH₂,CH₂—CH═CH₂, O—CH₂—CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃,O—(CH₂)₂—O—N(R_(m))(R_(n)), —O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substitutedacetamide (O—CH₂—C(═O)—N(R_(m))(R_(n)) where each R_(m) and R_(n) is,independently, H, an amino protecting group or substituted orunsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, OCF₃, O—CH₃, OCH₂CH₂OCH₃,2′-O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(CH₃)₂, —O(CH₂)₂O(CH₂)₂N(CH₃)₂, andO—CH₂—C(═O)—N(H)CH₃.

In certain embodiments, a 2′-modified nucleoside comprises a2′-substituent group selected from F, O—CH₃, and OCH₂CH₂OCH₃.

In certain embodiments, a nucleoside comprising a modified sugar moietyis a 4′-thio modified nucleoside. In certain embodiments, a nucleosidecomprising a modified sugar moiety is a 4′-thio-2′-modified nucleoside.A 4′-thio modified nucleoside has a β-D-ribonucleoside where the 4′-Oreplaced with 4′-S. A 4′-thio-2′-modified nucleoside is a 4′-thiomodified nucleoside having the 2′-OH replaced with a 2′-substituentgroup. Suitable 2′-substituent groups include 2′-OCH₃, 2′-O—(CH₂)₂—OCH₃,and 2′-F.

In certain embodiments, a modified oligonucleotide (or a region of amodified oligonucleotide) comprises one or more internucleosidemodifications. In certain embodiments, each internucleoside linkage ofan oligonucleotide is a modified internucleoside linkage. In certainembodiments, a modified internucleoside linkage comprises a phosphorusatom.

In certain embodiments, a modified oligonucleotide comprises at leastone phosphorothioate internucleoside linkage. In certain embodiments,each internucleoside linkage of a region of a modified oligonucleotideis a phosphorothioate internucleoside linkage.

In certain embodiments, a modified internucleoside linkage does notcomprise a phosphorus atom. In certain embodiments, an internucleosidelinkage is formed by a short chain alkyl internucleoside linkage. Incertain embodiments, an internucleoside linkage is formed by acycloalkyl internucleoside linkages. In certain embodiments, aninternucleoside linkage is formed by a mixed heteroatom and alkylinternucleoside linkage. In certain embodiments, an internucleosidelinkage is formed by a mixed heteroatom and cycloalkyl internucleosidelinkages. In certain embodiments, an internucleoside linkage is formedby one or more short chain heteroatomic internucleoside linkages. Incertain embodiments, an internucleoside linkage is formed by one or moreheterocyclic internucleoside linkages. In certain embodiments, aninternucleoside linkage has an amide backbone. In certain embodiments,an internucleoside linkage has mixed N, O, S and CH₂ component parts.

In certain embodiments, a modified oligonucleotide comprises one or moremodified nucleobases.

In certain embodiments, a modified nucleobase is selected from5-hydroxymethyl cytosine, 7-deazaguanine and 7-deazaadenine. In certainembodiments, a modified nucleobase is selected from 7-deaza-adenine,7-deazaguanosine, 2-aminopyridine and 2-pyridone. In certainembodiments, a modified nucleobase is selected from 5-substitutedpyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, a modified nucleobase comprises a polycyclicheterocycle. In certain embodiments, a modified nucleobase comprises atricyclic heterocycle. In certain embodiments, a modified nucleobasecomprises a phenoxazine derivative. In certain embodiments, thephenoxazine can be further modified to form a nucleobase known in theart as a G-clamp. In certain embodiments, a modified oligonucleotidecomprises one or more stabilizing groups that are attached to one orboth termini of an oligonucleotide to enhance properties such as, forexample, nuclease stability. Included in stabilizing groups are capstructures. These terminal modifications protect an oligonucleotide fromexonuclease degradation, and can help in delivery and/or localizationwithin a cell. The cap can be present at the 5′-terminus (5′-cap), or atthe 3′-terminus (3′-cap), or can be present on both termini. Capstructures include, for example, inverted deoxy a basic caps.

Suitable cap structures include a 4′,5′-methylene nucleotide, a1-(beta-D-erythrofuranosyl) nucleotide, a 4′-thio nucleotide, acarbocyclic nucleotide, a 1,5-anhydrohexitol nucleotide, anL-nucleotide, an alpha-nucleotide, a modified base nucleotide, aphosphorodithioate linkage, a threo-pentofuranosyl nucleotide, anacyclic 3′,4′-seco nucleotide, an acyclic 3,4-dihydroxybutyl nucleotide,an acyclic 3,5-dihydroxypentyl nucleotide, a 3′-3′-inverted nucleotidemoiety, a 3′-3′-inverted abasic moiety, a 3′-2′-inverted nucleotidemoiety, a 3′-2′-inverted abasic moiety, a 1,4-butanediol phosphate, a3′-phosphoramidate, a hexylphosphate, an aminohexyl phosphate, a3′-phosphate, a 3′-phosphorothioate, a phosphorodithioate, a bridgingmethylphosphonate moiety, and a non-bridging methylphosphonate moiety5′-amino-alkyl phosphate, a 1,3-diamino-2-propyl phosphate,3-aminopropyl phosphate, a 6-aminohexyl phosphate, a 1,2-aminododecylphosphate, a hydroxypropyl phosphate, a 5′-5′-inverted nucleotidemoiety, a 5′-5′-inverted abasic moiety, a 5′-phosphoramidate, a5′-phosphorothioate, a 5′-amino, a bridging and/or non-bridging5′-phosphoramidate, a phosphorothioate, and a 5′-mercapto moiety.

Certain Pharmaceutical Compositions

Any of the compounds provided herein may be prepared as a pharmaceuticalcomposition. In some embodiments, the pharmaceutical composition isprepared using a pharmaceutically acceptable salt of the compound.Nonlimiting exemplary pharmaceutically acceptable salts include sodiumand potassium. In some embodiments, a pharmaceutical compositioncomprises a compound provided herein (including a pharmaceuticallyacceptable salt thereof) and a pharmaceutically acceptable carrier ordiluent. Nonlimiting exemplary diluents include, for example, sterilewater and sterile saline, such as phosphate-buffered saline (PBS). Insome embodiments, a pharmaceutical composition comprises apharmaceutically acceptable salt of a compound provided hereinformulated in sterile water.

In certain embodiments, a pharmaceutical composition is administered inthe form of a dosage unit (e.g., tablet, capsule, bolus, etc.). In someembodiments, a pharmaceutical composition comprises a compound providedherein at a dose within a range selected from 25 mg to 800 mg, 25 mg to700 mg, 25 mg to 600 mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300mg, 25 mg to 200 mg, 25 mg to 100 mg, 100 mg to 800 mg, 200 mg to 800mg, 300 mg to 800 mg, 400 mg to 800 mg, 500 mg to 800 mg, 600 mg to 800mg, 100 mg to 700 mg, 150 mg to 650 mg, 200 mg to 600 mg, 250 mg to 550mg, 300 mg to 500 mg, 300 mg to 400 mg, and 400 mg to 600 mg. In certainembodiments, such pharmaceutical compositions comprise a compoundprovided herein present at a dose selected from 25 mg, 30 mg, 35 mg, 40mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270mg, 270 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 495mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585mg, 590 mg, 595 mg, 600 mg, 605 mg, 610 mg, 615 mg, 620 mg, 625 mg, 630mg, 635 mg, 640 mg, 645 mg, 650 mg, 655 mg, 660 mg, 665 mg, 670 mg, 675mg, 680 mg, 685 mg, 690 mg, 695 mg, 700 mg, 705 mg, 710 mg, 715 mg, 720mg, 725 mg, 730 mg, 735 mg, 740 mg, 745 mg, 750 mg, 755 mg, 760 mg, 765mg, 770 mg, 775 mg, 780 mg, 785 mg, 790 mg, 795 mg, and 800 mg. Incertain such embodiments, a pharmaceutical composition of the comprisesa dose compound provided herein selected from 25 mg, 50 mg, 75 mg, 100mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700mg, and 800 mg.

In certain embodiments, a pharmaceutical composition comprising acompound provided herein is administered at a dose of 10 mg/kg or less,9 mg/kg or less, 8 mg/kg or less, 7.5 mg/kg or less, 7 mg/kg or less,6.5 mg/kg or less, 6 mg/kg or less, 5.5 mg/kg or less, 5 mg/kg or less,4.5 mg/kg or less, 4 mg/kg or less, 3.5 mg/kg or less, 3 mg/kg or less,2.5 mg/kg or less, 2 mg/kg or les, 1.5 mg/kg or less, 1 mg/kg or less,0.75 mg/kg or less, 0.5 mg/kg or less, or 0.25 mg/kg or less.

In certain embodiments, a pharmaceutical agent is sterile lyophilizedcompound that is reconstituted with a suitable diluent, e.g., sterilewater for injection or sterile saline for injection. The reconstitutedproduct is administered as a subcutaneous injection or as an intravenousinfusion after dilution into saline. The lyophilized drug productconsists of a compound which has been prepared in water for injection,or in saline for injection, adjusted to pH 7.0-9.0 with acid or baseduring preparation, and then lyophilized. The lyophilized compound maybe 25-800 mg of an oligonucleotide. It is understood that thisencompasses 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300,325, 350, 375, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675,700, 725, 750, 775, and 800 mg of modified lyophilized oligonucleotide.Further, in some embodiments, the lyophilized compound is present in anamount that ranges from 25 mg to 800 mg, 25 mg to 700 mg, 25 mg to 600mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300 mg, 25 mg to 200 mg,25 mg to 100 mg, 100 mg to 800 mg, 200 mg to 800 mg, 300 mg to 800 mg,400 mg to 800 mg, 500 mg to 800 mg, 600 mg to 800 mg, 100 mg to 700 mg,150 mg to 650 mg, 200 mg to 600 mg, 250 mg to 550 mg, 300 mg to 500 mg,300 mg to 400 mg, or 400 mg to 600 mg. The lyophilized drug product maybe packaged in a 2 mL Type I, clear glass vial (ammoniumsulfate-treated), stoppered with a bromobutyl rubber closure and sealedwith an aluminum FLIP-OFF® overseal.

In certain embodiments, a pharmaceutical composition provided hereincomprises a compound in a therapeutically effective amount. In certainembodiments, the therapeutically effective amount is sufficient toprevent, alleviate or ameliorate symptoms of a disease or to prolong thesurvival of the subject being treated. Determination of atherapeutically effective amount is well within the capability of thoseskilled in the art.

In certain embodiments, the pharmaceutical compositions provided hereinmay additionally contain other adjunct components conventionally foundin pharmaceutical compositions, at their art-established usage levels.Thus, for example, the compositions may contain additional, compatible,pharmaceutically-active materials such as, for example, antipruritics,astringents, local anesthetics or anti-inflammatory agents, or maycontain additional materials useful in physically formulating variousdosage forms of the compositions of the present invention, such as dyes,flavoring agents, preservatives, antioxidants, opacifiers, thickeningagents and stabilizers. However, such materials, when added, should notunduly interfere with the biological activities of the components of thecompositions of the present invention. The formulations can besterilized and, if desired, mixed with auxiliary agents, e.g.,lubricants, preservatives, stabilizers, wetting agents, emulsifiers,salts for influencing osmotic pressure, buffers, colorings, flavoringsand/or aromatic substances and the like which do not deleteriouslyinteract with the oligonucleotide(s) of the formulation.

Lipid moieties have been used in nucleic acid therapies in a variety ofmethods. In one method, the nucleic acid is introduced into preformedliposomes or lipoplexes made of mixtures of cationic lipids and neutrallipids. In another method, DNA complexes with mono- or poly-cationiclipids are formed without the presence of a neutral lipid. In certainembodiments, a lipid moiety is selected to increase distribution of apharmaceutical agent to a particular cell or tissue. In certainembodiments, a lipid moiety is selected to increase distribution of apharmaceutical agent to fat tissue. In certain embodiments, a lipidmoiety is selected to increase distribution of a pharmaceutical agent tomuscle tissue.

In certain embodiments, INTRALIPID is used to prepare a pharmaceuticalcomposition comprising an oligonucleotide. Intralipid is fat emulsionprepared for intravenous administration. It is made up of 10% soybeanoil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water forinjection. In addition, sodium hydroxide has been added to adjust the pHso that the final product pH range is 6 to 8.9.

In certain embodiments, a pharmaceutical composition provided hereincomprises a polyamine compound or a lipid moiety complexed with anucleic acid. Such preparations are described in PCT publicationWO/2008/042973, which is herein incorporated by reference in itsentirety for the disclosure of lipid preparations. Certain additionalpreparations are described in Akinc et al., Nature Biotechnology 26,561-569 (1 May 2008), which is herein incorporated by reference in itsentirety for the disclosure of lipid preparations.

In certain embodiments, pharmaceutical compositions provided hereincomprise one or more compounds and one or more excipients. In certainsuch embodiments, excipients are selected from water, salt solutions,alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesiumstearate, talc, silicic acid, viscous paraffin, hydroxymethylcelluloseand polyvinylpyrrolidone.

In certain embodiments, a pharmaceutical composition provided herein isprepared using known techniques, including, but not limited to mixing,dissolving, granulating, dragee-making, levigating, emulsifying,encapsulating, entrapping or tableting processes.

In certain embodiments, a pharmaceutical composition provided herein isa liquid (e.g., a suspension, elixir and/or solution). In certain ofsuch embodiments, a liquid pharmaceutical composition is prepared usingingredients known in the art, including, but not limited to, water,glycols, oils, alcohols, flavoring agents, preservatives, and coloringagents.

In certain embodiments, a pharmaceutical composition provided herein isa solid (e.g., a powder, tablet, and/or capsule). In certain of suchembodiments, a solid pharmaceutical composition comprising one or moreoligonucleotides is prepared using ingredients known in the art,including, but not limited to, starches, sugars, diluents, granulatingagents, lubricants, binders, and disintegrating agents.

In certain embodiments, a pharmaceutical composition provided herein isformulated as a depot preparation. Certain such depot preparations aretypically longer acting than non-depot preparations. In certainembodiments, such preparations are administered by implantation (forexample subcutaneously or intramuscularly) or by intramuscularinjection. In certain embodiments, depot preparations are prepared usingsuitable polymeric or hydrophobic materials (for example an emulsion inan acceptable oil) or ion exchange resins, or as sparingly solublederivatives, for example, as a sparingly soluble salt.

In certain embodiments, a pharmaceutical composition provided hereincomprises a delivery system. Examples of delivery systems include, butare not limited to, liposomes and emulsions. Certain delivery systemsare useful for preparing certain pharmaceutical compositions includingthose comprising hydrophobic compounds. In certain embodiments, certainorganic solvents such as dimethylsulfoxide are used.

In certain embodiments, a pharmaceutical composition provided hereincomprises one or more tissue-specific delivery molecules designed todeliver the one or more compounds provided herein to specific tissues orcell types. For example, in certain embodiments, pharmaceuticalcompositions include liposomes coated with a tissue-specific antibody.

In certain embodiments, a pharmaceutical composition provided hereincomprises a co-solvent system. Certain of such co-solvent systemscomprise, for example, benzyl alcohol, a nonpolar surfactant, awater-miscible organic polymer, and an aqueous phase. In certainembodiments, such co-solvent systems are used for hydrophobic compounds.A non-limiting example of such a co-solvent system is the VPD co-solventsystem, which is a solution of absolute ethanol comprising 3% w/v benzylalcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/vpolyethylene glycol 300. The proportions of such co-solvent systems maybe varied considerably without significantly altering their solubilityand toxicity characteristics. Furthermore, the identity of co-solventcomponents may be varied: for example, other surfactants may be usedinstead of Polysorbate 80™; the fraction size of polyethylene glycol maybe varied; other biocompatible polymers may replace polyethylene glycol,e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides maysubstitute for dextrose.

In certain embodiments, a pharmaceutical composition provided hereincomprises a sustained-release system. A non-limiting example of such asustained-release system is a semi-permeable matrix of solid hydrophobicpolymers. In certain embodiments, sustained-release systems may,depending on their chemical nature, release pharmaceutical agents over aperiod of hours, days, weeks or months.

In certain embodiments, a pharmaceutical composition provided herein isprepared for oral administration. In certain of such embodiments, apharmaceutical composition is formulated by combining one or morecompounds comprising a modified oligonucleotide with one or morepharmaceutically acceptable carriers. Certain of such carriers enablepharmaceutical compositions to be formulated as tablets, pills, dragees,capsules, liquids, gels, syrups, slurries, suspensions and the like, fororal ingestion by a subject. In certain embodiments, pharmaceuticalcompositions for oral use are obtained by mixing oligonucleotide and oneor more solid excipient. Suitable excipients include, but are notlimited to, fillers, such as sugars, including lactose, sucrose,mannitol, or sorbitol; cellulose preparations such as, for example,maize starch, wheat starch, rice starch, potato starch, gelatin, gumtragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodiumcarboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certainembodiments, such a mixture is optionally ground and auxiliaries areoptionally added. In certain embodiments, pharmaceutical compositionsare formed to obtain tablets or dragee cores. In certain embodiments,disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar,or alginic acid or a salt thereof, such as sodium alginate) are added.

In certain embodiments, dragee cores are provided with coatings. Incertain such embodiments, concentrated sugar solutions may be used,which may optionally contain gum arabic, talc, polyvinyl pyrrolidone,carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquersolutions, and suitable organic solvents or solvent mixtures. Dyestuffsor pigments may be added to tablets or dragee coatings.

In certain embodiments, pharmaceutical compositions for oraladministration are push-fit capsules made of gelatin. Certain of suchpush-fit capsules comprise one or more pharmaceutical agents of thepresent invention in admixture with one or more filler such as lactose,binders such as starches, and/or lubricants such as talc or magnesiumstearate and, optionally, stabilizers. In certain embodiments,pharmaceutical compositions for oral administration are soft, sealedcapsules made of gelatin and a plasticizer, such as glycerol orsorbitol. In certain soft capsules, one or more pharmaceutical agents ofthe present invention are be dissolved or suspended in suitable liquids,such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Inaddition, stabilizers may be added.

In certain embodiments, pharmaceutical compositions are prepared forbuccal administration. Certain of such pharmaceutical compositions aretablets or lozenges formulated in conventional manner.

In certain embodiments, a pharmaceutical composition is prepared foradministration by injection (e.g., intravenous, subcutaneous,intramuscular, etc.). In certain of such embodiments, a pharmaceuticalcomposition comprises a carrier and is formulated in aqueous solution,such as water or physiologically compatible buffers such as Hanks'ssolution, Ringer's solution, or physiological saline buffer. In certainembodiments, other ingredients are included (e.g., ingredients that aidin solubility or serve as preservatives). In certain embodiments,injectable suspensions are prepared using appropriate liquid carriers,suspending agents and the like. Certain pharmaceutical compositions forinjection are presented in unit dosage form, e.g., in ampoules or inmulti-dose containers. Certain pharmaceutical compositions for injectionare suspensions, solutions or emulsions in oily or aqueous vehicles, andmay contain formulatory agents such as suspending, stabilizing and/ordispersing agents. Certain solvents suitable for use in pharmaceuticalcompositions for injection include, but are not limited to, lipophilicsolvents and fatty oils, such as sesame oil, synthetic fatty acidesters, such as ethyl oleate or triglycerides, and liposomes. Aqueousinjection suspensions may contain substances that increase the viscosityof the suspension, such as sodium carboxymethyl cellulose, sorbitol, ordextran. Optionally, such suspensions may also contain suitablestabilizers or agents that increase the solubility of the pharmaceuticalagents to allow for the preparation of highly concentrated solutions.

In certain embodiments, a pharmaceutical composition is prepared fortransmucosal administration. In certain of such embodiments penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art.

In certain embodiments, a composition is provided comprising a compoundas described herein, wherein the viscosity level is less than 60 cP. Incertain embodiments, the composition has a viscosity level less than 50cP. In certain embodiments, the composition has a viscosity level lessthan 40 cP. In certain embodiments, the composition has a viscositylevel less than 30 cP. In certain embodiments, the composition has aviscosity level less than 20 cP. In certain embodiments, a viscositylevel less than 20 cP allows for a compound concentration of about 200mg/mL, which, in some embodiments, is suitable for subcutaneousinjection.

In certain embodiments, one or more compounds provided herein isadministered as a prodrug. In certain embodiments, upon in vivoadministration, a prodrug is chemically or enzymatically converted tothe biologically, pharmaceutically or therapeutically more active formof an oligonucleotide. In certain embodiments, prodrugs are usefulbecause they are easier to administer than the corresponding activeform. For example, in certain instances, a prodrug may be morebioavailable (e.g., through oral administration) than is thecorresponding active form. In certain embodiments, prodrugs possesssuperior transmittal across cell membranes. In certain embodiments, aprodrug facilitates delivery of a modified oligonucleotide to thedesired cell type, tissue, or organ. In certain embodiments, a prodrugis a compound comprising a conjugated modified oligonucleotide. Incertain instances, a prodrug may have improved solubility compared tothe corresponding active form. In certain embodiments, prodrugs are lesswater soluble than the corresponding active form. In certainembodiments, a prodrug is an ester. In certain such embodiments, theester is metabolically hydrolyzed to carboxylic acid uponadministration. In certain instances the carboxylic acid containingcompound is the corresponding active form. In certain embodiments, aprodrug comprises a short peptide (polyaminoacid) bound to an acidgroup. In certain of such embodiments, the peptide is cleaved uponadministration to form the corresponding active form.

In certain embodiments, a prodrug is produced by modifying apharmaceutically active compound such that the active compound will beregenerated upon in vivo administration. The prodrug can be designed toalter the metabolic stability or the transport characteristics of adrug, to mask side effects or toxicity, to improve the flavor of a drug,and/or to alter other characteristics or properties of a drug. By virtueof knowledge of pharmacodynamic processes and drug metabolism in vivo,those of skill in this art, once a pharmaceutically active compound isknown, can design prodrugs of the compound (see, e.g., Nogrady (1985)Medicinal Chemistry A Biochemical Approach, Oxford University Press, NewYork, pages 388-392). In certain embodiments, a prodrug is a compoundcomprising a modified oligonucleotide is linked to a conjugated moietyin such a way as to allow for cleavage of the conjugate moiety andregeneration of the modified oligonucleotide upon in vivoadministration. A compound comprising a modified oligonucleotide linkedto a cleavable conjugate moiety, such as, for example, a compound ofstructure B, C, D, (I), or (II) described herein, may release themodified oligonucleotide in its unconjugated form, upon in vivoadministration.

Certain Routes of Administration

In certain embodiments, administering to a subject comprises parenteraladministration. In certain embodiments, administering to a subjectcomprises intravenous administration. In certain embodiments,administering to a subject comprises subcutaneous administration.

In certain embodiments, administering to a subject comprisesintraarterial, pulmonary, oral, rectal, transmucosal, intestinal,enteral, topical, transdermal, suppository, intrathecal,intraventricular, intraperitoneal, intranasal, intraocular,intramuscular, intramedullary, and intratumoral administration.

Certain Additional Therapies

Treatments for metabolic disorders may comprise more than one therapy.As such, in certain embodiments the present invention provides methodsfor treating metabolic disorders comprising administering to a subjectin need thereof a compound comprising at least one region complementaryto miR-103 and/or miR-107, or a precursor thereof, and furthercomprising administering at least one additional pharmaceutical agent.

In certain embodiments, the additional pharmaceutical agent is aglucose-lowering agent.

In certain embodiments, the glucose-lowering agent is a PPAR agonist(gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a GLP-Ianalog (such as albiglutide (Eperzan®, GSK)), insulin or an insulinanalog, an insulin secretagogue, a SGLT2 inhibitor, a human amylinanalog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, athiazolidinedione, or a sulfonylurea.

In certain embodiments, the glucose-lowering agent is a long-actinginsulin, such as insulin glargine (Lantus®, Sanofi-Aventis) or insulindetemir (Levemir®, Novo Nordisk). In certain embodiments, an additionaltherapy comprises an insulin pump.

In certain embodiments, the glucose-lowering agent is a GLP-I analog. Incertain embodiments, the GLP-I analog is exendin-4 or liraglutide.

In certain embodiments, the glucose-lowering agent is a sulfonylurea. Incertain embodiments, the sulfonylurea is acetohexamide, chlorpropamide,tolbutamide, tolazamide, glimepiride, a glipizide, a glyburide, or agliclazide.

In certain embodiments, the glucose-lowering agent is a biguanide. Incertain embodiments, the biguanide is metformin. In certain embodiments,blood glucose levels are decreased without increased lactic acidosis ascompared to the lactic acidosis observed after treatment with metforminalone.

In certain embodiments, the glucose-lowering agent is a meglitinide. Incertain embodiments, the meglitinide is nateglinide or repaglinide.

In certain embodiments, the glucose-lowering agent is athiazolidinedione. In certain embodiments, the thiazolidinedione ispioglitazone, rosiglitazone, or troglitazone. In certain embodiments,blood glucose levels are decreased without greater weight gain thanobserved with rosiglitazone treatment alone.

In certain embodiments, the glucose-lowering agent is analpha-glucosidase inhibitor. In certain embodiments, thealpha-glucosidase inhibitor is acarbose or miglitol.

In certain embodiments, the glucose-lowering agent is an antisenseoligonucleotide targeted to PTP1B. In certain embodiments, theglucose-lowering agent is an antisense oligonucleotide targeted toSGLT2.

In certain embodiments, an additional therapy is an anti-obesity agent.In certain embodiments, an anti-obesity agent is Orlistat, Sibutramine,or Rimonabant.

In a certain embodiment, the additional therapy is therapeutic lifestylechange. In certain embodiments, the therapeutic lifestyle changeincludes an exercise regimen and/or diet.

In certain embodiments the dose of an additional pharmaceutical agent isthe same as the dose that would be administered if the additionalpharmaceutical agent was administered alone.

In certain embodiments the dose of an additional pharmaceutical agent islower than the dose that would be administered if the additionalpharmaceutical agent was administered alone. In certain embodiments thedose of an additional pharmaceutical agent is greater than the dose thatwould be administered if the additional pharmaceutical agent wasadministered alone.

Further examples of additional pharmaceutical agents include, but arenot limited to, corticosteroids, including but not limited toprednisone; immunoglobulins, including, but not limited to intravenousimmunoglobulin (IVIg); analgesics (e.g., acetaminophen);anti-inflammatory agents, including, but not limited to non-steroidalanti-inflammatory drugs (e.g., ibuprofen, COX-I inhibitors, and COX-2,inhibitors); salicylates; antibiotics; antivirals; antifungal agents;antidiabetic agents (e.g., biguanides, glucosidase inhibitors, insulins,sulfonylureas, and thiazolidenediones); adrenergic modifiers; diuretics;hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin,progestin, somatostan, and thyroid hormones); immunomodulators; musclerelaxants; antihistamines; osteoporosis agents (e.g., biphosphonates,calcitonin, and estrogens); prostaglandins, antineoplastic agents;psychotherapeutic agents; sedatives; poison oak or poison sumacproducts; antibodies; and vaccines.

In certain embodiments, an additional therapy is a lipid-loweringtherapy. In certain such embodiments, a lipid-lowering therapy istherapeutic lifestyle change. In certain such embodiments, alipid-lowering therapy is LDL apheresis.

Certain Kits

Any compound provided herein can be present in a kit. The kit can alsocontain instructions for using a compound provided herein. In someembodiments, a compound provided herein can be present within a vial. Aplurality of vials, such as 10, can be present in, for example,dispensing packs. In some embodiments, the vial is manufactured so as tobe accessible with a syringe.

In some embodiments, the kits may be used for administration a compoundprovided herein to a subject. In such instances, in addition to acompound provided herein, the kit can further comprise one or more ofthe following: syringe, alcohol swab, cotton ball, and/or gauze pad. Insome embodiments, the compounds can be present in a pre-filled syringe(such as a single-dose syringes with, for example, a 27 gauge, ½ inchneedle with a needle guard), rather than in a vial. A plurality ofpre-filled syringes, such as 10, can be present in, for example,dispensing packs. The kit can also contain instructions foradministering the compounds.

Certain Experimental Models

In certain embodiments, the present invention provides methods of usingand/or testing compounds of the present invention in an experimentalmodel. Those having skill in the art are able to select and modify theprotocols for such experimental models to evaluate a pharmaceuticalagent of the invention.

Generally, compounds are first tested in cultured cells. Suitable celltypes include those that are related to the cell type to which deliveryof a compound is desired in vivo. For example, suitable cell types forthe study of the methods described herein include primary hepatocytes,primary adipocytes, preadipocytes, differentiated adipocytes, HepG2cells, Huh7 cells, Hep3b, SNU449, 3T3L1 cells, and C2C12 cells (murinemyoblasts).

In certain embodiments, the extent to which a compound interferes withthe activity of a miRNA is assessed in cultured cells. In certainembodiments, inhibition of miRNA activity may be assessed by measuringthe levels of the miRNA. Alternatively, the level of a predicted orvalidated miRNA target may be measured. An inhibition of miRNA activitymay result in the increase in the mRNA and/or protein of a miRNA target.Further, in certain embodiments, certain phenotypic outcomes may bemeasured. For example, suitable phenotypic outcomes include insulingsignaling. Suitable experimental animal models for the testing of themethods described herein include: ob/ob mice (a model for diabetes,obesity and insulin resistance), db/db mice (a model for diabetes,obesity and insulin resistance), high-fat fed C57B16/J mice, KKay mice,NZO-based mouse models, chemically-induced diabetic mouse models, Zuckerdiabetic rats, and aP2-SREBP transgenic mice.

Certain Quantitation Assays

The effects of a compound on the activity of its target RNA(s) may beassessed by a variety of methods known in the art. In certainembodiments, these methods are be used to quantitate microRNA levels incells or tissues in vitro or in vivo.

In certain embodiments, changes in target levels and/or activity aremeasured by microarray analysis. In certain embodiments, changes intarget levels and/or activity are measured by one of severalcommercially available PCR assays, such as the TaqMan® MicroRNA Assay(Applied Biosystems).

In vitro activity of anti-miR compounds may be assessed using aluciferase cell culture assay. In this assay, a microRNA luciferasesensor construct is engineered to contain one or more binding sites ofthe microRNA of interest, and a luciferase gene. When the microRNA bindsto its cognate site in the luciferase sensor construct, luciferaseexpression is suppressed. When the appropriate anti-miR is introducedinto the cells, it binds to the target microRNA and relieves suppressionof luciferase expression. Thus, in this assay anti-miRs that areeffective inhibitors of the anti-miR of interest will cause an increasein luciferase expression.

Activity of anti-miR compounds may be assessed by measuring the mRNAand/or protein level of a target of a microRNA. A microRNA binds to itscognate site within one or more target RNAs, leading to suppression of atarget RNA, thus inhibition of the microRNA results in the increase inthe level of mRNA and/or protein of a target of the microRNA (i.e.,derepression). The derepression of one or more target RNAs may bemeasured in vivo or in vitro.

EXAMPLES

The following examples are presented in order to more fully illustratesome embodiments of the invention. They should, in no way be construed,however, as limiting the broad scope of the invention.

Those of ordinary skill in the art will readily adopt the underlyingprinciples of this discovery to design various compounds withoutdeparting from the spirit of the current invention.

Where provided, statistical significance is defined as follows: ****=pvalue of <0.0001; ***=p value of 0.0001 to 0.001; **=p value of 0.001 to0.01; *=p value of 0.01 to 0.05.

Throughout the examples, unless otherwise indicated, dosages orconcentrations of conjugated compounds refer to the amount of the entirecompound, and not a portion thereof. For example, a 5 mg/kg dose means 5mg of the conjugated modified oligonucleotide, per kg body weight.

Example 1 Anti-miR-103/107 Compound Screening

Previous studies have tested a cholesterol-conjugated, 2′-OMe modifiedanti-miR-103/107 compound in mouse models of impaired insulinsensitivity and glucose tolerance. While efficacy was observed followingtreatment with this compound, the required dose to achieve efficacy washigh, and also required intravenous administration, which is potentiallyinconvenient for the treatment of a chronic disease such as diabetes.Additional studies have tested a 2′-MOE/2′-fluoro modifiedanti-miR-103/107 compound, however compounds comprising 2′-fluoromodifications may cause immune stimulation when administered to animals.In view of the need for a therapeutic agent to be efficacious,convenient to administer, and safe, a screen was performed foranti-miR-103/107 compounds that are candidate therapeutic agents. Anumber of properties were evaluated, including efficacy in models ofinsulin resistance and diabetes, cross-reactivity with microRNAs ofrelated sequence, stimulation of inflammation, viscosity, andpharmacokinetic profile.

Hundreds of compounds were designed, having varying lengths and chemicalcomposition. The compounds are tested in a number of assays, to evaluatein vitro inhibitory activity, in vitro cell viability, metabolicstability (i.e. resistance to endonucleoase activity in a liver lysate),in vivo immunostimulatory activity (as measured by in vivo induction ofIFIT and/or OASL), viscosity, efficacy in relevant disease models,safety, and pharmacokinetics. Of the hundreds of compounds that weredesigned, only a few compounds met the selection criteria for allproperties evaluated.

Example 2 Cross-Reactivity of Anti-miR-103 Compounds within miR-15Family

One criteria for selecting a potential therapeutic candidate was a lackof cross-reactivity with microRNAs having similar nucleobase sequence.Nucleobases 1-6 of miR-103 and miR-107 are identical to nucleobases 2-7of members of the miR-15 family, which includes miR-15a, miR-15b,miR-16, miR-195, miR-497, miR-503, miR-424, and miR-646 (see Tablebelow). Although there is little sequence similarity outside the seedregion, due to the importance of targeting the seed region, the abilityof anti-miR-103/107 compounds to also inhibit a miR-15 family member wasevaluated, to ensure that anti-miR-103/107 compounds would not alsoinhibit a miR-15 family member. Because miR-15 family members areproposed to act as tumor suppressors, it is preferable to avoidinadvertent inhibition of a miR-15 family member.

Compounds were tested for the ability to inhibit miR-16 in a luciferaseassay, and/or to hybridize to miR-16 (via a biochemical assay thatmeasures the ability of an anti-miR to associate with the target miR inthe Ago complex). miR-16 was selected a representative member of themiR-15 family.

Through testing the ability of the compounds to hybridize to miR-16, itwas observed that compounds with complete complementarity to nucleotides1-6 of miR-107 and miR-103 were able to hybridize to miR-16. Changes tothe anti-miR-103/107 sequence were tested to determine whetherintroduction of a mismatch at the position complementary to position 1of miR-103/107 (which corresponds to position 2 of miR-16 and itsrelated family members) could reduce binding to miR-16. The relevantnucleobase positions are underscored in Table A below.

TABLE A SEQ miR/anti-miR Sequence ID NO miR-16 (3′ to 5′)3′-GCGGUUAUAAAU 14 GCACGACGAU-5′ miR-103 (3′ to 5′) 3′-AGUAUCGGGACA  1UGUUACGACGA-5′ anti-miR-103/107 5′-ATAGCCCTGTAC 20 (5′ to 3′)AATGCTGCU-3′ U at 3′ end anti-miR-103/107 5′-ATAGCCCTGTAC 21 (5′ to 3′)AATGCTGCA-3′ A at 3′ end Anti-miR-103/107 5′-ATAGCCCTGTAC 22 (5′ to 3′)AATGCTGCC-3′ C at 3′ end

When the nucleobase at this position was changed from a U to an A, itwas observed that the anti-miR no longer hybridized to miR-16. Thismismatch did not significantly affect the ability of the compound toinhibit the activity of miR-103/107. Thus, an anti-miR nucleobasesequence was identified that inhibited miR-103/107, with minimal to nocross-reactivity with a miR-15 family member. The elimination ofcross-reactivity was observed for a number of anti-miR-103/107 compoundsof varying lengths and nucleoside sugar composition (cEt, 2′-MOE,2′-OMe, and DNA), suggesting that the effect of the nucleobase change isindependent of the chemical modifications in the anti-miR. An exceptionwas observed with 2′-F/2′-MOE modified compounds, which retainedcross-reactivity despite having a mismatch at the 3′ terminus of thecompound.

Similarly, when the nucleobase at the 3′ terminus was changed from a Uto a C, it was observed that the anti-miR no longer hybridized tomiR-16, yet the mismatch did not significantly impact the ability of thecompound to inhibit the activity of miR-103/107. Thus, the eliminationof cross-reactivity, with simultaneous retention of potency, wasobserved for multiple nucleobase changes at the position opposite the 5′terminal position of miR-103/107.

Example 3 Efficacy in Models of Insulin Resistance

To determine the effects of anti-miR-103/107 compounds on glucose andinsulin levels, compounds are administered to high-fat fed obese mice(also called diet-induced obese mice or DIO mice), a model of impairedglucose tolerance and type 2 diabetes. Studies are conducted accordingto standard protocols for this model, as described below.

General Protocol for DIO Model

Mice on a high fat (60% of Kcal from fat—Research Diet RD12492) arerandomized into treatment groups based on similar baseline bodyweight,blood glucose and insulin. The animals are then dosed once weekly viasubcutaneous injection near the subscapular region with a volume of 4mL/kg. Bodyweight is measured and monitored weekly.

Fasting blood glucose and fasting plasma insulin are measured weeklyafter a 4 to 6 hour fast. For example, for the first blood collection, 2or 3 days after the second dose (week 1), the animals are fasted for 4hours and blood glucose is measured via tail nick using a hand heldglucometer (GE100). Final blood collection for glucose and insulin is 2to 4 days after the final dose. In some studies, during week 3, an oralglucose tolerance test (OGTT) is performed. An oral glucose tolerancetest (OGTT) determines how quickly glucose is cleared from the bloodafter glucose administration. After a 4 hour fast, blood is taken formeasurements of fasting glucose and insulin. Next, 2 g/kg of dextrose isadministered to each animal 30 minutes after the oral dose of dextrose,blood is taken again for measurements of glucose and insulin. After fourweeks of dosing (total of 5 doses), animals are sacrificed 72 to 96hours after the last dose. Alternatively, animals may be dosed for atotal of 6 or 7 doses.

Liver, kidney and adipose (epidydmal and subcutaneous depots) arecollected for PK analysis.

Liver and adipose (epidydmal, subcutaneous and brown fat) are collectedfor target gene expression.

Liver is also collected for triglyceride levels. Blood is collected forserum analysis.

An insulin resistance score (HOMA-IR) can be calculated according to thefollowing formula: fasting plasma glucose (mg/dl) times fasting seruminsulin (ng/ml) divided by 16.34. Low HOMA-IR values indicate highinsulin sensitivity, whereas high HOMA-IR values indicate low insulinsensitivity (insulin resistance).

Insulin sensitivity may be evaluated using a hyperinsulinemic euglycemicclamp assay. In this assay, catheterized mice receive an infusion ofglucose and insulin. The insulin is infused at a constant high level(hyperinsulinemic), while the glucose is infused at a variable rate tomaintain blood glucose at a constant, normal (euglycemic) level. Therate of glucose infusion indicates the sensitivity to insulin, e.g. anincreased glucose infusion rate indicates an increased sensitivity toinsulin. For a DIO mouse, fed a high fat diet for 20 weeks, a typicalinfusion rate is 5-10 mg/kg/min. For a normal mouse, fed a normal dietfor 24 weeks, a typical infusion rate is 30-40 mg/kg/min.

Anti-miR-103/107 Compound Screening in DIO Model

A 2′-F/2′-MOE modified compound (compound 97243, below) had previouslydemonstrated efficacy in a mouse model of insulin resistance anddiabetes, however this compound induces expression of the IFIT gene inan in vivo assay, and hybridizes to the miR-16 sequence, making thecompound unsuitable as a potential therapeutic agent. However, due toits efficacy, this compound in the mouse models of insulin resistancewas used as a benchmark for in vivo screening of compounds that were atleast as efficacious, yet did not cause immune stimulation and are notcross-reactive with the miR-15 family.

Compound 97243 has the structure:T_(E)G_(E)A_(F)U_(F)A_(F)G_(F)C_(F)C_(F)C_(F)U_(F)G_(F)U_(F)A_(E)^(m)C_(E)A_(E)A_(F)U_(F)G_(F)C_(F)U_(F)G_(F) ^(m)C_(E)T_(E) (SEQ ID NO:23) where subscript “F” indicates a 2′-fluoro nucleoside, subscript “E”indicates a 2′-O-methoxyethyl nucleoside, all linkages arephosphorothioate and subscript “m” indicates 5-methylcytosine.

Compound 12743 (structure in Table B below) was designed, synthesizedand tested in the in vitro luciferase and IFIT assays. As the compoundperformed well in these assays, it was further tested for efficacy. Inthis study, DIO mice (fed a high fat diet for ˜15 weeks) were sortedinto treatment groups based on body weight, fasting insulin and fastingglucose. Treatments were administered subcutaneously, once every 6 to 7days, for a total of 5 treatments. On day 8 of the study, and onceweekly thereafter, blood was collected after a 4 hour fast to measureglucose or insulin. Compound 12743 improved insulin sensitivity, asdetermined by HOMA-IR calculations in the DIO (for example, FIG. 3, 2week data for compound 12743; FIG. 4, 3 week data for compound 12743)and db/db models, and as determined by hyperinsulinemic euglycemic clampin the DIO model. Liver triyglycerides were also lowered followingtreatment with compound 12743.

Analysis of the expression levels of direct target genes of miR-103/107following inhibition with compound 12743 revealed compound-mediatedactivity in both adipose and liver tissue. To identify compounds withfurther improved efficacy, and enhance delivery of anti-miR to theliver, GalNAc-conjugated anti-miR compounds were synthesized and tested.Conjugated anti-miR-103/107 compound was formed by conjugating astructure in FIG. 2 to the 3′ end of the modified oligonucleotide.Compound structures are shown in the Table below, where subscriptsubscript “E” indicates a 2′-O-methoxyethyl nucleoside, subscript “S”indicates an S-cEt nucleoside, all linkages are phosphorothioate andsubscript “m” indicates 5-methylcytosine.

TABLE B Anti-miR-103/107 Compounds Sequence and Chemistry(Modified Oligo- Compound nucleotide or MO) Structure 12743A_(E)T_(E)A_(E)G_(E) ^(m)C_(E) ^(m)C_(E) ^(m)C_(E) UnconjugatedT_(E)G_(E)T_(E)A_(E) ^(m)C_(E)A_(S)ATG_(S) CTG_(S)C_(S)U_(S)(SEQ ID NO: 20) 19743 A_(E)T_(E)A_(E)G_(E) ^(m)C_(E) ^(m)C_(E) ^(m)C_(E)Structure I of FIG. T_(E)G_(E)T_(E)A_(E) ^(m)C_(E)A_(S)ATG_(S)2A, where X₂ is a CTG_(S)C_(S)U_(S) phophodiester linkage,(SEQ ID NO: 20) m is 1, N_(m), is a β-D- deoxynucleoside (dA),X₁ is a phosphodiester linkage 19843 A_(E)T_(E)A_(E)G_(E) ^(m)C_(E)^(m)C_(E) ^(m)C_(E) Structure I of FIG. T_(E)G_(E)T_(E)A_(E)^(m)C_(E)A_(S)ATG_(S) 2A, where X₂ is a CTG_(S)C_(S)U_(S)phophodiester linkage, (SEQ ID NO: 20) m is 2, N_(m) is a β-D-deoxynucleoside (dA), X₁ is a phosphodiester linkage

The conjugated compounds were tested for the ability of the anti-miR tobe released from the conjugate structure. Compound was administered toDIO mice, and metabolites in liver tissue were measured. Compound 19843was efficiently metabolized to the unconjugated anti-miR. In contrast,compound 19743 was not efficiently metabolized to the unconjugatedanti-miR, suggesting that a conjugate linked via two DNA A nucleosidesis more efficiently metabolized than a conjugate linked via one DNA Anucleoside. Additional studies with different anti-miR-103/107 compoundswere performed, and confirmed that for anti-miR-103/107 compounds, thepresence of two DNA A nucleosides leads to more efficient cleavage thana single DNA A nucleoside.

The compounds were tested for efficacy in the DIO model. As noted above,compound 12743, an unconjugated anti-miR, resulted in improved insulinsensitivity in the DIO model. Compound 19843 is a GalNAc-conjugatedversion of compound 12743 (see Table above), and was tested in the samestudy as described above for compound 12743.

Previous studies (Trajkovski et al., Nature 2011) suggested that theimprovements in insulin sensitivity following miR-103/107 inhibitionwere driven mainly by activity in adipocyte tissue, rather than in livertissue. Further, miR-103 and miR-107 are most highly expressed inadipose tissue and brain tissue, with low levels found in liver tissue.As the GalNAc conjugation biases delivery of a compound to the livertissue (e.g., hepatocytes), it was surprisingly observed thatconjugation to GalNAc resulted in a 3-5 fold improvement in efficacy, asdetermined by improvement in insulin sensitivity (FIG. 3, 2 week datafor compound 19843; FIG. 4, 3 week data for compound 19843). Livertriglycerides were also reduced in a statistically significant manner.

Metabolites of the GalNAc-conjugated compounds were measured, and ametabolite retaining a 3′ A was observed. As the presence of a 3′A couldresult in a compound having a higher affinity towards a member of themiR-15 family, the metabolite containing the 3′A was tested forcross-reactivity, however was not cross-reactive.

To determine whether GalNAc conjugation of compound 97243 could improvethe profile of the compound, the 2′-F/2-MOE modified anti-miR compoundwas conjugated to GalNAc at the 3′ terminus as follows (Table C):

TABLE C Sequence and Chemistry (Modified Oligo- Compoundnucleotide or MO) Structure 47843T_(E)G_(E)A_(F)U_(F)A_(F)G_(F)C_(F)C_(F)C_(F) Structure I of FIG.U_(F)G_(F)U_(F)A_(E) ^(m)C_(E)A_(E)A_(F)U_(F) 2A, where X₂ is aG_(F)C_(F)U_(F)G_(F) ^(m)C_(E)A_(E) phophodiester linkage,(SEQ ID NO: 23) m is 2, N_(m) is a β-D- deoxynucleoside (dA),X₁ is a phosphodiester linkage

This compound also had an A in place of a U at the 3′-terminus, todetermine whether introduction of this mismatch would reduce oreliminate cross-reactivity. Although the compound did exhibit efficacyin the DIO model, as measured by fasting blood glucose, fasting plasmainsulin, and HOMA IR, the onset of efficacy was delayed relative toother compounds. Additionally, the compound induced expression of IFITin an in vitro assay, and exhibited cross-reactivity with miR-16,despite the presence of the A nucleobase at the 3′ terminus. Thus, thiscompound, like the unconjugated compound 97243, was not considered asuitable candidate for a therapeutic agent.

Compounds 12743 and 19843, which were efficacious in the DIO model, didexhibit cross-reactivity with miR-16. In view of this, additionalcompounds (as shown in Table D) were designed with an A in place of a Uat the 3′ terminus of the anti-miR. Due to this unexpected improvementin efficacy following conjugation to GalNAc, these additional compoundswere also conjugated to GalNAc at the 3′ terminus. The anti-miR portionof compound 45943 is a 9 nucleoside portion of compound 12743 and 19843,which was also conjugated to GalNAc.

TABLE D Sequence and Chemistry (Modified Oligo- Compoundnucleotide or MO) Structure 45943 ^(m)C_(E)A_(S)ATG_(S)CTG_(S)C_(S)Structure I of FIG. 2A, (a 9 nucleoside where X₂ is a portion of 12743)phophodiester linkage, (SEQ ID NO: 24) m is 1, N_(m) is a β-D-deoxynucleoside (dA), X₁ is a phosphodiester linkage 47043C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S) Structure I of FIG. 2A,A_(S) ^(O)A^(O)A^(O)C_(S)A_(S)A_(S)U_(S)G_(S) where X₂ is aC_(S)U_(S)G_(S)C_(S)A_(S) phophodiester linkage,  (SEQ ID NO: 7)m is 2, N_(m) is a β-D- deoxynucleoside (dA), X₁ is a phosphodiesterlinkage 39243 C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)Structure I of FIG. 2A, (SEQ ID NO: 6) where X₂ is aphophodiester linkage,  m is 2, N_(m) is a β-D- deoxynucleoside (dA),X₁ is a phosphodiester linkage

Compounds 45943 and 47043 were tested in the DIO model.

As shown in FIGS. 3 and 4 compound 45943 did not reduce fasting glucose,fasting insulin, or improve HOMA IR at 2 weeks or 3 weeks. Livertriglycerides were not reduced. Thus, this chemically modified,9-nucleoside anti-miR conjugated to GalNAc was not efficacious in amouse model of insulin resistance. Thus, a truncated version of theactive compound 12743 did not retain activity.

Compound 47043 was tested as follows. C57BL/6 mice were fed a high-fatdiet (60% kcal from fat) for ˜15 weeks. Groups of 8 mice each weretreated as follows: (1) PBS; (2) compound 47043 at 3 mg/kg; (3) compound47043 at 10 mg/kg.

One day prior to treatment, blood was collected after a 4 hour fast, andanimals were sorted into treatment groups. Treatments were administeredonce weekly, by subcutaneous injection, for a 7 treatments (days 0, 5,13, 19, 26, 33, and 36 of the study, with day 0 being the day of thefirst treatment). Blood was collected weekly after a 4-6 hour fast ondays 8, 15, 21, 28, and 32 of the study, for measurements of fastingglucose and fasting insulin. On day 21 (or the end of week 3) of thestudy, a oral glucose tolerance test (OGTT) was performed following a 4hour fast, with blood collections just prior to and 30 minutes followingadministration of oral glucose. Animals were sacrificed on day 39 of thestudy. As shown in FIGS. 5, 6, and 7, compound 47043 exhibitedsignificant efficacy in the DIO model, at a dose as low as 3 mg/kg, asdetermined by reductions in fasting glucose, fasting insulin, and HOMAIR, which together indicate improved insulin sensitivity. Additionally,as shown in FIGS. 6 and 7, oral glucose tolerance was improved followingtreatment with compound 47043.

Liver triglyceride content was also measured in the DIO mice treatedwith 47043. Triglyeride was extracted from the liver with acetone, andmeasured by colorimetric assay (Infinity Triglyceride Liquid Reagent).As shown in FIG. 8, liver triglyceride content was reduced followingtreatment with compound 47043, relative to treatment with PBS.

As treatment with compound 47043 resulted in a significant improvementin insulin sensitivity, it was tested for cross-reactivity with miR-16.Consistent with the observation that an anti-miR with an A in place of aU at the 3′ terminus is not cross-reactive, no cross-reactivity wasobserved between compound 47043 and miR-16.

Compound 47043 was further evaluated in a safety study. Wild-type micewere injected with a single, 300 mg/kg dose of compound. Three daysafter the injection, mice were sacrificed, and tissues and blood werecollected. IFIT and OASL mRNA levels were measured in liver tissue.Spleen weight was measured for comparison to body weight. ALT levels inblood were measured. Compound 47043 did not exhibit increases in IFIT,OASL, spleen weight or ALT. Other compounds targeted to miR-103/107,with different anti-miR structures (e.g. number and placement of sugarmodifications) did exhibit increases in these safety parameters.

The viscosity of compound 47043 was measured. Below a concentration of230 mg/g, viscosity was below 20 cP, permitting a dosing solutionconcentration of approximately 200 mg/mL, which could be administeredvia a subcutaneous injection. Conversely, compounds with differentanti-miR structures (e.g. number and placement of sugar modifications)were highly viscous, making it difficult for the compound to beadministered via a subcutaneous injection. These data furtherdemonstrate that the structure of the anti-miR (type, number andplacement of sugar modifications) affects its viscosity, which is animportant consideration in choosing a compound that can be administeredvia a subcutaneous injection.

The intended active metabolite of 47043 is the full cEt 10-mer(C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S); SEQ ID NO: 6). Thepharmacokinetic profile of compound 47043 was also evaluated inwild-type mice to determine (1) how efficiently the anti-miR is cleavedfrom the conjugate; (2) how efficiently the adjacent cEt 10-mers arereleased; (3) whether DNA A nucleosides remain attached to the full cEt10-mer; and (4) the stability of the intended active metabolite. Sevendays following subcutaneous administration of a single dose of compound47043, liver and kidney tissues and plasma were collected formeasurement of the parent compound and metabolites. It was observed thatin the liver, 90% of the compound was metabolized to the cEt 10-mer(approximately 22%) or a cEt 10-mer with a DNA A (either at the 5′ endor 3′ end of the 10-mer; approximately 67%). In the kidney,approximately 50% of the compound was metabolized to the cEt 10-mer orcEt 10-mer with a DNA A (either at the 5′ end or 3′ end of the 10-mer).Oligonucleotides generally accumulate to the highest levels in kidneytissue, followed by liver tissue. For compound 47043, the kidney toliver ratio was 0.5. In contrast, compounds with different anti-miRstructures exhibited different metabolic products, and in some cases ahigher kidney to liver ratio. For example, an anti-miR that was 19nucleosides in length, with cEt, 2′-MOE and DNA sugar moieties, wassusceptible to metabolism in the middle of the compound, due to thepresence of three DNA nucleosides. Cleavage at this position metabolizedthe intended active metabolite (the full 19-mer), resulting in reducedefficacy. This compound also exhibited a higher kidney to liver ratio of1.5.

Based on the efficacy and safety data, compound 47043 was identified asa candidate agent for the improvement of insulin sensitivity andreduction of liver triglycerides.

Example 4 DIO Efficacy Studies

To further evaluate compound 47043, additional dosages of compound weretested in the DIO mouse model.

C57BL/6 mice were fed a high-fat diet (60% kcal from fat) for ˜15 weeks.Groups of 8 mice each were treated as follows: (1) PBS; (2) compound47043 at 1.7 mg/kg; (3) compound 47043 at 5 mg/kg; (4) compound 47043 at15 mg/kg; and (5) compound 47043 at 45 mg/kg. A group of 4 normal (lean)mice was used as an additional control group.

Prior to initiation of dosing, blood was collected after a 4 hour fast,and animals were sorted into treatment groups based on fasting glucose,fasting insulin and body weight. Treatments were administered onceweekly, by subcutaneous injection, for a total of 7 doses. 10 daysfollowing the first dose (after two doses), and weekly thereafter forthe remainder of the study, blood was collected after a 4-6 hour fastfor measurements of fasting glucose and fasting insulin Animals weresacrificed three days after the seventh and final dose of the study.Fasting glucose and fasting insulin were used to calculate HOMA-IR after1, 2, 3, 4, and 5 weeks of treatment. An oral glucose tolerance test(OGTT) was performed at after 5 weeks of treatment. In this OGTT, bloodwas collected at a single timepoint, at 30 minutes after the oralglucose administration, rather than over multiple timepoints, to permitthe measurement of insulin which requires a larger volume of blood. Atthe end of the study, liver tissue was collected for measurement ofliver triglycerides.

As shown in FIG. 9A, as assessed by weekly HOMA-IR, compound 47043improved insulin sensitivity in a dose-responsive manner.

As shown in FIG. 9B, treatment with compound 47043 resulted in increasedinsulin sensitivity, as evidenced by the reduced amount of insulinsecreted, particularly at the higher doses of compound, in response tothe glucose challenge. A trend toward reduced blood glucose levels wasobserved, indicating an improvement in the ability of the body to clearglucose after the oral administration (FIG. 9C).

Liver triglyceride content was also measured. Triglyeride was extractedfrom the liver with acetone, and measured by colorimetric assay(Infinity Triglyceride Liquid Reagent). As shown in FIG. 9D, a trendtowards reduced liver triglyceride content was observed following 5weeks of treatment with compound 47043, relative to treatment with PBS.

Liver triglycerides were also measured in an independent DIO study, andafter 10 weeks of treatment a trend toward lowered triglycerides wasobserved in this study as well, with statistically significantreductions at the 15 mg/kg and 45 mg/kg doses (FIG. 9E).

To test the effects of a single dose of compound 47043, an additionalstudy was performed in the DIO model, with mice treated as follows: (1)PBS; (2) compound 47043, 10 mg/kg; (3) compound 47043, 30 mg/kg; (4)compound 47043, 60 mg/kg; (5) compound 47043, 100 mg/kg. Mice weresorted into groups of 8 based on body weight, fasting glucose, fastinginsulin and HOMA-IR. A single dose of PBS or compound was administered,and after one week blood was collected following a 4 hour fast. Fastingplasma insulin and fasting plasma glucose were used to calculateHOMA-IR.

As shown in FIG. 10, after a single dose of compound 47043,statistically significant reductions in HOMA-IR were observed.

Example 5 Db/Db Efficacy Study

The inhibition of miR-103/107 in the db/db model, a genetic model ofobesity, diabetes, and dyslipidemia.

Compound 47043 was tested as follows. db/db mice (Jackson Laboratories)approximately 7 weeks of age were sorted into treatment groups based onbodyweight, fasting insulin and fasting glucose. Mice were fed a normalrodent chow diet throughout the study. Groups of 8 mice each weretreated as follows: (1) PBS; (2) compound 47043 at 10 mg/kg twice weekly(3 or 4 days between doses); (3) compound 47043 at 30 mg/kg twice weekly(3 or 4 days between doses); (4) compound 47043 at 30 mg/kg once weekly.Treatment was continued for 9 weeks. Blood was collected for glucosemeasurements after a 4 hour fast on a weekly basis, beginning 1 weekafter the twice weekly treatment groups has received 2 doses and theonce weekly treatment group had received 1 dose. In this study, insulinlevels were not measured, as insulin levels are not a reliable indicatorof improvements insulin sensitivity in the db/db model, due to thepossibility of beta cell failure occurring in the animals. At the end ofthe study, liver tissue was collected for measurement of livertriglycerides.

As shown in FIG. 11A, as expected due to the increasing severity ofdisease over time in the db/db model, the PBS-treated mice exhibitedincreased fasting glucose levels throughout the course of the study. Incontrast, fasting glucose levels in db/db mice treated with compound47043 not only did not increase, the fasting glucose levels decreasedduring the study. Thus this study demonstrated that treatment withcompound 47043 reversed the severe hyperglycemia that the db/db micedevelop with age. Due to the rapid disease progression of this model,two treatment groups included twice weekly dosing. However, the 30 mg/kgdose showed similar efficacy for both weekly and twice weekly dosing.

Liver triglyceride content was also measured. Triglyeride was extractedfrom the liver with acetone, and measured by colorimetric assay(Infinity Triglyceride Liquid Reagent). As shown in FIG. 11B, a trendtowards reduced liver triglyceride content was observed followingtreatment with compound 47043, relative to treatment with PBS.

This study confirmed the efficacy of compound 47043 in a different modelof diabetes, in addition to the DIO model.

Example 6 Hyperinsulinemic Euglycemic Clamp Assay in DIO Model

Insulin sensitivity may be evaluated using a hyperinsulinemic euglycemicclamp assay. In this assay, catheterized mice receive an infusion ofglucose and insulin. The insulin is infused at a constant high level(hyperinsulinemic), while the glucose is infused at a variable rate tomaintain blood glucose at a constant, normal (euglycemic) level. Therate of glucose infusion indicates the sensitivity to insulin, e.g. anincreased glucose infusion rate indicates an increased sensitivity toinsulin. For a DIO mouse, fed a high fat diet for 20 weeks, a typicalinfusion rate is 5-10 mg/kg/min. For a normal mouse, fed a normal dietfor 24 weeks, a typical infusion rate is 30-40 mg/kg/min.

Compound 47043 was tested in the clamp assay, in DIO mice. Miceapproximately 21 weeks of age were assessed for baseline fastingglucose, fasting insulin and body composition, after a 6 hour fast. Micewere placed into groups of 13 to 14 mice each, for treatment as follows:(1) PBS; (2) compound 47043, 3 mg/kg; (2) compound 47043, 10 mg/kg; (3)compound 47043, 30 mg/kg; compound 47043, 60 mg/kg. Treatments wereadministered subcutaneously, once per week for a total of 5 doses. Theclamp procedure was performed 24 hours after the fifth and final dose,and after an overnight fast. Insulin was infused at a constant rate of 4mU/kg/min. The parameters measured included glucose infusion rate at 20minute intervals over the entire 120 minute infusion period (FIG. 12A);clamped glucose infusion rate, which is the average glucose infusionrate during the ‘clamped’ portion of the infusion period, when glucoseinfusion rate has stabilized, from the 70 minute to 120 minutetimepoints (FIG. 12B); whole body glucose turnover (FIG. 12C); clampedhepatic glucose production, (FIG. 12D); and brown adipose glucose uptake(FIG. 12E).

As shown in FIG. 12, treatment with compound 47043 resulted in adose-responsive improvement in glucose infusion rate, indicating anincrease sensitivity to insulin (i.e., the body has a greater capacityto handle increased amounts of glucose). Additionally, whole bodyglucose turnover was improved. Hepatic glucose production was decreased,while brown adipose glucose uptake was increased, suggesting that theliver and peripheral tissues (e.g. adipose) contribute to theimprovements in insulin sensitivity.

This results of this provide further evidence that compound 47043 isimproving insulin sensitivity.

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the appended claims. Each reference (including, but not limitedto, journal articles, U.S. and non-U.S. patents, patent applicationpublications, international patent application publications, GENBANK®accession numbers, and the like) cited in the present application isspecifically incorporated herein by reference in its entirety.

1-49. (canceled)
 50. A method of treating at least one metabolicdisorder in a subject or preventing or delaying the onset of at leastone metabolic disorder in a subject, comprising administering to thesubject a therapeutically effective amount of a compound comprising thestructure:

wherein X is a phosphodiester linkage; each N of N_(m) is adeoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is5′-C_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)AAC_(S)A_(S)A_(S)U_(S)G_(S)C_(S)U_(S)G_(S)C_(S)A_(S)-3′, wherein eachnucleoside followed by a subscript “S” is a S-cEt nucleoside, eachnucleoside not followed by a subscript is a deoxynucleoside, and eachinternucleoside linkage between two S-cEt nucleosides is aphosphorothioate linkage, and the remaining internucleoside linkages arephosphodiester linkages; and wherein Y is linked to the 3′ terminus ofMO.
 51. The method of claim 50, wherein at least one metabolic disorderis selected from pre-diabetes, diabetes, metabolic syndrome, obesity,diabetic dyslipidemia, hyperlipdemia, hypertension,hypertriglyceridemia, hyperfattyacidemia, hypercholesterolemia, andhyperinsulinemia.
 52. The method of claim 51, wherein the diabetes istype 2 diabetes.
 53. The method of claim 50, wherein the subject hasfatty liver disease.
 54. The method of claim 53, wherein the fatty liverdisease is selected from non-alcoholic fatty liver disease (NAFLD),alcoholic fatty liver disease, alcoholic steatohepatitis, andnon-alcoholic steatohepatitis (NASH).
 55. The method of claim 53,wherein the subject has non-alcoholic steatohepatitis (NASH).
 56. Themethod of claim 55, wherein the subject has type 2 diabetes.
 57. Themethod of claim 50, wherein the compound is comprised in apharmaceutical composition.
 58. The method of claim 57, wherein thepharmaceutical composition comprises a pharmaceutically acceptablecarrier.
 59. The method of claim 58, wherein the pharmaceuticalcomposition is an aqueous composition.
 60. The method of claim 56,wherein the compound is comprised in a pharmaceutical composition. 61.The method of claim 60, wherein the pharmaceutical composition comprisesa pharmaceutically acceptable carrier.
 62. The method of claim 61,wherein the pharmaceutical composition is an aqueous composition.
 63. Amethod of treating at least one metabolic disorder in a subject orpreventing or delaying the onset of at least one metabolic disorder in asubject, comprising administering to the subject a therapeuticallyeffective amount of a compound having the structure:


64. The method of claim 63, wherein at least one metabolic disorder isselected from pre-diabetes, diabetes, metabolic syndrome, obesity,diabetic dyslipidemia, hyperlipdemia, hypertension,hypertriglyceridemia, hyperfattyacidemia, hypercholesterolemia, andhyperinsulinemia.
 65. The method of claim 64, wherein the diabetes istype 2 diabetes.
 66. The method of claim 63, wherein the subject hasfatty liver disease.
 67. The method of claim 66, wherein the fatty liverdisease is selected from non-alcoholic fatty liver disease (NAFLD),alcoholic fatty liver disease, alcoholic steatohepatitis, andnon-alcoholic steatohepatitis (NASH).
 68. The method of claim 66,wherein the subject has non-alcoholic steatohepatitis (NASH).
 69. Themethod of claim 68, wherein the subject has type 2 diabetes.
 70. Themethod of claim 65, wherein the compound is comprised in apharmaceutical composition.
 71. The method of claim 70, wherein thepharmaceutical composition comprises a pharmaceutically acceptablecarrier.
 72. The method of claim 71, wherein the pharmaceuticalcomposition is an aqueous composition.
 73. The method of claim 69,wherein the compound is comprised in a pharmaceutical composition. 74.The method of claim 73, wherein the pharmaceutical composition comprisesa pharmaceutically acceptable carrier.
 75. The method of claim 74,wherein the pharmaceutical composition is an aqueous composition.